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1.1 Osteoporosis: a major health problem 
Osteoporosis is an important public health care problem in the Western world. More than 
40% of the women will have experienced a fracture by the time they reach the age of 70. 
Moreover. the incidence of hip fracture appears to be increasing, and this is explained only in 
part by a longer life expectancy1. In the Netherlands. this trend has also been observed: 
Hoogendoorn described an increase in the number of fractures of the hip in men and women 
of over 50 years. which number gradually increased year by yea?. In 1972 approximately 6000 
subjects aged 65 years and over were admitted to the hospital for fractures of the hip, while 
10 years later this number had increased by 65% to more than 10,000 patients3• Based on 
recent data it has been estimated that the total number of hip fractures in the year 2010 will 
be increased to 22,7264• 
The very high prevalence of this fracture, resulting in morbidity with the risk of invali-
dation and social isolation, has lead to an increasing interest of both (candidate) patients and 
medical practitioners in this disorder. 
Osteoporosis is the most common metabolic bone disease, and is sometimes compared to 
hypertension: in both conditions irreversible damage may occur without significant prodromal 
symptoms or warnings, and in both conditions treatment should be started before symptoms 
occur. 
1.2 Definition of osteoporosis and osteopenia 
Difficulty in defining osteoporosis not only arises from the multiplicity of its etiologic 
and pathogenetic factors, but also from differences in points of view. From a clinical and 
radiological stand point osteoporosis is seen as a fracture syndrome, while an epidemiologist 
would describe osteoporosis as a major public health problem in the general aging population. 
Histologically, osteoporosis is characterized by diminishment of bone volume, caused by 
increased bone resorption by osteoclasts and/or decreased bone formation. From a 
densitometric point of view, Nordin suggested that osteoporosis should be defined as a bone 
mineral mass more than two standard deviations below that of young normal subjects as 
measured by photon absorptiometry5. For several reasons (see 3.8) there has been much 
criticism of such a densitometric definition of osteoporosis. 
Clinically, osteoporosis is defined as a condition in which bone tissue is reduced in mass 
and quality. resulting in a diminished strength with an increased susceptibility to fractures. 
Typical osteoporotic fracture sites are the vertebral bodies, the proximal femur and distal 
radius. A fall, blow, or any other form of trauma that would not injure the average person can 
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easily cause one or more fractures in a person with osteoporosis. As a consequence of this 
clinical definition, the bone disorder manifests itself by fracture. During the last decades 
intensive research has been done to develop techniques to diagnose osteoporosis before 
fractures occur, in other words to determine the fracture risk. The assessment of bone mass 
and quality is as yet mainly restricted to measuring the bone mineral mass at certain regions of 
interest. The clinical definition of osteoporosis is now widely accepted, while it is also 
generally accepted to define a low state of bone mass as yet without fractures as osteopenia. 
However, osteopenia is still a poorly defined entity, and no agreement exists whether a bone 
mineral mass (2 standard deviations) below the normal average for sex and age-group indicates 
osteopenia. 
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1.3 Classification of osteoporosis 
There are two recognized categories of osteoporosis: primary and secondary (Table I). 
Primary osteoporosis is a state of low bone mass with increased fracture risk which occurs in 
the absence of known disorders that may affect bone structure and quality. Four subtypes are 
recognized: 
1) idiopathic osteoporosis, mainly occurring in young premenopausal women and in young 
and middle aged men, 
2) 
3) 
juvenile osteoporosis, occurring before puberty, 
postmenopausal osteoporosis (also called type 
postmenopausal women aged 50-70 years, 
osteoporosis). occurring in 
4) age-related osteoporosis (also called senile or type II osteoporosis). 
The latter two conditions are by far the most common forms of osteoporosis. 
Differences in the rate of loss between the bone compartments may lead to these two distinct 
forms of osteoporosis. In 1947 Albright described these two types of osteoporosis6 , a clinical 
observation, which was supported by photonabsorptiometry several decennia later7 • Type I 
osteoporosis occurs mainly in postmenopausal women between the age of 51 to 65 years and is 
characterized by vertebral (crush) fractures and distal forearm (Calles-)fractures, while 
fractures of the hip are relatively rare. This type of osteoporosis is the result of a 
disproportionally high trabecular bone loss in comparison with cortical bone loss8 . Type II 
osteoporosis occurs predominantly in women and men above the age of 75 years. This type is 
characterized by the loss of cortical as well as trabecular mineral mass resulting in a high 
prevalence of hip fractures {but vertebral (wedge) fractures are common as well). 
Secondary osteoporosis represents a fracture syndrome resulting from bone loss caused 
by conditions or diseases that are known to affect bone, such as immobilization, glucocorticoid 
excess, nutrient and vitamin deficiencies, alcoholism, endocrinopathies (thyreotoxicosis. 
hyperparathyroidism, oestrogen or androgen deficiency), multiple myeloma, rheumatoid 
arthritis and many other diseases. Recently Johnson et al reported on 300 consecutive persons 
who were presented to an osteoporosis clinic9 • They found that 60% (180) had osteoporosis, of 
these 180 patients 83 (46%) showed one or more conditions or diseases contributing to the 
syndrome of osteoporosis. 
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Table I 
Clinical classification of osteoporosis 
PRIMARY OSTEOPOROSIS 
1) Idiopathic osteoporosis 
2) Juvenile osteoporosis 
3) Postmenopausal osteoporosis (type I) 
4) Age-related osteoporosis (type II) 
SECONDARY OSTEOPOROSIS 
Endocrinopathies 
Hypogonadism 
Hyperadrenocorticism 
Thyreotoxicosis 
Hyperparathyroidism 
Acromegaly (?) 
Gastrointestinal diseases* 
Gastrectomy 
Malabsorption syndromes 
Chronic liver diseases 
Miscellaneous causes 
Glucocorticoid osteoporosis 
Immobilization 
Alcoholism 
Anorexia nervosa 
Osteogenesis imperfecta 
Multiple myeloma 
Rheumatoid arthritis and other connective tissue diseases 
Pregnancy 
* Combinations with osteoporosis and osteomalacia 
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1.4 Diagnosis of osteoporosis 
As a consequence of the clinical definition of osteoporosis the diagnosis should include 
the confirmation of a fracture. This is routinely done by X-ray investigation of the spine. and 
(as indicated on clinical grounds) of the hip, distal forearm or other skeletal sites (e.g. the ribs 
or the humerus). Standard radiographs of the spine can establish the diagnosis osteoporosis 
only in the absence of specific causes of fractures such as a significant trauma, a focal bone 
disorder (e.g. a metastasis) or other abnormalities. Furthermore, the kind of fracture and the 
location may be typical for osteoporosis. Although no clear definition exists of osteoporotic 
fractures, fractures of the hip, vertebrae or distal forearm should raise the suspicion of os-
teoporosis. 
AU patients presenting with one or more osteoporotic fractures should be evaluated 
comprehensively to exclude secondary osteoporosis, while assessment of the degree of bone 
loss may be helpful in monitoring the effectiveness of subsequent treatment. 
The general medical evaluation should include: 
I) Medical history; special attention is aimed at chronology, location, type and severity of 
back pain, location and kind of fractures, previous treatment (glucocorticoids, anti-epi-
leptics. estrogens, diuretics, etc), age at menopause (natural or surgical), diet (calcium, 
protein (?), vitamin D intake, alcohol and tobacco). 
2) Physical examination. Of course, clinical examination can not assess the amount of bone 
lost and in fact the most important information to be obtained by a physical examinatiOn 
concerns possible causes of secondary osteoporosis. Examination with regard to 
osteoporosis itself should include a measurement of height and of the arm span and a 
careful investigation of signs and symptoms of vertebral fractures: spinal angulation, 
upper abdominal transversal skin fold and leaning of the ribs on the pelvis should be 
noted. Although no general agreement exists, it might be useful to do a complete blood 
cell and differential count, routine blood chemistry plus (including measurements of 
calcium, alkaline phosphatase, creatinine. protein spectrum~ thyroid function and 
erythrocyte sedimentation rate. To exclude osteomalacia a measurement of 25-(0H) 
vitamin D3 may be helpfuL Abnormalities in these studies might point to a form of se-
condary osteoporosis. A dexamethasone screening (suppression) test and a bone marrow 
examination should be reserved for special cases. 
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1.5 Radiography, osteoporosis and osteopenia 
A routine radiograph is insensitive with respect to the estimation of bone mineral mass: 
the bone mineral density must have decreased by at least 30% before a reduction can be 
observed10. However~ vertebral deformities such as ballooning of intervertebral discs and 
wedging or collapse of vertebral bodies may indicate osteoporosis. 
Radiographic criteria for osteopenia of the spine are: 
1) a pattern of vertical stratification (representing the remaining vertical plates and 
trabeculae in the vertebrae). 
2) decreased radio-density. recognized by visibility of the iliac crest through L4 and L5 on 
the lateral spine film. and decreased contrast in radio-density between the interior of 
the vertebral body and the adjacent soft tissue~ 
3) the increased relative density of the vertebral endplates compared with the central part 
of the vertebral body. 
For the hip. changes in cancellous pattern of the upper part of the femur~ have been 
graded according to the Sing index11• A comparable index was developed for the calcaneus12. 
Correlations with the results of quantitative methods of bone mineral assessment are weak. Al-
though it appears to be a simple method. it is rarely used in clinical practice~ probably because 
it is time consuming and the standardization remains a difficult issue. 
1.6 Osteoporotic fractures 
As stated before. non-traumatic fractures may help to define osteoporosis. The diagnosis 
of vertebral fractures in clinical practice is usually biased by the personal view of the 
physician who interprets the lateral X-ray films of the spine. Several methods have been 
developed to quantify spinal deformity. Doyle used an index of biconcavity of the lumbar 
vertebrae13 and Horsman's method is based on the number and severity of the vertebral defor-
mities14. Recently arbitrary criteria have been developed to define spinal fractures and how to 
measure spinal deformity15 16 17• These criteria are used for monitoring osteoporosis and its 
treatment. although in daily clinical practice these methods are seldomly used. 
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Typical fractures in osteoporotic patients are: 
1) wedge fracture of a vertebral body, sometimes called anterior wedging (ventral height of 
the vertebral body amounts to 80% of the dorsal height or less), the limit of 80% may 
however, vary per region of the vertebral column15, 
2) collapse fracture (both anterior and posterior compression); this regards especially the 
vertebrae Thl2 through L4, 
3) severe biconcavity can be seen as an osteoporotic fracture (central compression), 
4) fractures of the hip, 
5) Cones fractures. 
1.7 Scope of the thesis 
The first aim of this thesis was to investigate the clinical potentials of the most common 
non-invasive methods of bone mineral assessment. 
First, the calculation routine of one of the measurement devices used in this thesis, the 
Dual Photon Absorptiometry (DPA) of the vertebrae L2 through L4, was modified. Our 
modification resulted in a faster performance. This is described in the Appendix. 
Secondly, reference values were obtained by measuring 171 healthy dutch females, this 
was done by measuring the mineral density in the proximal and distal forearm by Single 
Photon Absorptiometry (SPA) and in the lumbar vertebrae 2-4 by Dual Photon 
Absorptiometry (DPA). BaSed on these results a transversal study was preformed of the rate of 
bone loss over the decades at the various measuring sites. This is described in detail in Chapter 
5. 
Thirdly. the diagnostic sensitivity of several non-invasive methods to detect osteoporosis 
(SPA, DPA and Single Energy Quantitative Computed Tomography (SEQCT or QCT) den-
sitometry of the vertebrae Ll through L3) were studied by comparing a group of osteoporotic 
females with a group age-matched healthy women (Chapter 6). 
The second aim was to study several potential determinants of the bone mineral mass 
applying the non-invasive techniques for bone mineral assessment. 
In order to study the importance of endogenous estrogens and their binding protein and 
body mass index as determinants of the bone mineral mass in elderly postmenopausal women 
we selected two groups of women from the open population with high and low estrone levels, 
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respectively. Within these groups a subdivision was made based on body mass index and on the 
serum level of sex hormone binding globulin (SHBG). The results obtained with SPA, DPA 
and QCT are given in Chapter 7. 
In order to investigate the effect of glucocorticoids on bone mineral density we 
performed two studies: I) A cross-sectional study was done in patients with Primary Biliary 
Cirrhosis with and without glucocorticoid treatment (Chapter 8). 2) a longitudinal study was 
carried out to investigate the possible bone sparing effect of the vitamin D3 metabolite, la-
hydroxyvitamin D3 on glucocorticoid-induced bone loss in patients with chronic obstructive 
lung disease. The results are described in Chapter 9. 
Finally, a survey has been performed about the usefulness of several putative risk 
factors with regard to osteoporotic fractures (Chapter 10.). Based on data from the literature 
the usefulness of mass screening is discussed. 
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CHAPTER2 
NON-INVASIVE METHODS FOR THE ASSESSMENT 
OF BONE MINERAL MASS 
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2.1 Introduction 
The increasing interest in osteoporosis has lead to the development of several methods 
for measuring the bone mineral content and density in a non-invasive way. Beginning with the 
quantitative assessment of cortical thickness, the field has steadily grown throughout the years. 
Several quantitative methods for assessing bone mineral status are now operational. These 
techniques are whole body calcium measurements as well as regional measurements at various 
skeletal sites. 
Assessment of human total body calcium is difficult to achieve in vivo. Neutron 
activation of the whole body followed by whole body counting of 49Ca has been used for this 
purpose. The only other techniques which are able to estimate total body calcium, are dual 
photon absorptiometry or dual energy X-ray absorption (DEXA) of the whole skeleton, which 
method will be discussed later on. Clinically better applicable is the approach of the regional 
measurements of the bone mineral mass. These techniques provide information focused on 
fracture sites and they are nowadays common practice in the research of osteoporosis and 
other metabolic bone diseases. 
In this chapter an overview of the various available methods of quantitative bone 
mineral assessment will be given. 
2.2 Precision and accuracy 
In evaluating the various methods of the assessment of the bone mineral content and 
density it is necessary to determine their precision and accuracy1. The precision or 
reproducibility of a measurement is usually given as the coefficient of variation (CV) of the 
results of repeated measurements of the same object or subject, this is calculated by dividing 
the standard deviation by the mean. Especially in longitudinal studies, a high precision or 
reproducibility is of the utmost importance in assessing changes over time of the bone mineral 
content and density and in deciding whether an observed difference constitutes a real biologic 
change or not. It was shown by LeBlanc et al. that two measurements with a scanner with a 
CV of 4% would have to differ more than 5.6% (the square root of (42+42)) to be confident 
(confidence level of 95%) that a real change had occurred2• 
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In the evaluation of a reported precision of a measuring device several aspects are of 
importance: 
1) short- and long-term precision (for real long-term precision assessment phantoms are 
necessary)~ 
2) repeated measurements with and without repositioning~ 
3) CV's obtained with phantoms, normal subjects or osteoporotics~ 
4) intra- and inter-observer variations. 
In general the short-term reproducibility is better than the long-term one. Both systemic 
and random errors contribute to this difference3 • 
Repositioning of the object under investigation will introduce additional variance in the 
results of repeated measurements. Therefore it is of importance to know whether the CV is 
based on measurements with or without repositioning. 
Repeated measurements of osteoporotics show a larger CV than those of normals or 
phantoms4 • This is partly explained by a more difficult location of the region of interest (for 
spinal measurements), a low bone mineral mass in relation to the mostly normal soft tissue 
mass. 
Intra- and inter-observer variations are nowadays a relatively small problem, because 
most devices operate (semi)-automatically. 
Accuracy is a measure of the degree to which the bone mineral measurement agrees 
with the true (or an accepted "true") bone mineral mass5• These "true" values are generally 
obtained by measuring cadavers followed by chemical or physical analysis6 • Accuracy is 
important in cross-sectional studies in which results between two or more populations or 
investigations are compared. In Table I the precision, accuracy and radiation doses are given. 
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Table I 
Precision, accuracy and radiation dose of several non-invasive methods for measuring bone 
mineral mass. 
Radiogrammetry 
QMD 
SPAprox 
SPAdist 
DPA 
DEXA 
QCT 
2.3 Radiogrammetry 
Precision 
1-2% 
I% 
1.0% 
1.9% 
2.3-3.7% 
1.5% 
2,7% 
Accuracy 
2-5% 
2-5% 
3-5% 
1.0% 
20% 
Radiation References 
50-100 pSv 8 
50-400 I'Sv 10 
20-100 pSv 11,13,14,15 
20-100 pSv 11,13,14,15 
50 I'Sv 3A,6,15,17 
10-30 pSv 15,19 
l-10 mSv 1,15,22,23, 
24,25,26 
Radiogrammetry is the measurement of the thickness of the cortex of metacarpal or 
phalangeal bones using standard antero-posterior radiographs. The outer and inner diameter of 
the metacarpal or phalangeal bones are measured. Advantages of this method are the relative 
simplicity. the low costs and negligible radiation dose. Disadvantages are the limitation to the 
peripheral skeleton: No information is obtained on the cancellous bone. Furthermore, this 
method does not take into account the possible existence of intracortical porosity. 
The correlation of metacarpal bone density with bone density measured at other sites 
with other techniques is reasonable and is comparable with that of the results of single photon 
absorptiometry of the distal forearm. For epidemiological investigations with large numbers of 
participants and a long period of follow up metacarpal radiogrammetry appears to be a 
valuable tool'. The precision is improved by multiple measurements of the metacarpal bones 
and is than 1-2%8• 
2.4 Radiographic densitometry 
Quantitative radio-microdensitometry (QMD) of a phalanx on standardized radiographs 
gives an indication of the BMD. The density of the bone on the radiograph is analyzed with an 
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optical microdensitometer together with a simultaneously radiographed aluminum reference 
wedge9• Because two standardized radiographs are made in planes perpendicular to each other 
an estimation of the bone mineral content per unit of volume can be achieved. The results are 
expressed in mm aluminum equivalent/mm3• In normal people the coefficient of variation was 
found to be less than I%10• 
2.5 Photon Absorptiometry 
2.5.1 Single photon absorptiometry (SPA) 
SPA was first described by Cameron and Sorenson in 196311. They developed a method 
to measure bone mineral content and bone width. The technique uses a linear scan by a 
radiation beam across the region of interest. The beam consists of gamma photons emitted by 
1251 and a detection system measures the attenuation. The source holder and detector-
photomultiplier are mechanically coupled and move with a constant speed over the region of 
interest which is placed between source and detector. The collimated beam e25I 27,5 KeY.) 
passes through the forearm, which is surrounded by a soft tissue-equivalent (mostly water) to 
constant thickness. The attenuated beam is detected by a Nai crystal-photomultiplier and 
transformed into a digital read out against the position of the scanning device. The result is 
expressed in arbitrary units (U) per unit of axial length of bone (the region of interest) or 
after calibration in grams hydroxyapatite (Ha) per em. By division of this result by the bone 
width (measured at the individual scans) the data are expressed as U or g Ha/cm2 and are thus 
normalized for inter-individual comparison. Most commercial available devices have some 
kind of fat correction, the raw value of BMC is corrected by an algorithm based on the 
various amount of fat in the surrounding soft tissue. This is of particular importance since 
treatment of osteoporosis may alter body composition, without a fat correction the results of 
bone mineral content measurements by SPA may be spuriously altered12• In our laboratory the 
coefficient of variation was determined by measuring (with repositioning) 50 normal subjects 
and proved to be 1.9% and 1.0% for the distal and proximal site, respectively13• The proximal 
measurements show a better CV than the distal ones, this is because small differences in the 
location of the forearm in the apparatus (repositioning) will result in a slightly different 
measurement site. The difference in bone mineral density along the forearm is smaller in the 
proximal site (tubular bone of relatively constant composition). The accuracy has been 
determined by measuring excised bones or phantoms containing known weights of bone 
mineral. This was done by Cameron11• who found values about 3%. later higher values (6-8%) 
were found some of this difference may have been related to whether or not the calibration 
bone samples contained bone marrow14• The radiation dose is low (20 to 200 J,LSv) with a 
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negligible whole-body dose15• 
2.5.2 Dual photon absorptiometry (DPA) 
DPA is developed to measure the bone mineral content of lumbar vertebrae (mostly L2 
through L4)~ the femoral necks or the whole skeleton. As is the case with SPA~ the 
measurement is an integral one, which means that cancellous bone and cortical bone can not be 
measured separately. 
The dual photon source employed in DPA devices is mostly Gadolinium 153, but a 
combination of other radionuclides is also possible. The advantage of Gadolinium 153 is the 
common decay of both photons (100 and 44 KeV), as this source is commonly used we restrict 
ourselves to the description of the use of this source. 
The physical half-life of Gadolinium153 decaying to·srable Europium153 is 242 days. The 
source strength used is 1-1.5 curie and a lifetime of about 18 months is common in clinical 
routine. A collimated beam of two gamma photons with energies of 100 Ke V and 44 Ke V is 
attenuated by the object. A detector is coupled to the source-holder, which is located at the 
other site of the object measures the non-absorbed photons. 
The method is based on the following principle: absorption of photons is dependent of 
the photon energy, the kind of absorbing material and the thickness of the absorber. In this 
case the absorber consists of soft tissue and bone mineral in bone tissue. To eliminate the 
influence of the (variable) soft-tissue mass on the results of bone mineral measurement two 
separate measurements are done with two different energies. The principle is that the mass 
attenuation coefficients of bone and soft tissue differ as a function of photon energy. By using 
two photon energies it is possible to calculate the attenuation in soft tissue independent from 
the attenuation in bone. Subsequently, the computer calculates the BMC. 
The algorithms used to calculate the BMC and BMD are discussed in the appendix. 
Several manufacturers are developing new methods such as the replacement of the 
detector by a gamma scintillation camera. Gamma cameras are readily available at nuclear 
departments and can register two energies simultaneously. However, there are considerable 
difficulties such as scatter from the patient and scatter from the high energy after passage 
through the patient to the lower energy window. Improvements are the use of multiple 
detectors~ which decrease the scan time. There is also interest in obtaining lateral measure-
ments, because in the case of severe calcifications of the aorta in the lumbar region the frontal 
measurement will give a spuriously high BMC. In our laboratory the coefficient of variation 
was determined by measuring (with repositioning) 20 osteoporotic women and proved to be 
3.7% and 2.3.% for BMC and BMD, respectively13• The accuracy based on multiple 
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measurements of excised vertebrae or spines of cadavers is between 5 and 10%16 17• 
However~ future developments will probably be influenced by the break-through of the 
Dual Energy X-Ray Absorptiometry technique. 
2.6 Dual Energy X-Ray Absorptiometry (DEXA or DXA) 
An important new method for assessment of bone mineral mass is Dual Energy X-Ray 
Absorptiometry (DEXA or DXA) also known as Quantitative Digital Radiography (QDR). The 
concept of DEXA is quite similar to DPA~ but differs from DPA in that the radioactive source 
is replaced by a special X-ray tube. Like the emission of two photons with different energy 
and absorption characteristics in DPA~ DEXA uses dual energy X-rays. The advantage of this 
X-ray source is the much higher intensity compared to Gadolinium153• A tube with an average 
current of 1 rnA produces 500 to 1000 times more photon flux than a new 1 Curie 
Gadolinium153 source. DEXA is used in the same regions of interest as DPA. 
In order to overcome technical problems such as instability of the x-ray source and 
beam hardening due to polychromaticity. an internal reference device is implemented. The 
apparatus measures the patient together with a calibration disk consisting of various x-ray 
absorbing reference materials (the calibration wheel). This is done on a pixel-by-pixel basis 
for both energies, so that when the x-ray beam is detected it contains information of both the 
unknown patient absorption characteristics and the known absorption characteristics of the 
calibration wheel. 
Advantages of this method over DPA are a faster performance (5 min. versus 20 min. 
with DPA for a lumbar scan), a higher resolution and consequently a better precision. The 
very high correlation (r=0.94) found for the lumbar vertebrae between DEXA and DPA 
underlines once more that principally the BMC is assessed in a similar manner18• In normal 
people the coefficient of variation was found to be less than 1.5% for spinal measurements and 
2.9% for measurements of the hip19• 
2. 7 Quantitative Computed Tomography (QCT) 
QCT is the only non-invasive technique for bone mineral assessment which is capable of 
measuring selectively the cancellous and cortical BMD. This capability is a great advantage 
over the other methods because cancellous bone has a higher metabolic turnover rate than 
cortical bone20 21. Another advantage of the method is the fact that QCT measurements can be 
performed with commercially available Computed Tomography (CT) scanners with minor 
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adaptations only. The method is described in chapter 6. The precision based on measurements 
of phantoms is 1-2%, but in vivo the precision is much poorer1. We found a precision of 2.5% 
and 2.7%. respectively, for L2-L3. in scanning (with repositioning) 10 osteoporotic women 
twice22• The radiation dose is higher than with photon or roentgen absorptiometry23 24• 
The accuracy of QCT is less than with the other non-invasive methods and is about 
20%25• Intravertebral fat may lead to an underestimation of the BMD. due to the lesser 
attenuation by fat. Intravertebral fat increases with age and bone marrow mass falls, in order 
to overcome this problem Dual Energy QCT (DEQCT) has been utilized. To this end CT 
scanners have been programmed to make scans of the same slide with both high and low 
kilovolt tube potentials. The differences of the density values are used as a measure for the 
bone mineral density25• 
1.8 Other techniques: 
Compton scattering (CS) 
Photon absorptiometry and QCT have in common the attenuation of an energy beam by 
the tissue which is measured. Furthermore, the source of the beam, the object under 
investigation and the detector are placed in line. CS, however, employs a scatter-detector at 
different angles with the line source-object. The method is based on the scattering of X-rays 
or photons by the electrons of an atom, whereby part of their energy is transferred to the 
electrons. Consequently, the energy of the x-ray or photons falls and is dependent on the angle 
of the scatter. The method is rather complicated and the radiation dose is between 3 and 
10.000 pSv5• Furthermore, a disadvantage is the inability to distinguish between bone tissue 
and bone marrow, Also no distinction can be made between the cortical and cancellous bone 
compartments. Precision and accuracy are between 3 and 5%. Up to date there have no 
important clinical applications been described of CS. 
Neutron activation (NA) 
In vivo Neutron Activation (NA) is a complex technique and only operational in a few 
research centres, because of the special equipment needed for the particle acceleration and the 
difficulties in detecting the very low levels of radiation activated from the elements. With this 
method neutrons from an accelerator (or reactor) are used which bombard the total natural 
(constant) fraction of 48Ca in the body. By absorbing a neutron the calcium nucleus is excited. 
The 48Ca changes to 49Ca. a radioactive isotope with a half-life of only about 9 minutes. By 
counting the decay of 49Ca externally an estimate of the total amount of calcium in the body is 
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made. As a consequence of the neutron bombardment other elements in the human body are 
also converted e4Na, 38Cl, 32P and others). The gamma rays emitted are detected by a whole-
body counter and subsequently analyzed by a spectrometer system. NA cannot distinguish 
between cancellous and cortical bone. However, the major disadvantage is the high radiation 
dose of 2000-30000 p.Sv27 28• 
Because it is an expensive and extremely complicated method and has a high radiation 
exposure NA is not suitable for routine practice and will be a research tool only. 
Magnetic resonance imaging (MRI) 
MRI is a non-invasive technique, that recently has become operational in clinical prac-
tice and that does not use ionizing radiation. In vivo recording of 31P MR spectra of the bones 
of the fingers and wrist has been reported29• Signals from soft tissue and bone marrow 31P 
may interfere with the precision and accuracy. No clinical experiences on bone analysis have 
been reported up till now. 
Broadband ultrasonic attenuation (BUA) 
BUA of the ankle or patella is used to assess bone mineral mass and structure. The great 
advantage is the absence of radiation which opens the possibility for large scale population 
investigations. The method is based on measuring the rate of change of attenuation with 
varying the frequency of the ultrasound. A moderate but significant correlation (r=0.75, 
p<O.OOI) between BUA and SPA of the forearm was found in patients with different disease 
conditions30• 
An important aspect of BU A is the possibility to study trabecular structure by ultrasonic 
parameters31• BUA is a rather new technique and little clinical experience is available. 
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CHAPTER 3 
BIOLOGICAL AND CLINICAL ASPECTS 
OF BONE MINERAL MEASUREMENTS 
37 

3.1 Introduction 
In recent years much effort has been put into the development of non-invasive 
assessment of bone mineral mass and the possible prediction of the fracture risk in suspected 
osteopenia or in osteoporosis. Various techniques have been developed to quantify the bone 
mineral mass, each of which provided different information on cancellous and/or cortical 
bone mineral mass in the axial or peripheral skeleton. It has been demonstrated that the 
compressing or breaking strength of bone is linearly related to mineral content1 2 . 
Another indication for bone mineral measurement is the monitoring of the longitudinal 
course of the bone mineral mass. For instance to evaluate the effect of aging, disease or 
medication (e.g. glucocorticoids). 
3.2 Bone mineral mass, content and density 
The term bone mineral mass may be used to refer to the mass of hydroxyapatite (Ha) in 
the whole skeleton. However, the results of regional measurements may also be referred to as 
bone mineral mass. The term bone mineral content (BMC) is reserved for the absolute mass of 
bone mineral measured in the forearm (as in the case with SPA, expressed as units or grams 
Ha/cm), or measured in the lumbar spine along the region of interest L2-L4 (as with DPA, 
expressed as units or gram Ha per L2-L4). This expression is mostly used in longitudinal 
studies of the same individual. Evidently. exact reposition of the region of interest is 
mandatory in this type of study. 
It is now widely accepted to use the term bone mineral density (BMD) for two types of 
measurements. Strictly speaking density means mass divided by volume (e.g. g of Ha/ml). This 
applies to the results of QCT. The results of the photon absorptiometric devices are expressed 
as arbitrary units and after calibration in g Ha. Dividing this entity by the projected surface 
of the measured bone region (which generally applies to the lumbar vertebrae measured by 
DPA) gives the dimension g HA/cm2, which is also called BMD. This expression is especially 
used for inter-individual comparisons, because it corrects for the size of the bone measured 
and thereby for the total body mass3 • 
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3.3 Peak bone mineral mass 
Research on osteoporosis has been focused on the rate of bone mineral loss, and only 
recently attention has been given to the peak bone (mineral) mass (also called peak adult bone 
mass). It is becoming increasingly clear that the (peak) bone mass from which the bone loss 
starts off is a major factor in the pathophysiology of fractures. Moreover, because it appears 
to be difficult to replace lost bone, more effort has to be aimed at preventing bone loss and at 
attaining a higher peak bone mass in growing individuals. Recently it has been demonstrated 
with QCT that vertebral cancellous BMD reaches its peak around the time of cessation of 
longitudinal growth at epiphyseal closure 4• In contrast, with DPA it appears that bone 
(mineral) mass increases until the mid-thirties5• Because of the reluctance to expose the 
growing individual to gamma radiation. data are relative scare concerning peak bone (mineral) 
mass based on densitometric studies. Consequently. little is known about the factors which are 
thought to influence peak bone mineral mass, such as genetic factors, exercise (weight loading 
factors), nutrition (Calcium, proteins, calories, vitamin D) and environmental factors (sun ex-
posure). In two cross-sectional studies on premenopausal women a significant positive 
correlation was observed between daily calcium intake and (peak) bone mass 6 7• 
The (limited) information on peak bone mass and its determinants is based on cross-sectional 
and not on longitudinal studies, that would have been more conclusive. Nevertheless, incre-
asing attention is directed towards the peak bone (mineral) mass of young women as an impor-
tant risk factor of osteoporotic fractures of elderly women. 
3.4 Bone mineral mass and bone loss 
In order to determine rates of bone loss densitometric and biochemical methods are 
employed. Two bone mineral mass measurements with a certain interval of time will give the 
overall result of bone formation and bone resorption. The significance of differences between 
the results of repeated measurements is dependent on the precision of the method used (see 
2.2) and the order of magnitude of the expected rate of loss of bone (mineral) mass. On the 
other hand, also biochemical parameters have been studied in order to estimate the rate of 
bone loss8 9. 
It has been estimated from cross-sectional and longitudinal studies with SPA and DPA 
that in women peak bone mass is reached at the age of 30-35 years. There is probably 
essentially no premenopausal bone loss from the age of 1& to 4410• In the last decennium befo-
re the menopause axial BMD diminishes by 7 -&%, while loss of peripheral BMD (mainly corti-
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cal) is minimal or absent11• After the menopause an acceleration of cancellous (and to a lesser 
extend cortical) bone loss occurs12, followed by a lower rate of bone loss at higher age13 14 • It 
has been documented that in the first ten years after menopause 50% of the total vertebral 
bone loss takes place15• By DPA measurements it was shown that about 20% of the lifetime 
femoral neck bone mineral loss and 30% of the trochanteric loss occurs in the early post-
menopausal period16• The total loss of bone mineral content is 30-35%17 18• 
Although on male human beings less information is available, there is probably a diffe-
rent pattern of bone loss: after the age of 35 years a more or less constant rate of loss of bone 
mineral occurs leading to a total loss of 10%19• 
With QCT the number of studies of the normal population is lower than those with 
DPA. Bone loss assessed with QCT is comparable to the results obtained by DPA. It appeared 
that the first years after ovariectomy the rate of bone mineral loss was 5 to 7 times higher in 
the lumbar vertebrae (cancellous bone) than measured at the forearm with SPA (cortical 
bone)20• From these results it has been concluded that cancellous bone is more sensitive to 
estrogen deficiency than cortical bone. Consequently. it illustrates the importance to study 
selectively the cancellous bone compartment. With QCT a mean yearly cancellous vertebral 
bone loss of 1.0-1.2% is observed in women from 20 to 80 years. Also with thjs method an 
acceleration of the rate of loss is observed around the menopause21• 
3.5 Bone mineral mass and loss at different skeletal sites 
During more than 20 years SPA measurements of the forearm have been performed in 
research and daily practice. The relatively cheap equipment and the good precision are 
responsible for the popularity of this method. The technique for ultra-distal measurements in 
the forearm has been developed in an attempt to measure a higher percentage of cancellous 
bone and to better predict the bone mineral mass at an axial site (more cancellous bone). The 
results of the measurements at the ultra-distal and more proximal sites in the forearm correlate 
very well with the bone mineral mass of the whole body22, but only moderately with spinal 
BMr>23 24 • Furthermore. the correlation between peripheral and axial bone mass weakened 
with aging23• Moreover. there was no correlation between the rate of bone loss at the various 
sites25• Some investigators even claim that the peripheral bone mineral mass will predict 
vertebral fractures better than axial measurements26• These controversies are partly due to 
differences in method and patient selection. 
While evidence is accumulating that bone mineral mass measurements at different 
skeletal sites yield different information, there is still uncertainty to what extent the results of 
peripheral and axial measurements can predict vertebral and other osteoporotic fractures. As 
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could be expected the results of measurements of the bone mineral density at the so-called 
fracture sites correlated better with the incidence of those fractures than those of 
measurements at other skeletal sites27• There appear to be different patterns of bone loss at the 
various sites not only during aging1\ but also in disease or in response to medical treatment28 
(e.g. fluoride29). 
In general, the peripheral bone mineral mass provides at least in normals a reasonable 
impression of the total bone mineral content. In the individual however. information obtained 
at the forearm is insufficient to predict BMD of the lumbar vertebrae or the hip. 
3.6 Bone mineral mass and seasonal variations 
Because the occurrence of seasonal variations in 25-hydroxyvitamin D levels is well es-
tablished30 3 1, several investigators looked for evidence of seasonal variations in bone mineral 
mass. Krolner described a cyclic fluctuation of the lumbar bone mineral mass, which he 
explained by differences in mechanical loading of the vertebrae over the year32• This finding 
was confirmed by investigators from the Mayo clinic, who found an average higher BMD of 
the lumbar spine of 1.4% in the late summer33• Later other investigators reported a seasonal 
variation of the peripheral bone mass accompanied by cyclic fluctuations of alkaline 
phosphatase and whole body retention of 99Tc-diphosphonate34• Using neutron activation 
Tothill et al, however, could not find evidence of a seasonal variation of bone mineral mass35. 
Although no agreement exists about the existence and, if so, the magnitude of seasonal 
differences in bone mineral mass, it is of importance to keep this phenomenon in mind when 
longitudinal studies are performed or when data on bone mineral mass obtained in different 
seasons are compared. 
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3.7 Bone minerai mass, bone strength .and fractures 
In clinical practice bone mineral measurements are perf onned to predict the risk of 
fractures or to monitor therapeutic interventions. However, several studies report a lack of 
discriminatory power of bone densitometric measurements in the separation of women with 
and without fractures (see also chapter 6). This relative insensitivity of densitometric 
measurements in "predicting" fractures (or better: diagnosing already existing fractures) might 
be explained by: 
1) a wide biological variation in both the fracture and the non-fracture groups, 
2) several forms of potential bias inherent to cross-sectional designs, such as 
postfracture bone loss due to immobilization or, on the contrary, spurious elevations of 
bone mineral density due to callus formation. Furthermore, healthy case-controls may 
not be as healthy as expected, 
3) limited correlation between the results of cortical measurements and the occurrence 
of certain fractures or between the bone mineral mass at peripheral and axial sites 
respectively, 
4) a poor correlation in vivo between bone mineral mass and bone strength in the 
regions where osteoporotic fractures occur. 
Because most densitometric methods measure cortical and cancellous bone together, no 
distinction can be made between cortical or cancellous bone losses. In certain regions of the 
skeleton changes in cancellous bone mass might reduce bone strength to a higher extent than 
quantitatively comparable changes in cortical bone mass. 
The inadequacy of this -of necessity- mass-based approach of osteoporosis has directed 
attention to causes of fragility other than reduced bone mineral mass, the so-called "quality 
versus quantity" concept. One of those qualitative (intrinsic) bone factors is fatigue damage, a 
well known phenomenon of solid materials. It is understandable that accumulated fatigue 
damage associated with a low turnover of bone tissue, may weaken bone quite apart from its 
mass36• This is illustrated by the increased incidence of fractures in osteopetrosis, where bone 
density is above normal, but bone turnover rate is low. Unfortunately, it is at the moment 
nearly impossible to quantify fatigue damage in an individual. The importance of this 
phenomenon is as yet not its application in daily clinical practice, but awareness of this con-
cept will lead to a better understanding why fractures occur. Furthermore, fatigue damage 
fractures may be conditioned by the age of bone tissue (e.g. the proportion of dead bone). 
which means that a low bone turnover may favour the occurrence of this type of fracture. 
This may have consequences for therapeutic interventions. 
43 
Another factor contributing to fragility apart from bone mineral mass is connectivity or 
the degree with which bone plates and trabeculae are connected with each other. Kleerekoper 
et al. have investigated the three-dimensional architecture of vertebrae by high resolution CT 
scanning and found evidence for a lower connectivity in severely osteoporotic bone than in 
normal bone37• The decrease in bone mass and the loss of connectivity in the vertebral body 
cancellous bone will lead to an extreme loss of strength with age38 39. Besides fatigue damage 
and decreased connectivity of trabeculae, changes in chemical properties of the bone matrix 
and mineral depositions are of importance in determining the quality of bone. These three 
intrinsic factors of bone quality are also operating in other solid materials. However, bone 
differs from solid materials by a "built-in-repair" mechanism, namely the osteocytes. It has 
been postulated that these osteocytes (bone remodelling units) are stimulated by fatigue 
damages40 • This hypothesis raises a number of fascinating questions: What is the nature of the 
signal that is produced by fatigue microdamage? How is this signal detected and processed? 
In a recent paper Heaney postulated a three-dimensional fracture space: Low bone mass, 
fatigue damage and cancellous discontinuity are placed on three axes41• This scheme may help 
to understand why some people will have fractures and others will not, given the same amount 
of bone mineral mass and why they develop fractures of a specific type (Calles- and hip-
fractures as examples of fatigue damage and vertebral crush fractures as an example of 
trabecular discontinuity). Another important aspect of this scheme is that it places bone mass 
in a larger context, as only one of the intra-osseous factors causing fragility. Furthermore the 
interaction between these factors is interesting: as bone mass declines more strain is put on the 
remaining bone elements thereby increasing the amount of fatigue damage, whereas less mass 
will also lead to less connectivity and thus to a higher fragility. Not taken into account in this 
scheme as intra-osseous factors are the relative quantity and the chemical quality of the 
mineral (Ha) and organic components (collagen and other) of the bone tissue. 
Extra-osseous factors in the development of fractures are the neuromuscular condition 
(the tendency to fall) and the energy absorbing quality of the surrounding subcutaneous 
adipose tissue. In a postal survey of 2000 females and 2000 males it was shown that the higher 
incidence of distal forearm fractures in the perimenopausal period is correlated with a higher 
tendency to fall during that period42• Furthermore, in a longitudinal survey several risk factors 
for falling were identified and their adjusted odds ratio"s were calculated varying from 28,3 
for sedative use to 1,8 for foot problems43• 
It should be kept in mind, that although in vitro studies show a high correlation between 
bone strength and bone mineral mass38 39, in vivo the above mentioned factors may lessen the 
correlation between fracture incidence and bone mineral mass. 
The effects of age and bone mass were studied simultaneously on fracture risk by Hui et 
al44• They observed that both age and bone mass are important determinants of future 
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fractures. In addition. age appeared to be a stronger predictor of hip fractures, whereas 
midshaft radius bone mass was a strong predictor of fractures at the forearm. A difference in 
age of 10 years compared with a comparable difference in bone mass (0.1 gjcm, which is the 
average population decline in 10 years) showed a two and a half times greater fracture risk. In 
other words a bone mass of an older age is more fragile than an equivalent younger bone mass, 
which is completely compatible with the concept of fatigue damage and a less sufficient repair 
mechanism. 
In conclusion. the risk of fractures is determined by several factors and not only by 
bone mass. Factors like bone architecture (trabecular connectivity), age and quality of the 
bone tissue (fatigue damage) and the tendency of elderly people to be increasingly involved in 
minor traumatic events may be equally important for the occurrence of osteoporotic fractures. 
3.8 Bone mineral mass and the fracture threshold 
The fracture threshold (FT) is a hypothetical level which should discriminate between 
individuals with a high or low risk of developing osteoporotic fractures. Knowledge of such an 
FT would be most helpful in determining which individual is at risk for osteoporosis and 
should be treated prophylactically. It will be clear that for defining an FT. quantitative 
te<:hniques will be necessary. Based on a prospective study, Ross et al. defined it as the BMC 
at which the risk of fractures doubles as compared to the risk in premenopausal women45• 
Others chose their FT at the lower limit of BMC of young normals46: either below the 1Oth 
percentile or more than 2 standard deviations below the mean of young normals. This would 
imply that 50% of all the women aged 65 and over are classified as osteoporotics. If the 
highest BMD in the osteoporotic group is defined as FT. the bone mass of half of the women 
above 55 years and of almost all women above the age of 70 will be below this threshold. 
Therefore~ the choice of such a cut-off level is highly arbitrary and as a consequence of these 
definitions an important percentage of normal women will be classified as high risk or (pre-
?)osteoporotic. 
Several studies have compared fracture with non-fracture cases and although the latter 
had higher average BMCs or BMD's the differences were small and the overlap was con-
siderable (see Chapter 6). Because of these findings, the usefulness of densitometric measure-
ments for detecting osteoporosis has been questioned, however several longitudinal studies 
have shown that bone mineral measurements may predict future fractures to some extent (this 
issue is discussed in detail in Chapter 1 0). Furthermore~ there exists controversy about which 
measurement device at which skeletal site and in which bone compartment (cancellous or 
cortical) is the best method with regard to these issues47 48• 
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CHAPTER4 
TREATMENT OF POSTMENOPAUSAL 
AND GLUCOCORTICOID OSTEOPOROSIS 
51 

4.1 Introduction 
The treatment of osteoporosis has two aims. Firstly. the treatment of spinal fractures 
consists of analgetics and in severe cases by short periods of immobilization. In order to reduce 
further bone losses the patient should be instructed to ambulate as soon as possible. Fractures 
of the long bones, especially of the femoral neck may require surgical intervention and this 
will not be discussed here. Particularly in these older patients immobilization carries a very 
high risk of morbidity and mortality. 
The second goal in the treatment of osteoporosis is to prevent new fractures. This means 
preventing further reduction in bone mass and when possible increasing bone mass. Because 
the amount of bone (mineral) reflects the balance of bone formation and bone resorption, 
therapy (or rather secondary prophylaxis) is aimed at increasing osteoblast recruitment and 
activity while inhibiting osteoclast recruitment and activity. 
Medical treatment of osteoporosis consists of drugs which can modify the processes of 
bone remodelling. Roughly, three groups of drugs are used: 
1) inhibitors of bone resorption, such as calcium, estrogen, calcitonin and bisphosphonates, 
2) stimulators of bone formation, such as fluoride and possible anabolic drugs, 
3) drugs with a different or complex action, such as vitamin D derivatives, thiazide drugs, 
combinations of drugs (ADFR, see 4.3.8.). 
4.2 Primary and secondary prevention 
Once osteoporosis is established (and fractures have occurred), it appears to be very 
difficult to increase bone mass and prevent future fractures. Therefore, regardless of the type 
of osteoporosis, much attention has been given to 
the prevention of early postmenopausal bone loss. Because almost 50% of the total loss of the 
cancellous bone mass is lost in the early postmenopausal years1 , prevention should be exerted 
especially in this period. This is called primary prevention. Therapeutic interventions when 
fractures already have occurred is called secondary prevention. 
Of course the final criterium with regard to the effectiveness of preventive strategies is 
the reduction of the incidence of fractures. 
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4.3 Postmenopausal osteoporosis 
4.3.1 Calcium 
Calcium and calcium-regulating hormones have important effects on bone~ but it is 
generally accepted that abnormalities in the secretion of calcium-regulating hormones are not 
the primary determinants in the pathogenesis of osteoporosis2• A distinction has to be made 
between studies investigating physiologic (low or high calcium intake) or supra-physiologic 
(pharmacologic) calcium supplementations. There are several epidemiologic studies 
investigating different amounts of dietary calcium intake. In his cross-sectional study 
Matkovic et al found a 60% to 75% reduction in hip fracture in Yugoslav women with calcium 
intakes in the range of 1,000 to 1,100 mgjday, compared to the incidence of hip fracture in 
women with intakes of about half that level3 • The women with the higher calcium intake had 
also a higher intake of calories, while the average body weight was comparable between the 
two groups of women. This might lead to the conclusion that the women with the higher 
calcium intake had probably a higher level of physical activity, and thereby higher bone 
mineral mass and less fractures. Holbrook et al reported, in a prospective study, a 60% lower 
rate in hip fracture in individuals with high intakes (above 765 mgjday) versus those with low 
intakes (below 470 mg/day) of calcium4 • These observations are compatible with those from a 
recent study in which it was shown that healthy older postmenopausal women with a daily 
calcium intake of less than 400 mg can reduce their bone loss by increasing their calcium 
intake to 800 mg per day5• This latter study is an example of the bone sparing effect of 
increasing calcium intake, although the intake of 800 mg of calcium a day is not supra-
physiologic. The conclusion from this study is probably that correction of a deficient calcium 
intake to a normal intake reduces bone mineral loss. 
In another (prospective) study, however, it was concluded that a reduced intake of 
dietary calcium does not seem to be a risk factor for hip fracture6• Moreover, no protective 
effect of a higher habitual calcium intake on the rate of cortical bone loss in the forearm 
could be demonstrated in a 8-years follow up study7• In an other study the same investigators 
could not find a correlation between habitual daily calcium intake (range 560-2580 mgfday) 
and either bone mineral content of the radius. the lumbar spine and the femoral neck8 • 
Comparable results of dietary calcium and peripheral bone mineral loss in postmenopausal 
women are reported by Recker and Heaney9 • 
It was estimated from a calcium balance study that dietary calcium in the post-
menopause should be as much as 1500 mg daily10• On the other hand well controlled clinical 
trials could not demonstrate a beneficial effect of supra-physiological elementary calcium 
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suppletion after the menopause11 12 13 14. In combination with estrogens calcium supplemen-
tation may be beneficial15, although this observation is not confirmed by others16• 
The positive effects of thiazides on calcium balance have been well documented17 15• It 
is interesting that thiazide users had significantly more bone mineral content than non-users 
did19, but further work is required to investigate the effect of thiazides on fracture risk. 
In conclusion, it is amazing that there still exists no consensus about the efficacy of a 
high dietary calcium intake during childhood and in the perimenopausal years~ however a 
deficient calcium intake (less than approximately 500 mgjday) should be corrected to 800-
1000 mg daily. Furthermore, the prescription of extra calcium as a therapeutic or preventive 
drug in the management of osteoporosis has to be investigated prospectively20 21• 
4.3.2 Estrogens 
The usefulness of estrogens for the prevention of postmenopausal bone loss has been 
clearly demonstrated in cross-sectional22 and Iongitudinal23 24 25 studies as well as in 
retrospective ("case-control") studies26 27. Beneficial effects of estrogens have been observed 
both in the axial and in the appendicular skeleton28 29 . A dose-related inhibiting effect of 
estrogen treatment on bone loss was demonstrated by Horsman et al30• Furthermore, they 
showed that the minimal effective daily dose was 25 microgram ethinyl estradiol. Christiansen 
eta!. showed that already 1 mg 17B-estradiol-valerate inhibits bone mineral loss. while 2-4 mg 
daily may even increase bone mineral mass31• For conjugated equine estrogens (Premarin) the 
minimal effective dose turned out to be 0.625 mg32. 
It must be pointed out that all of these prospective studies on postmenopausal bone loss 
have been carried out in non-osteoporotic postmenopausal and/or oophorectomized women. 
Additionally, also women with established postmenopausal osteoporosis will benefit from 
treatment with combined estrogens/progestagen therapy (2 mg estradiol + 1 mg norethisterone 
acetate)33. 
A new development is the transdermal administration of estrogens. Although few 
controlled studies on bone mass measurements and fractures are available~ there is supportive 
evidence that transdermally administered estrogen will also reduce bone resorption34 3~ 36. 
There is general agreement about the bone preserving properties of estrogens~ and in 
early postmenopausal osteoporosis estrogen replacement therapy (ERT) is regarded as the 
treatment of first choice. 
Nowadays, in women with an intact uterus estrogen therapy is no longer given without a 
progestagen, because of the increased risk for endometrial hyperplasia or carcinoma37 38 39• 
The concomitant administration of an exogenous progestagen (this combination is called 
hormonal replacement therapy, HRT) has to be sufficient in dosage and duration to prevent 
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hyperplasia of the endometrium by the ERT. Moyer et al showed that a cyclic combination of 
estrogen and progestagen in postmenopausal women leads to partial maturation of the 
endometrium and significantly reduces the number of mitoses in both gland and stromal 
cells40 • It is generally accepted that the risk of endometrial carcinoma can be abolished by 
giving an adequate dose of progestagen cyclically41• In one prospective study it was shown that 
the use of estrogens with cyclic progestagens either removed the increased risk of endometrial 
carcinoma or delays its onset42• No agreement exists as to the minimal frequency of the proge-
stagen cycles necessary to prevent endometrial hyperproliferation (monthly?, 3-monthly?). 
Another possibility is the continuous substitution of both estrogens and progestagens. the latter 
in a low dosage43 44• No long-term prospective studies on this issue (with respect to fracture 
risks) have yet been published. 
Apart from the protection against endometrial hyperproliferation. several other effects 
of progestagen addition during estrogen therapy are unwanted and of little benefit to the 
patient. These include recurrence of menses, mastodynia. fluid retention. lower abdominal 
cramps and cyclic changes in mood. Uncertainty exists about the relation between HRT and 
the risk of (increased) breast cancer45 46• While breast cancer is affecting one in 16 women, 
already a small enhancement of the relative risk due to HRT might induce a major increase in 
breast cancers. The association between exogenous estrogen use and cardiovascular mortality 
has been controversial. There exists evidence that estrogens will increase the risk of 
cardiovascular disease47, and recently a negative association between estrogen use and 
cardiovascular disease mortality has been reported4 a. However, the favourable changes in 
serum lipids induced by estrogen therapy49 may to some extent be counteracted by 
progestagens. There is evidence that little negative effects on serum lipoproteins occur with 
medroxyprogesterone acetate (Provera) and dydrogesterone (Duphaston)45 50• 
Although consensus is reached about the effectiveness of estrogens in secondary 
prevention5\ there still are many unanswered questions about the optimum age to start HRT 
and especially how long this therapy should be continued. 
4.3.3 Anabolic steroids 
Anabolic steroids (e.g. methandrostenolone) are believed to prevent the loss of bone in 
patients with established osteoporosis52, although this was not confirmed by others53• A 
double-blind controlled study performed by Geusens and Dequeker showed a beneficial effect 
of another anabolic steroid (nandrolone, 19-nor-testosteron) on bone mineral mass at the 
radius54 • In an open study a comparable result was found by Need et al55 56• Later the same 
authors reported an increase in vertebral density in osteoporotic postmenopausal women. The 
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study was designed as an open uncontrolled trial with a follow up of maximal one year57• Of 
importance with respect to BMC and BMD measurements is the observation of Johansen et al 
about the apparent positive influence of soft tissue body composition changes on bone mineral 
assessment during nandrolone therapy58• They reported an increase in lean body mass and a 
decrease in fat mass, and therefore a fat-corrected BMC of for example the forearm is 
indispensable. It was concluded that nandrolone may increase fat-corrected BMC of the radius 
by an increase in bone size with a constant BMD. No significant changes were observed at the 
spine. 
Commonly reported side effects are changes of the voice and an increase in growth of 
facial hair. Orally administrable anabolic steroids (17-alkyl-derivatives) may induce liver 
damage. Nandrolone has to be administrated intramuscularly and it appears not to cause liver 
damage. The place of anabolic steroids in the treatment of osteoporosis remains to be 
elucidated and special attention should be given to their side effects. 
4.3.4 Calcitonin 
Since calcitonin is an inhibitor of osteoclastic activity, a deficiency of this hormone may 
theoretically be involved in the pathogenesis of osteoporosis and, consequently, substitution 
might prevent further bone loss. However. calcitonin levels and reserve have not found to be 
decreased in osteoporosis59 and no low bone mass has been found in patients without thyroid 
glands 5°. On the other hand, Alevivazaki et al reported a case of a young male patient with 
osteoporosis and no detectable plasma concentrations of calcitonin. Genomic clones 
representing his calcitonin gene were analyzed and one single base alteration was detected61• 
Reginster et al demonstrated that intranasal calcitonin can counteract early postmeno-
pausal bone loss62• Several investigators found a bone sparing effect of intranasally given 
calcitonin in the spine but not in the peripheral skeleton63 64• An additional finding is the 
analgesic effects of calcitonin on acute and chronic back pain in different forms of 
osteoporosis 55• 
The major disadvantage of calcitonin is that it has to be injected or has to be 
administrated intranasally, furthermore the costs of this treatment are impressive compared 
with the other treatment regimens for osteoporosis. 
4.3.5 Bisphosphonates 
Like calcitonin bisphosphonates are potent inhibitors of bone resorption. In an 
uncontrolled study it was demonstrated that treatment of patients with osteoporosis with 3-
amino-1-hydroxypropylidene-1,1-bisphosphonate (APD, pamidronate) resulted in an 3% 
57 
annual increase in lumbar spine bone mineral mass66• It has furthermore been shown that 
during treatment for 6 months with tulidronate, another bisphosphonate, bone mineral density 
at the lumbar spine did not significantly change, while the placebo group showed a significant 
decrease of 2.1%67• In two prospective double-blind placebo controlled studies of 
postmenopausal osteoporosis etidronate (Didronel) was given in a cyclical (intermittent) 
scheme: lumbar BMD increased, while the incidence of new vertebral fractures (deformations) 
was lowered68 69• 
APD appeared also to be effective in the treatment of juvenile osteoporosis70 • 
The role of bisphosphonates in the treatment of osteoporosis has to be investigated 
further. but this type of agent appears to be interesting in future treatment regimes. It is 
advisable to restrict this kind of treatment only for severe cases of osteoporosis. 
4.3.6 Fluoride 
It is known that fluoride is able to increase bone formation in vitro and in vivo71 72 73, 
although at higher doses osteomalacia changes of bone have been reported74• Despite the 
impressive bone formation stimulating effects of fluoride. there is controversy about the effect 
of fluoride on the incidence of fractures. There exists some epidemiological evidence that 
non-pharmacological doses fluoride may reduce the incidence of fractures75 76• whereas the 
therapeutic use of fluoride may result in stress fractures of the lower extremities77 and may 
lead to an increase in spinal crush fractures78• Recently it was demonstrated that treatment 
with 75 mg NaF daily resulted in a higher spinal bone mineral mass. but without a decrease of 
spinal fracture79• Moreover. in that study a significant increase of the incidence of non-
vertebral fractures has been observed in the fluoride treated patients. In contrast with these 
findings, Manelle et al found a beneficial effect of fluoride on spinal fracture incidence 5°. 
It is concluded that (long-term) fluoride therapy with 75 mg daily will increase axial 
bone mineral mass, but the higher rate of non-vertebral fractures during the therapy appear to 
make fluoride a dangerous drug. 
4.3. 7 Vitamin D and its derivatives 
Some investigators have suggested that patients with postmenopausal osteoporosis have 
impaired intestinal calcium absorption81 82 83. 1,25-(0H)2 vitamin D3 (calcitriol) is the most 
important hormone in the regulation of the intestinal calcium absorption84 and several studies 
have demonstrated low 1,25-(0H)z D3 serum levels in patients with osteoporosis85 86 87• There 
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is a decreased synthesis of 1~25-(0H)z D3 in response to PTH infusion in women with 
postmenopausal osteoporosis88• Additionally, administration of 1 ~5-(0Hh D 3 to 
postmenopausal women (with or without osteoporosis) restores calcium absorption to 
premenopausallevels89• It is therefore not surprising that the effect of 1,25-(0H)z D3 on bone 
mass has been investigated. The findings have been conflicting, with some reports suggesting 
that 1 ,25-(0H)z D3 is without value in the treatment of postmenopausal osteoporosis90 91, 
while others have found favourable results92 93• In these two latter studies the beneficial effect 
of 1 ,25-(0H)z D3 was achieved by decreasing bone resorption, no increase in bone formation 
could be observed. It is not clear why the results of these 4 studies show a discrepancy, it 
might be due to differences in calcium intake, vitamin D status (or sun exposure) or 
differences in patient selections. 
Higher doses of 1,25-(0H)z D3 (2 .ug/day) caused a marked stimulation of bone 
formation94• However, relatively small doses (0.5 ,ugjday) will normalize intestinal calcium 
absorption, whereas higher doses (>1.0 ,ug/day) with a normal or high calcium intake will 
inevitably result in hypercalcemia and/or hypercalciuria. This small therapeutic range and the 
potential toxicity are disadvantages of this therapy (e.g. in combination with thiazide diuretics 
or a higher calcium intake the risk at hypercalcemia, decreased renal function or formation of 
kidney stones is considerable). 
Finally, most side effects are dose related and further studies of efficacy and safety of 
lower doses of 1,25-(0H)z D3 (up to 0.5 ,ug/day) are necessary, a parenteral route (and higher 
doses) or other vitamin D metabolites might be of interest. 
4.3.8 Combinations of drugs 
Normally the activities of osteoblasts and osteoclasts are rather tightly coupled in order 
to fill in the resorption sites with newly formed bone. The theory behind the combination 
therapy is that by giving the appropriate drugs sequentially and intermittently, it may be 
possible to both stimulate bone formation and depress bone resorption. ADFR stands for 
Activate-Depress-Free-Repeat, which is the sequence of this kind of therapy. The treatment 
starts with an activating {A) agent to recruit~ stimulate and thereby synchronize osteoclasts 
(e.g. oral phosphate, PTH or PTH-fragments, 1,25-(0H)zD3 , thyroid hormone). The newly 
recruited and activated osteoclasts will stimulate by chemical signals adjacent osteoblasts and 
bone formation will take place. Before osteoclasts will have removed large amounts of bone 
they are "turned off' by a depressing agent (D). To depress resorption bisphosphonates (or 
calcitonin) are commonly used. Because osteoclasts will function for 2 to 3 weeks and 
generations of osteoblasts for 2 to 3 months it was thought to be possible to increase bone mass 
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in this way. During the free (F) period new bone might be formed. After this cycle the proce-
dure is repeated (R). 
Several ADFR studies have been published95 96 or are under investigation. Although no 
general agreement exists about the efficacy of ADFR therapy~ it is believed that the main 
effect is probably due to the antiresorptive action. This is illustrated by the results of the 
intermittent etidronate treatment trials mentioned above67 68• 
4.3.9 Exercise 
Physical activity, as the counterpart of immobilization, is commonly accepted to have a 
beneficial role in preserving and probably restoring bone mass97• Despite this consensus there 
are still controversies about exercise. The controversy is probably due to the fact that too 
much exercise is harmful for the skeleton. For example, female marathon runners may become 
amenorrheic and osteoporotic because of the induction of hypoestrogenism98 and infantry 
recruits may easily develop stress fractures99• Also intensive exercise over the age of 50 years 
may be associated with low bone density100• However, most studies report a beneficial role of 
exercise in increasing bone mineral mass101 102 103• 
In a recent report by Kirk et al it was found that long-distance running enhances 
vertebral bone density in premenopausal women, while it does not appear to prevent age 
and/or gonadal hormone dependent bone loss in postmenopausal women104• 
The mechanism by which physical activity exerts its influence on bone remodelling is 
not clear, although it was thought that weight-loading activities were important. The 
observation that also swimming (a non-weight-loading activity) may enhance bone mass is 
interesting and deserves further investigation. 
Exercise seems to be an attractive alternative for drug therapy in increasing bone 
mineral mass, although intensive exercise (overexercise) may be harmful to the bone mineral 
mass. It remains unclear for which group of patients and to which extent exercise is beneficial. 
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4.4 Glucocorticoid osteoporosis 
4.4~1 Introduction 
Supraphysiologic doses of glucocorticoids and endogenous hypercortisolism may induce 
bone loss and ultimately osteoporosis105• The first description of osteoporosis in the presence 
of an excess of endogenous glucocorticoids is of Mooser106• Later Cushing described the 
syndrome bearing his name as a clinical entity107• 
4.4.2 Pathophysiology 
The mechanism whereby glucocorticoids induce bone loss is not entirely understood. 
although evidence is abundant that there is a reduction of bone formation as well as a 
stimulation of bone resorption108 109 110• The effect on the osteoblasts has generally been attri-
buted as a direct inhibitory effect of glucocorticoids, while the increased osteoclastic activity 
has been regarded as a secondary phenomenon, probably due to an elevated parathyroid 
hormone (PTH) secretion or an enhanced PTH activity111 112 113 114 115• Secondary 
hyperparathyroidism in glucocorticoid excess has not been generally found116• Another 
mechanism whereby glucocorticoids may interfere with calcium homeostasis is the diminish-
ment of the absorption of intestinal calcium117 118• This is assumed to be a direct effect of 
glucocorticoids on the gut that may be partly overcome by the administration of 
supraphysiologic amounts of vitamin D(-derivatives)119• 
In addition to an impaired intestinal absorption of calcium an increased urinary calcium 
excretion has been reported in patients treated with glucocorticoids96• which appears as least 
in part to be due to a reduced tubular reabsorption of calcium in these subjects120• Impaired 
absorption of intestinal calcium and an increased calcium loss in the urine may both explain 
the sometimes reported secondary hyperparathyroidism in glucocorticoid-treated patients. 
Furthermore, Feldman has demonstrated the presence of glucocorticoid receptors in 
bone cells121 and negative effects of glucocorticoids on cell growth, RNA, protein and 
collagen synthesis have been demonstrated122 123 • 
Other mechanisms whereby glucocorticoids may interfere with bone metabolism are 
currently under investigation. They include prostaglandins, growth hormone, insulin growth 
factor-I and other growth factors 124 • 
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4.43 The clinical syndrome 
It has been shown that (depending upon dosage) chronic glucocorticoid excess induces 
loss of especially trabecular bone, leading to a high incidence of vertebral compression 
fractures. Children and postmenopausal women are prone to the deleterious effects of 
glucocorticoids. The former because high bone turn-over makes bone more susceptible for 
glucocorticoid action (and because of inhibition of growth), the latter because an excess of 
glucocorticoids, in addition to the negative effects on bone resorption and formation, will 
suppress adrenocortical activity leading to a lower adrenal production of androgens and 
ultimately a lower production of estrogens in adipose and other tissues125• 
Only a few cases are reported about the reversibility of steroid-induced osteoporosis. 
Aloia et al published the cases of two patients (aged 14 and 21 years) showing an increase in 
total body calcium content after treatment of Cushing syndrome, although two older patients 
did not show such an improvement126. Recovery from steroid-induced osteoporosis was con-
firmed by densitometric and histomorphometric data of a case report by Pocock et al127• 
Although the clinical syndrome of glucocorticoid-induced osteoporosis is well known, a 
dose-response curve of steroids on bone mass is difficult to assess. Most studies differ 
considerably with respect to potencies of, dosages of and duration of treatment with 
glucocorticoids. Moreover, the patients are mostly not comparable with regard to the nature, 
severity or duration of the underlying disease, initial bone mass, menopausal state, mobility 
and sex. Despite these shortcomings. Dykman et al. found that fractures occurred when the 
cumulative dose of glucocorticoids exceeded 30 g equivalent of prednisone128• 
Earlier studies addressing this issue have been restricted to patients with rheumatoid 
arthritis, renal disease82 and asthmatics129• We studied the possible effect of glucocorticoids in 
patients at different stages of primary biliary cirrhosis. This was of particular interest because 
it has been assumed that glucocorticoids would be rather strongly contraindicated in these 
patients because of the negative effects of the liver disease itself on bone mass. This study was 
cross-sectional and is reported in Chapter 8. 
4.4.4 Prevention and treatment 
The last decennium studies on therapeutic interventions have been reported. Several 
approaches are or have been investigated in an attempt to: 1) increase bone formation or 2) 
decrease bone resorption or 3) counteract negative interactions of excess glucocorticoid with 
vitamin D action. 
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4.4.4.1 Derivatives of vitamin D 
Several experimental studies showed variable effects of pharmacological doses of 
vitamin D or its derivatives on calcium metabolism during glucocorticoid excess130 131 132• In 
glucocorticoid-treated patients, Hahn et al demonstrated a beneficial effect of 25-
hydroxyvitamin D on calcium absorption, a reduction of iPTH and an increase in forearm 
bone mass133• Braun et a1 showed that placebo-controlled administration of 2 p.g of lo:-
hydroxyvitamin D3 for 6 months to glucocorticoid-treated patients raised calcium absorption 
and reduced the serum iPTH level and the hydroxyprolinuria, while exerting a positive effect 
on the trabecular bone volume as determined with histomorphometry116• 
In a randomized placebo-controlled trial we studied prospectively for 2 years the effect 
of 1 p.g lo:-hydroxyvitamin D3 daily in asthmatic who had chronic treatment with at least 7.5 
mg prednisone daily. The results of this study were presented in a paper read at the second 
International Symposium on Osteoporosis ( 1987) in Aalborg (Denmark) and the study is 
described in Chapter 9. 
The final answer concerning the possible effectiveness of active vitamin D derivatives 
(e. g. lo:-hydroxy- or 1,25-dihydroxyvitamin D3) in the treatment or prevention of 
corticosteroid osteoporosis has not yet been given. 
4.4.4.2 Calcium supplementation 
As stated above treatment with vitamin D or its active derivatives can improve the 
calcium absorption in steroid-treated patients. Therefore it seems likely that adequate calcium 
supplementation may be beneficial in these patients. A daily supplementation of I g of 
elementary calcium decreased the fasting urinary hydroxyproline-creatinine ratio, suggesting 
an inhibition of bone resorption in steroid-treated patients134• In a prospective trial using 
microcrystalline hydroxyapatite versus placebo only a slight reduction in the rate of bone loss 
was observed135• It is surprising that despite the advantages of safety and low cost of calcium 
supplementation in steroid-treated patients relatively little is know about its effects. 
4.4.4.3 Stimulating bone formation 
Because osteoblastic activity is directly suppressed by steroid treatment, stimulation of 
bone formation has been applied in glucocorticoid-treated patients. Fluoride in combination 
with calcium and vitamin D proved not to be effective in preventing steroid-induced bone loss 
in the forearm136• Using bone histomorphometry Meunier et al showed a beneficial effect of 
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fluoride on trabecular bone in glucocorticoid-treated patients137• Although the stimulation of 
osteoblasts by fluoride is widely accepted~ much doubt has risen about the antifracture 
efficacy of this drug 79• 
Other putative bone formation stimulating agents are the anabolic steroids. One of the 
synthetic anabolic substances is nandrolone decanoate of which it was shown that~ whether or 
not. in combination with micro crystalline calcium hydroxyapatite~ it may induce an increase 
in forearm bone mineral density in corticosteroid-treated patients136 139 
4.4.4.4 Inhibiting bone resorption 
Steroid treatment will among other effects result in an increased bone resorption106• 
Several agents are known to be able to inhibit osteoclastic activity and are being investigated 
with regard to their effect in glucocorticoid-induced bone-disease. Ringe et al reported on 38 
glucocorticoid-treated patients randomly allocated to two groups: one group receiving 100 IU 
of salmon calcitonin subcutaneously every other day and a control group140• The calcitonin-
treated group showed a significant increase in forearm bone mineral density while the control 
group lost bone. 
Recently~ it was demonstrated that APD given for one year may prevent bone loss and 
even may increase (transiently?) bone mineral mass in glucocorticoid-treated patients141• 
4.4.4.5 A new glucocorticoid drug 
Recently, a new synthetic steroid (Deflazacort) has been developed. It has been claimed 
to have on weight basis the same degree of anti-inflammatory activity as prednisolone, while 
on the same basis its negative effects on bone mineral mass would be less142 143• It was also 
shown that statural growth proceeded normally in children treated with deflazacort144• 
Evidence was provided that deflazacort produced minimal or no changes in the levels of iPTH 
and nephrogenous cyclic adenosine 3',5'-monophosphate (cAMP), whereas equivalent amounts 
of prednisone did145• However, since the glucocorticoid receptor in bone appears to be the 
same as in other target organs it remains questionable whether it is possible to separate the 
anti-inflammatory effect from the catabolic effect of glucocorticoids146• 
4.4.4.6 Thiazide diuretics 
Glucocorticoids not only reduce intestinal calcium absorption but will also enhance 
calcium excretion. Both mechanisms may lead to an increase of PTH secretion147• The 
hypocalciuric effect of thiazide diuretics in glucocorticoid-treated patients is well 
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documented148~ and with these agents an improvement of the calcium balance was observed17 
18
• However~ no clinical trials assessing the effects of thiazide diuretics on bone mineral mass 
in glucocorticoid-treated patients have been published. 
4.5 Conclusions 
No general agreement exists how to prevent or treat glucocorticoid-osteoporosis. Because 
glucocorticoids interfere at multiple sites with calcium and bone metabolism~ it seems unlikely 
that one single agent is able to counteract all deleterious effects of excess glucocorticoid on 
bone metabolism. 
Several regimens have been investigated with contradictory results (e.g. vitamin D and 
its derivatives)~ or without sufficient evidence of a favourable effect to justify widespread 
clinical application (calcium and thiazide d·iuretics). Still other agents {bisphosphonates~ 
calcitonin and anabolic steroids) appear to offer interesting possibilities but more clinical 
evidence of their effectiveness is needed. 
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Peripheral and axial bone mass in Dutch women. 
Relationship to age and menopausal state 
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Bone mineral density was measured in 171 healthy Dutch females using single 
photon absorptiometry at the forearm (distal and proximal sites) and dual photon 
absorptiometry of the second to fourth lumbar vertebrae. The cross-sectional data 
showed no peripheral bone loss before the menopause and an acceleration of bone 
loss at· an average interval of 15 years after the menopause. Vertebral bone loss was 
characterized by a premenopausal loss starting in the fifth decade ~nd from then 
onwards a fairly constant continuous loss of bone of approximately 7-8% per decade. 
The age-related bone loss for the population studied was 26.7% for the spinal column 
and 33.6 and 32.3%. respectively. for the distal and the proximal peripheral sites. 
Significant correlations were found benveen ail measurement sites, but these relation-
ships seemed too weak to allow the forearm measurements to be a predictor of spinal 
bone mass. 
It is concluded that bone loss follows different patterns at the various skeletal 
sites. Neth J Med 1988;32:226-234. 
Key words: Bone mineral density: Photon absorptiometry; Bone loss: Menopause; 
Normal female 
Introduction 
Osteoporosis is characterized by the occurrence of non-traumatic vertebral frac-
tures and fractures of the appendicular skeleton due to a decrease of mineral bone 
mass and a loss of bone structure. During the last few decades, osteoporosis has 
been recognized as a major health-care problem. especially in elderly women [1]. In 
Correspondence to: F.N.R. van Berkum M.D .. Department of Internal Medicine III and Clinical 
Endocrinology. University Hospital Rotterdam ''Dijkzigt'·. Dr. Molewaterplein 40. 3015 GD. Rotterdam. 
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the Western world, postmenopausal osteoporosis with vertebral compression frac-
tures occurs in 5-15% of all women between 51-60 years of age. In the U.S.A. 
osteoporosis has been estimated to occur in 25% of women of 65 years and older [2]. 
The risk of an osteoporotic fracture depends on the relationship between the 
severity of the trauma and the strength of the bone. which is determined by the 
bone mineral density and the bone structure [3]. 
Increasing interest in this common syndrome has led to the development of 
non-invasive techniques to measure mineral bone mass [4]. Methods such as single 
photon absorptiometry (SPA), dual photon absorptiometry (DPA) and quantitative 
computed tomography (QCT), have provided the opportunity for more detailed 
study of the patterns of bone loss. Nowadays. SPA and DPA are the most widely 
used techniques, while QCT, due to its costs and higher radiation exposure com-
pared to photon absorptiometry, is less attractive for epidemiological studies. At the 
forearm, bone mineral content (BMC) and bone mineral density (BMD) are 
measured with SPA. Although DPA and QCT can be applied for measurements at 
various anatomical regions in the skeleton~ the lumbar spine is the region of interest 
in most studies. There are several reports of cross-sectional studies of bone density 
measured in the forearm and in lumbar vertebrae [5-7]. However, there is no 
agreement on the question of the relative contribution of age and of menopause on 
bone loss in the axial and appendicular bone [8-10]. In other words: does one see 
an accelerated bone loss at the menopause at the various sites of measurement? The 
question whether the results of forearm measurements can predict vertebral bone 
density is another matter for debate [11,12]. 
The aim of the present study was to establish reference values at the various 
skeletal sites for the Dutch female population. information necessary to define 
whether bone density in an individual differs from normal. Furthermore, from these 
cross-sectional data, we estimated peripheral and axial bone loss in relation to age 
and menopausal state. Special emphasis was given to the correlations between the 
values obtained at the various measurement sites. 
Methods 
All participants were female volunteers and gave their informed consent. They 
were recruited by advertising in a local newspaper and from hospital employees. All 
women were white, in good health, ambulatory and not on medication thought to 
influence calcium metabolism. Excluded were those with a history of multiple 
fractures or with chronic back pain. No additional laboratory tests were performed. 
The ages ranged from 21 to 87 years. Women menstruating normally were regarded 
as premenopausal; those who had ceased menstruating for more than 6 months were 
classified as postmenopausal. 
Peripheral bone measurements were carried out at the right forearm according to 
the method described by Nilas et a!. [5] using a Nuclear Data llOOa bone density 
scanner. The forearm is placed in a water bath in order to obtain a constant soft 
tissue equivalent and is transversely scanned with a monochromatic iodine-125 
source emitting photons at 27.5 ke V. The scanning includes both radius and ulna 
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and is corrected for fat tissue. Measurements were performed both distal (SPAct'") 
and proximal (SPApcoxl to the site where ulna and radius are separated by a 
distance of 8 mm. Using this technique, the bone measured distally consists of more 
trabecular bone than that measured proximally [13]. The results are expressed as 
BMD in gjcm2• In our hands, the coefficient of variation based on 50 duplicate 
measurements in normal subjects is 1.9% for the distal site and l.O% for the 
proximal site [14]. 
Axial bone mass was assessed at the lumbar spine (DPA,pinol with L 2-L4 as the 
region of interest. Measurements were done with a Novo BMC-Iab 22a scanning 
device as described by Kr0lner and Nielsen [15]. This instrument uses a dichromatic 
Gadolinium-153 radiation source with emissions at 44 and 100 keV. The technique 
is based on the difference in attenuation of the two photon energies through a 
medium consisting of different materials, in this case bone and soft tissue. After 
calibration, the BMC is expressed in grams hydroxyapatite (gHa). Dividing the 
BMC by the projected region of interest results in BMD (gHajcm2 ). In order to 
correct for the interindividual differences due to differences in skeletal size, the 
results are expressed in BMD. In contrast, in longitudinal studies, use is often made 
of the BMC. The coefficient of variation calculated on duplicate measurements of 
the lumbar BMD of 20 osteoporotic patients in our laboratory is 2.3% [14]. 
In order to differentiate the effects of aging and menopausal state on the bone 
mineral mass, we divided the women into four groups: 71 premenopausal women 
(group 1), 35 women less than 10 years postmenopausal (group 2), 39 women 10 to 
19 years postmenopausal (group 3), and 24 women postmenopausal for 20 years or 
more (group 4). Two women could not be classified. The Student's t-test was used 
for unpaired data. A level below 0.05 was regarded as significant. Linear regressions 
and correlations were calculated using the method of least-squares. The number of 
data were too small for a meaningful analysis by segmented regressions. 
Results 
In Table 1, the distributions of height, weight and the results of the bone 
measurements are listed according to age. Females in the fourth decade had a 
significantly lower height than the women in the third decade. After the fifth decade 
there was a further, but not significant, decline in height when compared with the 
average height in the preceding decade. The peripheral sites showed no age-related 
bone loss before the fifth decade in contrast to the vertebral bone mass. which 
decreased significantly from the fourth decade onwards. After the average age of 45, 
there was loss of bone mass at all three measurement sites. An acceleration of 
peripheral bone loss was seen in the sixth decade, while axial bone loss was, once 
started, rather constant through all decades studied. In the last age-group studied, 
the peripheral bone mineral mass showed no significant decrease as compared with 
the preceding decade. Omitting the postmenopausal women from the fifth decade 
group and the premenopausal women from the sixth decade group did not essen-
tially alter the respective percentages of bone loss (data not shown). The overall 
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TABLE 1 
Weight. height and bone densities according to decade. 
Decade Weight Height SPAdist SPAprox DPAspine 
(kg) (em) (gHajcm2 ) (gHajcm2 ) (gHajcm2 ) 
Decade 3 
age 25±3.2 (n = 9) 67± 8.8 172±5.4 1.19±0.14 1.55±0.14 1.01±0.07 
Decade4 
age35±2.4(n~14) 62± 9.3 167±5.5" 1.13±0.14 1.47 ±0.16 1.02±0.07 
NS NS (7%) a 
Decade 5 
age 45 ±2.8 (n ~ 32) 66± 11.4 168±6.3 1.16±0.15 1.49±0.15 0.95±0.09 
(9%) b (6%) a (7%) a 
Decade 6 
age 54±2.9 (n =54) 66± 7.4 166±5.5 1.05±0.15 1.39±0.18 0.89±0.12 
(17%) b (17%) b (8%) a 
Decade 7 
age 64±2.9 (n ~ 41) 64± 8.8 165±4.6 0.85±0.14 1.13±0.19 0.81±0.12 
NS NS (7%) il 
Decades 8+9 
age 75±4.2 (n = 21) 65± 8.0 163±5.1 0.79±0.14 1.05±0.18 0.74±0.10 
SPAdist and SPAprox =single photon absorptiometry of the distal and proximal forearm, respectively: 
DPA~pine =dual photon absorptiometry of the lumbar spine (L 2 -L4 ). 
In parentheses: % bone loss compared with the preceding age-group. The data are expressed as 
mean± SD. a P < 0.05: b P < 0.002. 
bone loss comparing the age groups 20-30 years and 70-87 years was 26.7% for the 
vertebrae, 33.6% for the distal forearm site and 32.3% for the proximal forearm site. 
Rearranging the data according to the number of years since menopause (Table 
2) enabled us to rule out the influence of data from relatively young post-
TABLE 2 
Weight. height and bone densities according to menopausal state. 
Group Weight Height SPA rust SPAprox DPA~-pine 
Group 1 
(n ~ 71) 66±9.6 167±6.7 1.14±0.15 1.49±0.15 0.96±0.10 
(10%) b (6%)" (8%) b 
Group 2 
(n ~ 35) 67±8.2 166±6.0 1.03±0.16 1.40±0.17 0.88±0.13 
(17%) b (20%) b (7%)" 
Group 3 
(n ~ 39) 65±8.6 165±4.4 0.86±0.15 1.12±0.20 0.82±0.12 
NS NS (9%)' 
Group4 
(n = 24) 65±8.6 163±5.0 a 0.80±0.14 1.07 ±0.17 0.75±0.11 
See legends to Table 1. 
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Fig. L The individual values (n =171) for BMD at the three measurement sites plotted as a function of 
age; DPA~pinc =dual photon absorptiometry of the lumbar spine (L 2 -L4 ); SPAdi&t and SPAPT<>x =single 
photon absorptiometry of the distal and proximal forearm. respectively. The results are expressed in 
grams h)ldr~xyapatite per cm2• The shaded areas denote the 95% confidence limits. 
menopausal women on the results of women under the age of 50. In this way the 
effect of menopause on bone mass can be studied in more detail. The subjects were 
classified in groups 1 to 4 (see Methods). Group 2 was compared with group 1 (all 
premenopausal women). Groups 3 and 4 were compared with the preceding groups. 
The differences between the groups were expressed in percentages. Appendicular 
bone loss was maximal in group 3. This is again in contrast to the vertebral bone 
TABLE 3 
Correlation matrix of bone densities between the various skeletal sites. 
DPAspinc SPActist SPA!)I"OX DPA~pinc SPAdiM SPAprox 
Group 1 Group 2 
DPA~pinc 0.49 0.43 0.67 0.58 
SPAct,~t 0.86 0.87 
Group 3 Group 4 
DPAspinc 0.23"- 0.34"- 0.46 0.59 
SPAct;~t 0.87 0.88 
Correlations between single photon absorptiometry of the distal and proximal forearm (SPActist and 
SPAprox• respectively) and dual photon absorptiometry of the lumbar spine (DPAspinc)· The subjects are 
divided iilto groups as_ defined in Methods. All correlations P < 0.0001. except: "- P < 0.05. 
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Fig. 2. The individual values (n = 98) for BMD at the three measurement sites plotted against years since 
menopause: DPAspine= dual photon absorptiometry of the lumbar spine (L 2 -L4 ): SPAdist and SPAprox: 
single photon absorptiometry of the distal and proximal forearm. respectively. The results are expressed 
in grams hydroxyapatite per cm2• 
loss, which appeared to be constant between all groups. Therefore, comparison of 
Tables 1 and 2 only results in minor differences. The bone mineral densities are 
plotted against age in Fig. l. The plot shows the individual measurements and the 
95% confidence limits. The figure suggests a breakpoint around the age of 50. 
However, no significant difference in slope was detected. In Fig. 2, the results of 
bone mineral density are depicted against the number of years since menopause. 
Again there were no principal differences with the original plots. 
The correlations found between BMDs measured at the different sites are given 
in Table 3. In this table, the population studied is divided into 4 groups defined as 
mentioned in the Methods section. In all groups vertebral bone mineral density was 
significantly correlated with the densities at the other measuring sites. This correla-
tion was strongest for the women in group 2. As could be expected, the best 
correlations were found between the results of the two peripheral sites (SPAdis.t and 
SPA prox ). There were no· significant correlations between bone density parameters 
and Quetelet index (data not shown). 
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Discussion 
This paper contains data on bone densities in 171 healthy Dutch women. The 
study was undertaken to obtain reference values for the normal Dutch female 
population. Reference values are not only influenced by geographic and racial 
factors [16], but also by differences in techniques. Several cross-sectional studies 
have provided evidence that premenopausal loss of bone in the appendicular 
skeleton is low or absent and that bone loss during the early postmenopausal years 
is accelerated [6,7,10]. Our results show that the acceleration of the peripheral bone 
loss did not occur shortly after the menopause, but was maximal about 15 years 
after the menopause. Both distal and proximal sites in the forearm showed this 
pattern of bone loss, which may indicate that during that period mainly cortical 
bone is lost. It has been assumed that the relatively moderate decline observed in 
the 5th decade could be influenced by the presence of premenopausal women [10]. 
However, this moderate peripheral bone loss is also seen when the data are 
rearranged according to the number of years since menopause. This is in contrast to 
our findings with respect to the rate of loss of bone in the axial skeleton. Here the 
loss is already seen before the menopause and is constant thereafter. 
Some investigators found that axial bone mass follows a linear decrease with age 
[6,17], while others suggested a different pattern with a peak bone mass around 35 
years [7] and a sharp perimenopausal decline [18]. However, a premenopausal axial 
bone loss has not been found in all studies [19]. These discrepancies in the literature 
concerning the bone loss in the vertebral column are not only due to technical 
differences but also to a lack of uniformity in defining menopausal state and 
differences in inclusion and exclusion criteria. 
Mazess collected densitometric data from several laboratories in the U .SA. and 
found a diminution in the spinal bone mass prior to the usual age of menopause, 
but not during young adulthood [8]. That study could not exclude the influence of 
the data of women having an early menopause on this premenopausal bone 
diminution. Our study confirmed this vertebral bone loss before the age of 50, even 
after the exclusion of women who were postmenopausal before the age of 50 years. 
Evidence in favour of this observation is obtained from longitudinal studies in pre-
and_ postmenopausal women [20,21]. We found no acceleration of axial bone loss 
during the sixth decade. Once started, the rate of vertebral bone mineral loss 
remained fairly constant during life with a loss of approximately 7% per decade. 
However, in the later decades this rate of bone loss may be an underestimation (see 
below). An explanation for the spinal premenopausal bone loss may be found in a 
decreasing oestrogen production shortly before menses ceased [22]. 
The different patterns of bone loss at the various sites may depend on differences 
in bone composition but also on differences in skeletal function. The spinal column 
is weight-bearing and is affected by other mechanical forces than the forearm. A 
recent study revealed that trabecular bone accounts for approximately 25% of the 
bone mineral mass in whole female vertebrae [23]. The trabecular bone percentage 
in the forearm is estimated at the proximal and distal site at 7 and 25%, respectively 
[5,13], but these percentages are not firmly established. Photon absorptiometric 
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techniques cannot differentiate between cortical and trabecular bone at one site, nor 
between the bone itself and calcifications in the region of interest, which will be 
discussed below. Direct measurements of the bone compartments at the various 
skeletal sites can be done with QCT. Moreover, for definitive conclusions concern-
ing patterns of bone loss in these compartments a longitudinal study will be 
necessary. 
The correlations between peripheral and vertebral bone mineral density obtained 
in the normal population may be changed in various metabolic bone diseases [24]. It 
has, therefore, been suggested that peripheral measurements can only predict axial 
bone mass in normal individuals. Pocock showed that correlations between the 
results of forearm and axial measurements of about 0.66 are insufficient to predict 
axial bone on the basis of forearm mineral bone mass [12]. Our data show that the 
relationships between the peripheral and axial densities differ considerably between 
the groups studied. This could be explained by the already mentioned differences in 
patterns of bone loss at these measurement sites. In this respect, the possible 
interference by spondylosteoarthritis with the results obtained with DPA at the 
lumbar spine has also to be mentioned [7]. Inevitably, aortic calcifications andjor 
osteoarthritic lesions [25] within the region of interest will spuriously increase the 
results obtained by DPA. Unfortunately, both aortic calcification and osteoarthritic 
lesions increase with age, and because bone mass falls with age the relative influence 
will be greater in elderly women and in women with a low bone mass. 
The percentage of axial bone loss found in our study is comparable to that 
observed by others [8,17], but is probably an underestimation of the actual (trabecu-
lar) bone loss, due to the above mentioned opposing effect of calcified lesions. 
Although these lesions will heavily influence reference values, exclusion of women 
with osteoarthritis of varying severity would result in variably biased reference 
values. 
The consistent and rather high correlations between SPAdist and SPAprox found 
in all subgroups of the normal female population studied, raise the question whether 
these results may not provide us with essentially the same information. Previously, 
we found that it was impossible to differentiate a group of osteoporotic patients 
from normal females using the proximal measurement, while the distal measurement 
allowed such distinction [14]. The superiority of the distal over the proximal 
measurement can be explained by the higher content of trabecular bone in the distal 
forearm, which is generally considered to be affected earlier by postmenopausal 
osteoporosis than cortical bone. 
In conclusion, this study provides evidence for different patterns of bone loss at 
the three skeletal sites, whereby the forearm measurements show an acceleration of 
postmenopausal bone loss. Finally, these data indicate that forearm densitometry is 
not suitable as a screening technique for detecting low vertebral bone mass. 
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ABSTRACT 
We compared different methods of bone densitometry in women with spinal osteoporosis and normal sub-
jects to assess their discriminatory capability. The methods used included: quantitative computed tomogra-
phy of the spine (QCf) specified as to trabecular (QCTtrab) and cortical bone (QCTc0 rJ, dual-photon ab-
sorptiometry of the spine (DPAspine), single-photon absorptiometry of the distal and proximal forearm 
(SPAdist and SPAprox), and quantitative roentgen microdensitometry of the phalanx (QMD). A total of 2S 
postmenopausal osteoporotic women and 24 healthy comparison subjects matched for age and years since 
menopause were studied. In the osteoporotic group an average decrement of the axial bone mineral density 
of -SOOJo (p < 0.001) and -20% (p < 0.001) were observed for QCTtrab and QCTcort• respectively. For 
DPAsplne• SPAdistt SPAprox• and QMD the difference between normal and osteoporotic subjects was -200Jo 
(p < 0.001), -120Jo (p < 0.05), -7% (NS), and -6% (NS), respectively. With the peripheral measurements 
(SPA and QMD), alone or in combination, no adequate discrimination bc.tween women with or without ver-
tebral compression fractures could be obtained. Although QCTtrab'showd the highest diagnostic sensitivity 
(81 %). it appears not to be superior to DPAspine· Combinations of the various a.:xial and peripheral measure-
ments did not result in an essentially better sensitivity. 
In normal women as well as in osteoporotic individuals the trabecular and cortical QCT measurements 
showed two opposite trends, suggesting an increase in cortical and a decrease in trabecular density from Ll 
to L3. 
INTRODUCTION 
T HERE IS CURRENTLY DISCUSSION abOUt the optimal site and method for determining the risk of osteoporotic 
fractures. (Ul Moreover, because trabecular bone is 
thought to be more sensitive to hormonal deficiencies and 
metabolic bone disease than cortical bone, m it may be 
preferable to measure exclusively trabecular bone instead 
of a combination of trabecular and cortical bone. (•J Addi-
tionally, disagreement exists as to the best skeletal site and 
type of measurement for follow-up studies.(~7 l 
In an attempt to identify the measurement of choice, we 
selected a group of women with spinal osteoporosis and 
compared the results of various methods of bone density 
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assessment with the results in a group of normal subjects 
matched for age and years since menopause. The correla-
tions between these various measurements were studied, 
and discriminant analysis on the data was performed. 
MATERIALS AND METHODS 
A total of 25 postmenopausal osteoporotic women and 24 
healthy women were studied. The women were defined as 
having osteoporosis if they had radiographic evidence of at 
least one vertebral compression fracture without a history of 
significant trauma. A vertebral body deformity was con-
sidered a fracture when the anterior height or. in some 
cases for the lumbar vertebrae, the middle height was 
equal to or less than 80o/o of the posterior height of the 
vertebral body. History, physical examination, and routine 
laboratory tests were performed to exclude known causes 
of osteoporosis. The normal postmenopausal women were 
recruited by advertisement. They were included in the 
study if there was no radiographic evidence for vertebral 
fractures. The osteoporotic and normal subjects were pro-
spectively matched according to age and years since meno-
pause (for both parameters a difference up to 5 years was 
accepted). Characteristics of the participants arc given in 
Table 1. All women gave informed consent. 
Photon absorptiometry 
All participants were measured with.photon absorptiom-
etry as described elsewhere. ' 31 Peripheral bone measure-
ments were done at the right forearm according to the 
method described by Nilas et a!. ' 9 ' using a Nuclear Data 
llOOa bone density scanner. Measurements were per-
formed both distally (SPA<~,1sJ and proximally (SPAP,oJ in 
the right forearm. With this technique the bone measured 
distally consists of a higher proportion of trabecular bone 
than proximally. no) The results are expressed as bone min-
eral density (BMD) in arbitrary units (U/cm2). In our 
hands the coefficient of variation based on 50 duplicate 
measurements in normal subjects is 1.9% for the distal site 
and 1.0% for the proximal site. 
TABLE I. CHARACTERISTICS OF THE PARTICIPANTS'" 
Normals Osteoporotics 
Characteristic (n = 24) (n = 25) 
Age (years) 60.5 ± 5.0 59.5 ± 5.0 
Menopause (years) 50.0 ± 2.9 48.0 ± 5.7 
Years since menopause 10.6 ± 5.6 11.5 ± 5.3 
Height (em) 164 
"' 
3.9 !63 ± 7.9 
Weight (kg} 66.3 ± 5.8 68.5 ± 13.7 
~Mean values :t SO. None of the parameters showed a signifi-
cant difference between the two groups of women (Mann-Whitney 
V test): 
VAN BERKUM ET AL. 
For the photon absorptiometric measurements of the 
lumbar spine (DPAspinJ, L,-L was the region of interest 
(ROI). Measurements were done with a Novo BMC-lab 
22a scanning device as described by Kr0lner and Niel-
senY n Results were expressed as g hydroxyapatite (Ha) 
for L2-L4 (BMq or as g Ha per em' (BMD). The coeffi-
cient of variation calculated on the basis of duplicate mea-
surements of the lumbar BMD of 20 osteoporotic patients 
in our laboratory is 2.3%. 
QCT measurements 
A Philips Tomosca.n-350 (120 kVP, 200 MA) was used 
for the QCT measurements of the lumbar vertebrae. The 
midplane scans of Ll-L3 were selected from the lateral 
scanogram using a modification of the method of Kalender 
et al. < '" Instead of semiautomatically, we selected each 
midplane scan manually. Subsequently, these scans, with a 
slice thickness of 6 mm, were used to select the cortical and 
trabecular region of interest (Fig. l)Yl' The cortical ROI 
was defined as follows. From the center of gravity of the 
vertebral body radial lines were drawn through the cortical 
area. The area comprising the basivertebral vessels and 
their surroundings was excluded. The highest cr value on 
the radial lines was considered to correspond to the center 
of the cortex. Along the radial line. the inner and outer 
border of the cortex was defined between two consecutive 
points with the largest difference in cr values. The corti-
cal ROI consisted of all pixels measured between the deter-
mined outer and inner border, using all radial lines (ap-
proximately 120 in number). 
The trabecular ROI consisted of an approximately circu-
lar area, excluding (I) the sector comprising the basiverte-
bral vessels and their surroundings. and (2) a subcortical 
area 5 pixels wide. The surface area of the ROis depended 
on the vertebral size and varied from 1.18 to 2.93 em' for 
the cortical and 3.05 to 6.63 em' for the trabecular ROls. 
The CT values obtained were converted tO equivalent con-
centrations of dipotassium phosphate (mg K,HPO. per ml, 
BMD) using the cr values of a simultaneously measured 
phantom placed underneath the subjects. The phantOm 
contains tubes with various concentrations of K,HPO. (25-
400 mg/ml) representing the density range to be expected 
in human vertebral bone. 
The (short-term) coefficient of variation for the Qcr 
measurement was obtained by scanning 10 osteoporotic 
women twice with a interval of 30-60 minutes. This proce-
dure included repositioning of the patient on the CT table. 
The whole group w;J.S scanned within 4 months. Under 
these conditions the coefficient of variation for duplicate 
cortical and trabecular QCf measurements is 2.5 and 
2.7%, respectively, for L2-L3. 
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FIG. I. CT scan of L3 showing the cortical and trabecular ROI. respectively. For details sec Materials and Methods. 
Quantitative Roentgen microdensirometry 
of the phalanx 
The BMD at the middle phalanx of digital II of the right 
hand was measured by QMD. 1'"! This technique uses two 
standardized radiographs of the selected phalanx and a si-
multaneously radiographed aluminum reference wedge. 
Because the two radiographs are made in planes perpendic-
ular to each other. an estimation of the bone mineral con-
tent per unit of volume can be achieved. The radiographs 
are analyzed by an optical microdensitometer. The results 
are expressed in mm aluminum Eq/mm'. In normal people 
the coefficient of variation was found to be less than 
PloY~! 
Statistical analyses 
Comparisons of the results of the various methods of 
bo¥ ntineral measurement were done with Wilcoxon's 
two-sample test. The significance of the trend in the mean 
BMD of Ll-L3 as measured by QCI was assessed by the 
rank test of Friedman. To investigate whether combina-
tions of the various techniques of bone mineral assessment 
perform better in detecting spinal osteoporosis than each 
technique on its own, Fisher's linear discriminant analysis 
method was used. Finally, standard (Pearson) correlation 
coefficients were calculated between the results of the den-
sitometric measurements. P values smaller than 0.05 were 
considered significant. All P values are two-tailed. 
RESULTS 
Table 2 shows the mean values for each type of measure-
ment in the osteoporotic and normal groups. Because of 
technical difficulties, such as inadequacy in the localization 
of the ROI or vertebral collapse (in the osteoporotic group 
only), the number of observations may be lower than the 
number of participants. As can be seen in Table 2, all 
means of the axial measurements w.ere (highly) signifi-
cantly lower in the group with spinal osteoporosis. The 
means of the appendicular measurements were also lower 
in the osteoporotic women; however, the difference was 
only significant for SPAd;,;1• The individual data of the 
axial measurements are depicted in Fig. 2. 
To investigate the potential contribution of combina-
tions of the various techniques in detecting spinal osteopo-
rosis. several discriminant analyses were performed. The 
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TABLE 2. AsSESSMENT OF MlNERAL BONE MASSn. 
Normals Osteoporotics 
AJcial 
DPA 
BMC (g Ha per L2-L4) 36.9 ± 5.7 (22) 28.9 ± 7.2 (23)b 
BMD (g Ha per em~) 0.82 ± 0.10 (22) 0.66 ± O.ll (23)b 
QCT (mg K2HP04 per ml) 
Trabecular L1 91.1 :::1;: 27.0 (22) 45.9 :::1;: 25.4 (12)b 
Trabecular L2 83.5 :::1;: 29.0 (23) 40.8 ± 20.3 (23)b 
Trabecular L3 78.7 ± 26.6 (23) 36.2 ± 22.5 (24)b 
Mean trabecular L2 + L3 81.1 ± 27.4 (23) 40.3 ± 19.4 (22)b 
Cortical Ll 261.9 ± 36.1 (23) 205.3 :::1;: 35.2 (12)b 
Cortical L2 305.4 :::1;: 38.5 (23) 242.8 ± 55.6 (23)b 
Cortical L3 314.3 :::1;: 49.8 (23) 248.5 ± 44.4 (24)b 
Mean cortical U + L3 309.8 ± 42.6 (23) 247.1 ± 47.8 (22)' 
Peripheral 
SPA (U/cm') 
Distal 0.89 ± 0.18 (23) 0.78 ± 0.13 (2A)' 
Proximal 1.21 ± 0.23 (23) 1.13 ± 0.18 (24) NS 
QMD (mm Al Eq/mm') 0.490 :::1;: 0.52(23) 0.462 ± 0.39 (25) NS 
~Mean values :::1:: SD. Number of observations in parentheses. Significance determined by Mann· 
Whitney U test. 
bp < O.OOL 
0p < 0.05. 
NS "" not significant. Mean trabecular L2 + L3 denotes to the mean of the trabe<;ular QCT 
measurement of L2 and L3. Mean cortical L2 + L3 denotes tO the mean of the cortical QCT 
measurement of L2 and L3. 
r---l(~a~c;T:,:o~"~---"1 mg/ml 400 r---~~O;P~A,~,,~o;•r---~ g/cm~ I 1,2 mg/ml 150 
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FIG. 2. The results of the individual axial densitometric measurements. The horizontal lines denote the means. Details 
are given in Table 2. 
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QCT values of L1 were not included, leaving 23 cases in 
the osteoporotic and 22 in the control group. The best dis-
criminating combination of the appendicular measure-
ments could classify only 590'/o of the subjects correctly. Of 
the axial measurements, QCT1rab ofL2 and L3 appeared to 
have the highest percentage correctly classified (79-81 %), 
followed by DPA~pine with 70%. Adding more variables in 
a discriminant model already containing QCTtrab did not 
result in essential improvements. 
Table 3 shows the correlations among the results ob-
tained with the densitometric techniques. QCT1rab results 
showed a good correlation with DPA results for normal 
women (r = 0.76) and a moderate correlation for the os-
teoporotic women (r = 0.45). On the other hand, QCTcort 
versus DPA showed the opposite trend (r = 0.49 and 0.70, 
respectively). For both groups a moderate correlation was 
found between QCT1rab and QCTcon (r = 0.57 and 0.49, 
respectively). Except for SPActi~t versus SPAprox (r = 0.88 
and 0.69), the results of the various appendicular measure-
ments correlated moderately. at best. In the osteoporotic 
women the correlations between QMD and both SPA mea-
surements were even very low. In normal women both 
DPAspine and QCT1rab correl::ned with SPActist and 
SPAprox {0.62 < r < 0.70). The results of none of the ap-
pendicular measurements showed a significant correlation 
with QCTcon· 
The results of the QCT measurements of the trabecular 
part of the vertebrae show a significant decrcase in the 
mean BMD from Ll to L3 (Table 2). In contrast, there-
sults of the cortical measurements show an increase in the 
mean BMD from LI to L3. For the trabecular ROl the 
mean BMD decreased significant from Ll to L3 for the 
two groups combined as well as for the control group. The 
results of the cortical ROI showed a significant increase in 
the mean BMD for both groups. The QCT densities of Ll-
L3 were ranked for each subject to assess individual 
trends. The mean ranks, which are given in Table 4, were 
compared with Friedman's test. 
DISCUSSION 
The current study confirms earlier reports0 -~· 16- 19 ) that 
BMD measurements of the axial skeleton discriminate 
women with spinal osteoporosis from normal women 
better than do measurements of the appendicular bone 
mass, like SPA and QMD. Of the axial measurements 
QCTtrab appears to have the highest predictive value with 
approximately 80%, followed by DPAspine with 70%. 
Nevertheless, such a difference in diagnostic capabilities of 
QCTtrab and DPAspine must be confirmed in larger series 
of osteoporotic women and matched controls. 
The substantially larger decrement observed with 
QCTtrab (-50%) compared with DPAspine (-20%) was in 
agreement with that found by several other investiga-
tors''0-~') and suggests once more the higher diagnostic po-
tential of direct trabecular measurements in detecting spi-
nal osteoporosis. Although our study differs from the 
studies quoted by the fact that our normal subjects were 
matched to the osteoporotic women according to age and 
years since menopause, still the differences found between 
the two groups are as large as found by others. Further-
more, a significant difference of 20% in the cortical verte-
bral BMD was observed. That Jones et al. <»)were not able 
to detect such a difference between normal women and os-
teoporotic patients is probably because they used a com-
pletely different method to estimate compact bone density 
values. Additionally, differences in the selection and num-
ber of participants may have been important. Despite these 
differences it is clear that QCTcon does not provide impor-
tant additional information in this cross-sectional study. 
The significance of this parameter, however, needs to be 
assessed in larger series. 
Previous reports suggested that the average CT values of 
spongious bone of a single slice from various venebral 
bodies are relatively constant.<~o.m However, our data in-
dicate a systematic decrease in trabecular BMD from Ll to 
L3; on the other hand, the conical BMD appears to in-
TABLE 3. CORRELATIONS BETWEEl'o" THE VARIOUS MEASUREMENTS IN BoTH GROUPS;, 
DPAspin" QCT/rab QCTcon SPAdisr SPAprox QMD 
DPAspine 
QCT!rab 0.76 
(0.45)" 
QCTcon 0.49• 0.57 
(0.70) (0.49)" 
SPActist 0.62 0.70 0.16 NS 
(0.47)" (0.44)" (0.40) NS 
SPAprox 0.66 0.69 0.22 NS 0.88 
(0.34) NS (0.43)• (0.34) NS (0.69)" 
QMD 0.29 NS 0.41* 0.29 NS 0.53• 0.58 
(0.05) NS (0.23) NS (0.24) NS (0.15) NS (0.27) NS 
~All correlations p < 0.01 except(*) p < 0.05; NS "' not significant. The correlation coeffidents of the osteopo-
rotic group are in parenthese:>. QCTtrab represents the mean trabecular density of L2 and L3; QCTcon represents the 
mean cortical density of L2 and L3. 
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TABLE 4. RESULTS OF FRIEDMAN's TEST PERFORMED ON THE QCT 
MEASUREMENTS OF Ll TO L3 
Group N 
Trabecular Combined 32 
Controls 22 
Osteoporotics !0 
Cortical Combined 32 
Controls 22 
Osteoporotics 10 
crease. In our CT system a correction for beam hardening 
is implemented for the total range of possible attenuation 
values (for all detectors). This is achieved by using plexi-
glass (PMMA) bars of increasing thickness that cover the 
whole fan array. Therefore, differences in CT values can-
not be explained by differences in beam hardening associ-
ated with changes in overall cross-sectional thickness of the 
body. In addition, preliminary results obtained with DPA 
also showed an increase in BMD from L2 to L4 (data not 
shown). It remains to be elucidated whether there exists a 
parallel between our data and those obtained by Nottestad 
et a!. P~~ They observed in human cadaver vertebrae an in-
crease in the mean total body calcium content of the whole 
vertebral body from Ll to L3 and simultaneously a de-
crease in the percentage of trabecular bone calcium. 
Widely differing correlations among the results of the 
axial measurements and between the results of the axial 
and appendicular measurements have been reported in ap-
parently similar groups of patients. 1"·'9 •201 In general, as is 
the case in our study, the best correlations have been 
found between the results of various axial measurements, 
but moderate to even low correlations have been observed 
between the data derived from the axial and appendicular 
skeleton, respectively. It may be o: significance that in os-
teoporotic subjects a better correlation between the results 
of DPA and QCTcon was observed than in normal woman. 
This may indicate that in established spinal osteoporosis 
DPA results reflect mainly vertebral cortical bone. 
In our study the highest correlation between the results 
of a peripheral and an axial measurement is 0. 70 (SP Adist 
versus QCT1rabl· However. the implication of this appar-
ently reasonably good correlation is that a measurement at 
one site can account for approximately 490Jo of the vari-
ability (r') at the other site. Therefore. peripheral measure-
ments are not suitable to predict axial BMD. 
In conclusion, measurements of spinal trabecular bone 
density by QCT allow the best discrimination between 
healthy women and women with spinal osteoporosis. Fur-
thermore, in this study peripheral and axial cortical mea-
surements added little information on the degree of spinal 
osteoporosis. 
Mean rank: Ll-L2-L3 p 
2.56-1.94-1.50 0.0001 
2.64-1.86-1.50 0.001 
2.40-2.10-1.50 NS 
1.09-2.19-2.72 0.00001 
1.05-2.18-2.77 0.0001 
1.20-2.20-2.60 0.006 
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ABSTRACT 
Endogenous estrogen, androstenedione and sex hormone binding globulin (SHBG) levels 
were studied in relation to peripheral and axial bone mineral density (BMD) in 43 postmenopausal 
women (aged 68-72 years). From a larger population study two groups of women were selected with 
low and high endogenous estrone (E1) levels, respectively. The group with low estrone levels showed 
a lower BMD at all measurement sites, significantly so at the peripheral sites. Each group was 
divided further into 2 groups based on their SHBG levels. The BMD of the resulting 4 groups was 
tested along a ranking of increasing estrogen bio-availability. In the low-E1/high-SHBG-group a 
significantly lower forearm BMD was found than in the other groups. The body mass index (BMI) 
was significantly higher in the high-E1 group, Correction for the differences in BMI led to the loss 
of the differences in BMD between the low- and high-E 1 groups and also of the differences in 
BMD between the low-E1/high-SHBG and the high-E1/low-SHBG subgroups. When the low- and 
high-E1 groups were subdivided according to their BMI values the BMD of the low-E1/low-BMI 
subgroup was at all sites and with all methods considerably lower than that of the other three 
subgroups. In women around 70 years of age BMI is a main determinant of bone mass acting 
through its influence on estrogen and SHBG formation as well as through other mechanism(s). 
INTRODUCTION 
In the perimenopausal years endogenous estrogens are important for the conservation of the 
bone mineral mass1• In the early postmenopausal years bone mineral density (BMD) appears to be 
more related to estrogen deficiency than to age2• but this relationship is less clear in the late 
postmenopausal years3 •4. Riis et al5 found no differences in the levels of estrone (E1), estradiol (Ez) 
and androstenedione (A) nor in fat mass between groups of 70 year old women with and without 
osteoporotic fractures, whereas among early postmenopausal women (45-54 years old) the subjects 
with rapid forearm bone mineral loss had significantly lower E1, E2 and fat mass than the slow 
losers of bone mineral. 
Apart from the postmenopausal endogenous estrogen level itself the estrogen binding 
protein (sex hormone binding globulin; SHBG) may be of importance for the bone conserving 
activity of estrogens as the fraction of circulating sex steroids that is bound to SHBG is not avail-
able for receptor binding nor for metabolism6• Comparing elderly women (average age 75.6 years) 
with hip fractures to age-matched controls Davidson et al.7 found no differences in E2, E1 and 
testosterone (T). However, SHBG levels were significantly higher and free Ez and free T and 
percent ideal weight were lower in the osteoporotic group. The differences in SHBG • free Ez and 
free T disappeared when a subgroup of the fracture patients was matched according to percent ideal 
body weight. Subsequently, they reported on 30 women (aged 63 ± 1 years) with and without spinal 
fractures and found no lower levels of sex steroids (E2 , E1, T, A and DHEA(S)) and no higher 
SHBG in the osteoporotic group4• Based on a population study van Hemert et al. observed an inverse 
relationship between the level of SHBG and metacarpal bone mass in 746 normal ~omen aged 53-76 
years8.In a subgroup of women of 65 years and over a significantly higher SHBG level was found in 
women with osteoporotic fractures (mainly vertebral) compared to a group without fractures, while 
age and body mass index (BMI) did not differ between the 2 groups. In adults the SHBG level is 
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rather strongly inversely correlated to body weight and positively to age9 •10• Exogenous estrogen 
raises the SHBG level, while exogenous androgen lowers it11, 12• 
In the present study we investigated the influence of the SHBG level and BMI on 
peripheral and axial bone mineral mass in two groups of women, aged 68-72 years, selected from a 
normal population8 • 13 according to their low and high serum El level, respectively. 
TABLE I: Characteristics of the participants. 
Age (years) 
Years since menopause 
Height (em) 
Weight (kg) 
Body Mass Index (kg/m"'-) 
Estradiol (pmol/1) 
Androstenedione (nmol/1) 
SHBG (nmol/1) 
low serum E>. 
n = 23 
68.3 ( 1. 9) 
17.8 ( 1. 0) 
164.3 ( 1. 2) 
68.3 (1. 9) 
25.7 (0. 6) 
17.8 (3.9) 
2.5 (0.3) 
99.9 (9.5) 
high serum E>. p-value 
n = 20 
68.2 ( 1. 9) NS 
15.4 (0. 8) NS 
162.3 (1. 5) NS 
75.4 ( 1. 9) 0.02 
29.7 (0. 7) 0.0002 
49.1 ( 6. 1) 0.0001 
4. 7 (0.5) 0.0004 
76.4 (15. 7) NS 
Characteristics of the participants in the low (65.1 ± 4.3 pmol/1) and 
high E>. (288.9 ± 10.1 pmol/1) group, respectively. Values arc means. 
Standard errors of the mean between parentheses. 
Two-sided p-values calculated by t-test. 
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TABLE II: Results of the bone mineral mass assessments in 43 healthY 
postmenopausal women. 
low estrone high estrone p-value 
n . 23 n "' 20 
SPA dist. 0.84 (0.04) 0.96 (0.04) 0.05 
(units/cm2 ) 
SPA-prox 1. 11 (0.05) 1. 26 (0. OS) 0.03 
(units/cm2 ) 
DPA spine 0.77 (0.02) 0.83 (0.03) NS 
(g HA/cm2 ) 
QCT trllb 76. 1 (6.0) 85.5 (9.2) NS 
(mg/ml) 
QCT cor"C 259.9 (12. 7) 278.7 (12. 8) NS 
(mg/ml) 
Peripheral and llxial bone mineral densities of the high and low estrone 
groups. Values are means. Standard errors of the mean between 
parentheses. Two-sided p-values calculated by t-test. 
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MATERIALS AND METHODS 
43 Healthy women of 68-72 years were selected from a larger epidemiologic study 
comprising 746 women aged 58 to 77 years8 • 13• The selection was based on serum E 1 levels. 
According to Cauley et al.1to one single measurement of E1 is reproducible and reliable in 
characterizing a postmenopausal woman for epidemiologic research. One group (n=23) with low E1 
levels was selected at random from the lOth to 20th percentile and a second group (n=20) with high 
E1 levels from the 80th to 90th percentile. None of them used glucocorticoids or hormonal substitu-
tion. Previous use of these drugs never had exceeded 3 months. All women were volunteers and 
gave informed consent. 
Peripheral bone measurements were done at the right forearm according to the Single 
Photon Absorptiometry (SPA) method described by Nilas et ai15, using a Nuclear Data llOOa bone 
density scanner. Measurements were performed both distally (SPA-dist) and proximally (SPA-prox) 
in the forearm. With this technique the bone measured distally consists to a larger extent of 
trabecular bone than proximally16. The results are expressed as BMD in arbitrary units (U/cm2). A 
correction for the variability of the amount of fat in the forearm has been used17• 
For the Dual Photon Absorptiometric (DPA) measurements of the lumbar spine (DPA-
spine) L2 through L4 was the region of interest. Measurements were done with a Novo BMC-lab 22a 
scanning device as described by Kreiner and Nielsen18• The results are expressed as BMD in gram 
hydroxyapatite (HA) per cm2• 
For the Quantitative Computed Tomographic (QCT) densitometric measurements a Philips 
Tomoscan-350 was used. Trabecular and cortical measurements (QCT -trab and QCT -cort) were 
performed as described previously19• Scans, with a slice thickness of 6 mm, were made in the 
midplane of L1 through L3 as selected from a lateral scanogram. Results were converted to 
equivalent concentrations of di-potassium phosphate (mg K 2HP04/ml) by means of a simultaneously 
scanned phantom placed underneath the patient. The coefficient of variation was for SPA-prox 
and -dist (both BMD) 1.0 and 1.9 %, respectively, for DPA-spine (BMD) in osteoporotic patients 
2.3 % and for QCT -trab and -cart in normal women 2.5 % and 2.7 %, respectively. 
E 1 concentrations were measured by radioimmunoassay (RIA) as described by van 
Landeghem et ai20, estradiol (E2) concentrations by 
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TABLE III: Body mass index end results of various measurements of bone mass 
(BMD) in the four subgroups based on serum E1 and SHBG levels. 
Group low E'- low E, high E, High E1 
high SHBG low SHBG high SHBG low SHBG 
N 11 12 10 10 
BMI 24.4 (1. OO)if 26.4 (0.85) 28.3 (1.09) 29.1 (1.12) 
(kg/m2 ) 
SPA dist 0.78 (0.05)11* 0.90 (0.05) 0.90 (0.08) 1. 01 (0.04) 
(U/cm2 ) 
SPA prox 1.06 (0. 05)11* 1.16 (0.08) 1. 17 (0.08) 1.33 (0.05) 
(U/cm2 ) 
DPA spine 0.75 (0.04) 0.80 (0.02) 0.83 (0. 05) 0.84 (0.04) 
(g HA/cm2) 
QCT trab 71.0 (6. 9) 80.2 (9. 5) 80.2 (13.0) 90.8 (13.8) 
mg K:zHPQ.,.jm1) 
QCT cort 251.3 (18.3) 267.0 (18. 2) 275.5 (20. 9) 281.8 (16.3) 
mg K:zHPO.o..) 
Values are means. Between parentheses SEM. 
* p < 0.01 compared with high E1 I low SHBG group (analysis of variance). 
# p < 0.05 vs. the other groups (t-test). 
TABLE IV: Results of various bone mass measurements (BMD) in the four 
subgroups based on serum E1 end BM!. 
group low E, low E1 high E1 high E, 
low BMI high BMI low BMI high BMI 
BMI 22.7 ( 1. 8) 27.7 (2.3) 26.6 (1.4) .31. 1 (3. 1) 
(kg/cm2) 
N 11 12 10 10 
SPA dist 0.75 (0.05)11 0.92 (0. 05) 0.95 (0. 06) 0.96 (0.07) (U/cm2) 
SPA prox 1. 00 (0.06)11 1. 21 (0.06) 1.22 (0.06) 1.29 (0.08) 
(U/cm2 ) 
DPA spine 0. 72 (0. 04)# 0.82 (0.03) 0.84 (0.04) 0.83 (0.05) 
(g HA/cm2 ) 
QCT trab 58.5 (6.4)# 87.7 (7.5) 83.3 (9.2) 88.4 (18.8) 
(mg K:zHPO.,.fml) 
QCT cort 227.4 (22.2)# 281.6 (12.6) 269.5 (19.6) 290.9 (14.9) 
(mg K2HP04/ml) 
Values are means. Between parentheses SEM. 
:ff p s 0.01 vs. the other groups (t-test). 
Ill 
a RIA kit of Diagnostic Products Corporation (Los Angeles, California, USA) and androstenedione 
(A) levels by a RIA kit from Eurodiagnostics (Apeldoorn, The Netherlands). SHBG was measured as 
described by Hammond et al21• The inter- and intraasay variations of these determinations varied 
from 10.8-14.6 and 16.5-18.4 o/o, respectively8• 
DATA ANALYSIS 
The data were analyzed in two ways. First, group means comparisons were made using a t-
test for unpaired observations. The results for various comparisons are expressed as means and 
standard errors of the mean for each of the groups. Second. to test the mediating effect of plasma 
SHBG level the low and high estrone group were each divided in two subgroups with high and low 
SHBG levels, based on the median level of plasma SHBG. Similarly, the low and high E1 groups 
were each subdivided in two subgroups with low and high BMI values. according to the BMl 
median value. The differences between the resulting two times four groups were again studied with 
a t-test and differences across groups using analysis of variance. Two-sided p-values are used 
throughout. When applicable adjustments for confounding variables were made using multiple linear 
regression analysis. 
RESULTS 
The general characteristics of the two study groups and their blood analysis are given in 
Table I. As could be expected the serum gonadal hormone levels differ significantly between the 
groups. All the values of the bone mineral assessments (Table II) in the low-E1 group are lower than 
in the high-E1 group, significantly so for the forearm measurements 
Because the BMI was also significantly lower in the iow-E1 group (Table I) the BMD data 
were -by regression analysis- corrected for body mass. Subsequently. the difference in forearm 
BMD between the low- and high-E1 groups were no longer observed (Fig. I). On the other hand the 
significant differences in E2 and A between the two groups of women did not disappear after 
correction for BMI. To investigate whether the SHBG level modulates the effect of low and high 
estrogen levels on BMD, the two groups of women were divided in subgroups on the basis of the 
serum SHBG level. The forearm BMD was in the first (low-Edhigh-SHBG) subgroup significantly 
lower than in the fourth (high-E1/Iow-SHBG) subgroup (Fig. 2, Table ill). Because also the 
relationship between the SHBG level and BMD disappeared, when the data for the four subgroups 
were corrected for body mass. we again subdivided the low- and high-E 1 groups, this time 
according to low and high BMI values. As can be seen in Fig. 3 and Table IV the BMD was in the 
low-E1/Iow-BMI subgroup of women considerably lower than in the other three subgroups. This 
applied to the results of all types of measurement and at all sites measured. 
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*P ~ 0.01 versus the other groups. 
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DISCUSSION 
Using bone mass as a selection criterium several authors have established a rather strong 
correlation between the levels of estrogens and bone mass14 • 22• We decided to study this 
relationship, in the open population, by an opposite approach, i.e. using estrogen level as the 
selection criterium. In this way we found that the women selected with regard to low (from the lOth 
to the 20th percentile) and high (from the 80th to the 90th percentile) serum E1 had significantly 
different forearm BMD (two sites). The fact that in the lumbar vertebrae the BMD was not 
significantly different between the low- and high-E1 groups may reflect the lower precision of the 
methods used for that region as compared with those used at the forearm. To further analyze the 
importance of estrogen levels one has to consider factors influencing those levels and estrogen 
bioavailability, such as androstenedione (A), fat or body mass and SHBG. 
Postmenopausal estrogen levels are largely dependent on the adipose tissue aromatization of 
A secreted by the adrenal cortex. Accordingly, a correlation between the serum estrogen level and 
the adipose tissue mass (or the body weight) has repeatedly been demonstrated in pre- and 
postmenopausal women23 •24• Serum E1 was in this situation also dependent on the plasma A level25• 
Selection on the basis of low and high E1 levels in our hands resulted in a selection according to low 
and high body mass and serum A. Therefore, we had to exclude the possibility that the observed 
differences in BMD between the two groups had to be partly attributed to differences in these 
variables. In the population-based study, from which our subjects were afterwards selected, van 
Hemert et al8 demonstrated an independent relationship between age, SHBG, E2 and BMI on the 
one hand and peripheral bone mass on the other. In the present study the difference in A between 
the groups with low and high serum E1 was still observed after correction for body mass. However, 
no correlation between BMD at the various sites and serum A was found (data not shown). 
The biological effects of a steroid hormone are determined by the binding of the free 
hormone to the receptor. In the case of a constant concentration of estradiol an increased SHBG 
level will in the steady state be accompanied by a lowered free hormone concentration. In 
postmenopausal women the influence of SHBG is especially important because feed-back control of 
estrogen production is lacking. The results obtained in this study appeared to support this concept 
(Fig. 2 and Table III): When the patients of the two groups were ranked in categories of supposedly 
increasing estrogen activity a difference in BMD was observed. However, as mentioned we found a 
parallel significant difference in BMI between the low~ and high-E1 groups. In adults body weight 
and serum SHBG are inversely correlated8 •9 · 10• Correction of our data for the differences in BMI 
ll4 
led to a loss of the significant differences in BMD between the low-
and high-E1 groups as well as between the low-Edhigh-SHBG and high-E1/low-SHBG subgroups. 
Subdivision of the low- and high-E1 groups as to the BMI values revealed at all sites measured a 
considerable difference in BMD between the low-Edlow-BMI group and the other groups. 
Therefore. one may conclude that in the postmenopausal women selected BMI is a main determinant 
of bone mass acting by influencing the serum estrogen and SHBG levels. but in addition 
independently from these mechanisms. 
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To assess the impact of primary biliary cirrhosis on 
bone mass in general and the relative importance of 
the stage of the liver disease and of treatment with 
glucocorticoids for the possible development of os· 
teoporosis, bone mineral mass was measured by 
single and dual photon absorptiometry in 55 unse· 
lected female patients with longstanding primary 
biliary cirrhosis. Although most of the patients 'had a 
bone mineral density within the normal range, the 
bone mineral densities of the lumbar spine and distal 
and proximal forearm were 8o/o (P < 0.004), 8o/o 
(P < 0.03), and 5% (NS) respectively, lower than in 
age·matched healthy women. Multiple regression 
analysis showed that the histological stage of the 
liver disease (early stage vs. late stage) was an 
independent determinant of axial bone mineral den. 
sity, whereas the use of glucocorticoids resulted in 
only a moderate and not significant bone loss. Serum 
calcium proved to be significantly lower in the 
patients with late-stage primary biliary cirrhosis 
than in those with early-stage disease, whereas no 
significant differences were found in these groups 
with regard to several biochemical parameters of 
bone metabolism. In conclusion, in patients with 
primary biliary cirrhosis, bone loss was only moder-
ate and related to the histological stage. The effect of 
low-dose glucocorticoids on bone mass seemed not 
significant. 
Primary biliary cirrhosis (PBC) is a chronic disease of the liver typically encountered in middle~aged 
women; it is characterized by an inflammatory process 
affecting the intrahePatic bile ducts. This inflamma~ 
tion is accompanied bycholestasis and mayeventua1ly 
result in biliary cirrhosis and death of hepatic failure 
(1). 
Like other cholestatic liver diseases, PBC may be 
complicated by metabolic bone disease. Both osteoma-
lacia and osteopenia have been described in PBC 
(2-12). Nowadays, it is generally agreed that osteoporo~ 
sis is the more common and clinically more important 
lesion in PBC. In patients with PBC. prevalence rates 
of osteoporosis, based on histological criteria. have 
been reported to vary from Oo/c-1i""lo (8,10.11,13). The 
cause of osteoporosis in PBC is unknown. 
Currently there is no effective treatment for PBC. 
and results with various immunosuppressive or antiin-
flammatory drugs have been disappointing (14). Espe· 
dally in PBC, glucocorticoids are assumed to aggra· 
vate osteoporosis [1,15]. but this has never been 
extensively studied. 
The current study investigated the determinants of 
bone mineral density in 55 unselected female patients 
with PBC. Furthermore. we investigated whether glu· 
cocorticoids cause a further decrease of the bone 
mineral density in PBC. and if so, to what extent. 
Materials and Methods 
Patients 
From 1973 to 1988. a diagnosis of PBC was mo.dc in 
our department in 102 patients {89 women). Fourteen pa· 
tients {all women) were lost to follow-up and 22 (18 women) 
died. Of the 66 patients still followed up. 57 are women. Of 
these women. one was excluded because of severe polymyo-
sitis and consequent immobilization; the other was excluded 
Abbreviations used Jn this paper. BMD, bone mineral density; 
DPA,pon .. dual photon ab~rptfometry of the lumbal." spine; Hn. 
hydroxyapatite: OH·prol, hydroxyproline; 1,25-(0H),D,, 1.25· 
dihydroxyvitatnln D,; 25-(0H)D,. 25-hydroxyv:ltam.ln D,: PBC, pri· 
mary biliary cln-ho:ris: PTH, parathyroid hormone; SPA,,,.. tililglc 
photon ab~rptfometry of the distal forearm; SPA0,.,. single pho-
ton absorptiometry of the proximal forearm. 
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because incomplete data were obtained. The remaining 55 
patients (aged 39-75 years) were entered to the study. All 
patients' liver biopsy results were consistent wi.th PBC. and 
all hod positive tests for antimitochondrial antibodies. None 
of the patients had evidence of bone diseuse in their history 
or at physical examination. All poticnts received o diet 
containing at least 1.5 g of calcium daily, and vitamin D, (400 
IU/doy orally] was supplemented, when indicated by serum 
25-hydroxyvitamin D, (25-(0H)D:~l levels (six potients). In 
principle, therefore, oll patients may be considered to have 
had an adequote intake of co.lcium and vitamin D. 
Thirty patients had been treated for their PBC with 
D-penicillamine. azathioprine, colchlcine, cydosporin A, 
prednisone, or combinations of these drugs. Of these po-
tients. only five had been treotcd with azathioprine or 
cyclosporine A. Twenty-three patients had received gluco-
corticoids or were still treated with glucocorticoids. All 
potients were initially administered 30 mg of prednisone 
which was tapered off within 6 weeks to a maintenance dose 
of 10 mg. The meon duration of treatment was 6.3 years 
(range, 0.3-14.5 year$). For the calculation of the cumulative 
glucocorticoid dose, one patient with chronic asthma was 
excluded because reliable do.ta could not be obtained. 
To determine the relationship between the histological 
stage of PSC (assessed o.ccording to Scheuer (16)] and 
parameters of bone metabolism and bone mineral density 
[BMD), the potients were divided into groups of early-stage 
{stage I and II. n = 30) or late-stage [stage III and IV. n = 25] 
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disease (Table 1). Furthermore, the effects of treatment with 
glucocorticoids on the same parameters were studied, by 
subdividing the PBC patients in o. group who used or had 
used glucocorticoids (n = 23) and a group who had never 
used this type of drug (n = 32) (Table 2). Informed consent 
wo.s obtained from all participants. 
Biochemistry 
Serum concentrations of calcium, creo.tinine, inor-
ganic phosphorus, bilirubin, and albumin were meo.sured by 
sto.ndard methods. Serum calcium levels were corrected for 
the serum albumin concentration as described by Payne et 
a!. (17). Urinary hydroxyproline (OH-prol) excretion was 
measured o.ccording to a previously described method [18). 
Serum 25-[0H)D, levels were measured by a competitive 
protein binding assay, whereas 1,25-dihydroxyvitamin D~ 
[1,25-(0HJcD,]. immunoreo.ctive intact parathyroid hormone 
[PTH(l-84)] and osteocalcin were measured with commer-
cially avoilable kits (Jncstar Corp., Stillwater. MN). 
Assessment of Bone Mineral Moss 
All patients were measured with photon absorptiom-
etry. us described elsewhere [19). Peripherol bone meo.sure· 
ments were carried out at the right foreo.rm according to the 
method described by Nilo.s et a!. {20), using a Nuclear Data 
Table 1. Patient Characteristics, Bone Mineral Densities, and Biochemical Dota According to the Classification Based on 
Histological Stage of the Liver Disease 
Early stages 
No. 30 
Age (yr] 59.2"' 7.6 
Height( em) 162.6 :': 7.8 
Mean menopausol age" 48.3 
Wcight(kg:] 68.1 ± 11.8 
Quetdet index (kg/em') 25.7 ± 4.10 
Duration of PBC (yr) 8.2 ± 3.6 
Corticoids(n) 
" Cumulative dose (g) 25.8 '"- 25.5 
BMD" 
DP~ •• (%) 94.8 "' 14..7 
SPJ'.o~,(%) 96.1 ± 20.2 
SP~,(%] 100.2"' 17.2 
Serum 
Bilirubin ~moVL) 15 ± 17 
Calcium (mmoVL]< 2.35"' 0.07 
Albumin (giL) 4.2.6 ± 2.1 
PTH(pg/mL) 19 ± 10 
Osto::ocalcin (ng/mL] 3.5 :': 1.4 
25-(0H]D, [nmoVL) (3.3,2 :': 46.3 
1,25-(0H),D, (pmoLIL) 61.2"' 18.9 
Urine 
Calcium/creatinine (moL/mol) 0.30 ± 0.16 
OH-prollcreatinine [moL/mol) 0.02 "' 0.01 
TMP/GFR [mmoLIL] 1.1 :': 0.2 
Lote stages 
25 
56.1 '"- 9.7 
161.1 :': 5.7 
50.2 
61.7 ± 7.6 
23.7:!:. 3.1 
7.2:!:. 2.9 
n 
22.8"' 15.0 
85.4. "' 10.6 
85.8 :': 17.5 
91.5 :': 16.2 
3'1 '"- 4'1 
2.29 :': 0.15 
39.2 "'6.2 
20 '"- 10 
3.5 "'1.6 
70.9 '"- '11.0 
59.3"' 17.6 
0.35 ± 0.22 
0.02 "' 0.009 
1.1 '"- 0.2 
p 
NS 
NS 
NS 
<0.05 
NS 
NS 
NS 
0.05 
0.002 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NOTE. Tho:: values are expre .. _.s.OO as mean ± SD. The cumulative dose of corticoids is expressed as prednisone equivalents. 
"For both groups, the mNn age at menopnuse was calculated. 
1
'The BMDsare presented as percenrnges of age-matched control subjects. 
Normal values 
2-12 
2.20-2.65 
38-48 
10-55 
1.8-6.6 
>30 
40-101 
0.28"' 0.06 
0.02 :': 0.005 
0.81-1.35 
'Corrc<:ted for serum albumin. Forstntlstlcal evaluation. multiple linear regression a no lysis was used. as de:;c:ribed in Materials and Methods. 
GFR, glomerular filtration rate: TMP. maximal renal reabsorption of inorganic phosphate. 
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Table 2. Patient Characteristics. Bone Mineral Densjties 
ond Biochemical Data According to the 
Classification Based on Use of Glucocorticoids 
No. 
Ag~ (yr] 
M~an menopausal age• 
Hclght(cm) 
Weight[kg] 
Quetclet index [kg/em') 
Duration of PBC (yr) 
Early/late stage 
BMDb 
DPA,,In•[o/o] 
SPAd,,(%) 
SPA"""'(%) 
Serum 
Bilirubin (.umoVL] 
Cnlcium (mmeVL)' 
Albumin (g/L) 
PTH [pg/mL) 
Ostcoculcin (ng/mL] 
25-(0H]O,[nmoVL) 
1.25-(0H),D, (pmoVL) 
Urine 
Calcium/ crentinine 
[moL/mol) 
OH-prol/creatin!ne 
(moVmol) 
TMP/CFR [mmol!L] 
No 
steroids 
32 
59.2 :!: 8.5 
48.9 
160:!: 6.1 
64.7 ;t 8.4 
25.1 ;t 3.1 
6.9:!: 3.0 
19/13 
92.9 :!: 15.5 
95.5 :t 21.9 
101.1:!: 18.8 
24:!: 40 
2.35:!: 0.16 
40.9:!: 5.8 
23 ;t 7 
3.7:!: 1.4 
58.2:!: 21.3 
61.9:!: 18.9 
0.33:!: 0.20 
o.oz :t 0.09 
1.1 :t o.z 
Steroids 
23 
55.9 :t 8.7 
49.0 
163 ;t; 7.5 
65.9 ;t 13.4 
24..5 ± 8.7 
8.9 ;t 3.5 
11/12 
81.5 :t 10.6 
88.1:!: 14.9 
90.0:!: 12.6 
23:23 
2.34.:!: 0.81 
41.4 :!: 2.6 
27:!: 12 
3.2:!: 1.5 
78.0:!: 61.4 
58.2 ;t 17.8 
0.32:!: 0.17 
o.o3 " o.oi 
1.1:!: 0.2 
NOTE: The values are expressed as the mean :t: SO. 
"For both groups, the mean age at menopause wos calculated. 
p 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
t-rhe BMOs nrc presented as percentages of age-matched control 
subjects. 
'Corrected for serum albumin. For stltistica\ evaluation, multiple 
linenr regression analysis was used as described in Materials and 
Methods. For normal values. see Table 1. 
[Hj/Jrsholm. Denmark)1100a bone density scanner. Measure-
ments were performed both distally (SPAd~l and proximally 
(SPAI"''"). With this technique. the bone measured distally 
consists of trabecular bone in a higher proportion than when 
measured proximally (21). The results are expressed as BMD 
in orbitrary units [U/cmZ]. In our laboratory, the coefficient 
of voriation. based on 50 duplicate measurements in normal 
subjects. is 1.9'7o for the distal site and 1.0'7o for the proximal 
site. 
For the dual energy photon absorptiometric measure~ 
ments of the lumbar spine [DPA,P',.). 12-4 was the region of 
interest. Measurements were carried out with a Novo 
(Bagsvaerd, Denmark) BMC-lab Z2a scanning device, as 
described by Krolner and Nielsen (22]. Results were ex~ 
pressed as groms hydroxyapatite [Ho) per square centimeter 
[BMD). The coefficient of voriation calculated on the basis of 
duplicate measurements of the lumbar BMD of 20 patients 
with osteoporosis in our loboratory is 2.3'7o. 
Statistical Methods 
Bone densitometric values of the PBC patients 
(n = 55) were compared with values obtained from a group 
GASTROENTEROLOGY Vol. 99, No.4 
of age~matched heolthy subjects, randomly sampled from a 
reference group described previously [19). Differences were 
analyzed by Mann-Whitney's test. 
Multiple lineor regression analyses were performed to 
evoluate the dependency of the various densitometric val-
ues on age, histological stage of PBC, and the use of 
glucocorticoids. In this woy, the influence of diseose sl:ilge, 
glucocorticoids, ond age, respectively, on bone moss was 
evoluoted independently. Adding the variables (corrected) 
serum calcium and Quetelet index (or weight) in the regres-. 
sion model had no significant influence. The participants 
were clossified to subgroups according to use of glucocorti-
coidsand the histological stage. The Mann-Whitney test was 
used to compare the differences among the various parame-
ters in the subgroups. 
Results 
All Patients 
Mean BMDs at both the distal region of the 
forearm and in the lumbar spine were 8'7c lower in 
patients with PBC than in normal women of the same 
age (P < 0.03 and P < 0.004, respectively: Table 3). 
However. no significant difference was observed in 
the proximal forearm. In Figure lA-C, the axial and 
peripheral BMD values of the patients are plotted 
ngainst age. Although the mean DP A,p1ne and SPAd1, 1 
were significantly lower, most of the individual BMD 
values of the patients are within the normal range. For 
all biochemical parameters, no differences between 
the total PBC group and our reference values were 
found, including vitamin D metabolites, PTH. and 
osteocalcin. 
Early and Late Stage 
Using the criteria of Scheuer (16), the patients 
were subdivided in groups with early stages {I and Ill 
and late stages of PBC (III and IV). With this approach, 
the only significant difference in clinical characteris~ 
tics between these two groups was weight, which was 
lower in the late~stage group (Table 1). Late stage PBC 
appeared not to be associated with a longer duration 
of the liver disease. Of the biochemical parameters 
measured, only bilirubin was higher in the late·stage 
Table 3. Bone Minerai Densities in Patients With PBC ond 
Age~Motched Control Subjects 
Control subjects 
(n- 55) 
PBC 
{n- 55) 
Pvnlue 
DPA.,ono 
0.85 :t: 0.14 
0.78 :1: 0.12 
<0.004 
SPA,..,. 
0.97 :t: 0,19 1.30 :1: 0.25 
0.89 :t: 0.20 1.24 :t 0.2.2 
<0.03 0.18 
NOTE. BMDs nrc expressed in grnms hydroxyapatite or units per 
square centimeter= SO (see Mnterialsond Methods). The reference 
group is also described in the Motcrinls and Methods section. 
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g/cm' 
® 
A"" corticosteroids 
•"' no corticoste-roids 
Age in years 
Figure 1. Bone minctal dens.itie:; of (A) lumbm: spine (DPA.,,, •• ) and 
(B) distal (SPA.J,.J and [C) proximal [SPA,-) foreann ln 55 patiCill!l 
with PBC. Shaded areo Indicates tho 5th to S5tb percentiles 
determhlcd for 171 normal women. A, Patienl!l who used or bad 
used cortico~tcrolds: e, paticnl!l who never used cortlcostctoids. 
group, whereas on the other hand serum calcium and 
corrected calcium levels were significantly lower in 
this group (Table 1). Using the multiple regression 
method. we observed a tendency to lower age~ 
corrected peripheral and axial BMD values in the 
late-stage group. However. this difference reached 
significance (P < 0.002) only for DPA,pJn,· Weight or 
Quetelet index could not be identified as independent 
determinants of BMD in these groups. 
G!ucocorticoids 
The patients with PBC who used or had used 
glucocorticoids were also compared with those who 
1. 
0. 
30 
© 
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A =corticosteroids 
•"" no corticosteroids 
Age in years 
A"" cortocosterolds 
o =no corticosteroids 
Age in years 
had never used this type of drug. As shown in Table 1. 
no significant differences between both groups could 
be observed. Also, the cumulative dose of glucocorti-
coids was not correlated with the histological stage of 
PBC. Nevertheless, the steroid group tended to have 
lower age~corrected BMDs than the nonsteroid group. 
Multiple regression analysis indicated that for SP~x 
this trend just reached significance (P = 0.05). 
Discussion 
The results presented in this report confirm 
earlier reports that the peripheral BMD at the distal 
forearm is lower in female patients with PBC than in 
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age-matched control subjects [6,8). Furthermore, axial 
BMD, another parameter of trabecular bone mass, 
was also significantly lower in the patients with PBC. 
Only BMD measurements at the proximal forearm, 
largely reflecting cortical bone, did not show a signifi-
cant difference with our reference group. Therefore, 
these results suggest a preferential loss of trabecular 
bone compared with cortical bone in PBC·related 
bone disease. 
However, our findings are not in agreement with 
the severe form of bone loss as described by Hodgson 
et al. (10). These investigators reported that in approxi-
mately 50% of their patients with PBC. axial BMD 
values were even below the theoretical fracture thresh-
old, whereas we found a mean reduction of BMD of 
only 8% both in the lumbar spine and distally in the 
forearm compared with the results in age-matched 
control subjects. This discrepancy may be explained 
by differences in the populations of patients studied 
and in the statistical methods used. For instance. 
Hodgson et al. used a linear relationship for the 
age-related axial bone loss in control subjects. whereas 
the current report used the more common nonlinear 
function with an accelerated bone loss around the 
menopause [Figure lA-C and reference 19). 
At the presentation of PBC, there iS little evidence 
for metabolic bone disease (13); it remains to be seen 
whether early substitution with vitamin D and cal-
cium, as applied in our patients. prevents bone loss. In 
this respect, the available data are not conclusive. 
because only the effect of relatively short-term treat-
ment with vitamin D on bone loss has been reported 
(4.5). 
The importance of the histological stage of PBC for 
bone mass is illustrated by the significant difference 
between the axial BMD of our early-stage and late-
stage groups. To our knowledge, this is the first report 
of such a relationship. Another interesting observation 
in the current study was the slightly but significantly 
lower mean serum calcium level in patients with 
histological evidence of late-stage PBC. This was not 
accompanied by differences in the concentration of 
vitamin D metabolites or PTH. The latter observation 
might indicate a certain degree of hypoparathyroidism 
in this patient group. because the lower mean serum 
calcium level should have resulted in a higher mean 
PTH concentration. Also in other studies, normal or 
even subnormal serum immunoreactive PTH levels 
have been found (5,6). 
Unfortunately. we. had no opportunity to measure 
parameters of calcium absorption to investigate a 
possible relationship with serum calcium levels and 
bone mass. However. it has been reported that chronic 
intestinal calcium malabsorption seems to be impli-
cated in the pathogenesis of bone loss in patients with 
GASTROENTEROLOGY Vol. 99. No.4 
PBC (6). Consequently, our findings could be a reflec-
tion of this phenomenon. 
Several recent studies have shown that not osteoma-
lacia, but osteoporosis in the most frequently found 
metabolic bone disease in patients with PBC (5-12). 
Furthermore, histological analyses of bone biopsies 
have shown impaired osteoblastic function with de-
creased bone formation (9,10). Although we have not 
performed bone biopsies. the slightly lowered serum 
osteocalcin levels in our PBC patients, as compared 
with reference values. do not indicate a severely 
impaired osteoblast function. This is in agreement 
with the very moderate lowering of bone mass in our 
patients. 
The recently proposed hypothesis that toxic sub-
stances related to hepatic disease and cholestasis play 
a role in PBC-related bone disease remains attractive 
(10,12). For instance. copper and bile salts are known 
to have cytotoxic effects and are found in high concen-
trations in hepatocytes and other tissues of patients 
with PBC [10). In patients with Wilson's disease, 
copper may be implicated in the development of 
hypoparathyroidism [23). Toxic substances might not 
only interfere with osteoblast activity but might also 
depress parathyroid function (24,25). 
Several investigators consider the use of glucocorti-
coids in the treatment of PBC disadvantageous be-
cause of the induced bone loss (1,15). However, our 
observations do not indicate a clinically important 
long-term influence of glucocorticoids, in the doses 
used, on bone mass or biochemical parameters of bone 
turnover. A recent study by Diamond et al. (12) of 
patients with hepatic osteodystrophy points in the 
same direction. An explanation for this finding could 
be that most of our patients were kept on a relatively 
low maintenance dose of prednisone (10 mg daily). We 
did not observe lower serum osteocalcin levels as 
others did in glucocorticoid-treated patients (26). How-
ever, we have to emphasize that not all patients in the 
steroid group were treated at the time of measure-
ment. Because only a limited number of patients have 
been treated with azathioprine or cyclosporine A, it 
may be assumed that the potential negative effects of 
these substances on bone mass could not have influ-
enced our overall results significantly. 
In patients with rheumatoid arthritis~ low-dose glu-
cocorticoids also did not significantly diminish bone 
mineral content (27). Similar data were obtained by 
our group in patients with chronic obstructive lung 
disease (28). In this respect. the importance of· the 
cumulative dose of corticoids has been stressed by 
Dykman et al. (29). Indeed. in our patients the mean 
cumulative dose was below the critical level (30 g 
equivalent of prednisone) indicated by these authors 
for the occurrence of fractures. Therefore, we believe 
that relatively low doses do not strongly accelerate the 
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progression of osteoporosis in patients with PBC. This 
conclusion may have relevance for future studies, 
because long~term prospective controlled trials of 
corticosteroids in PBC are lacking. 
In conclusion, our study does not indicate the 
occurrence of a severe degree of bone loss in our 
patients with PBC. although we found a moderately 
lower BMD in patients with a late histological stage of 
PBC. Furthermore, the assumed deleterious effect of 
long~term {low~dose] glucocorticoids on BMD seemed 
to be minor in our patients. It remains to be deter~ 
mined whether the early substitution with vitamin D 
and calcium in our patients has had a beneficial effect. 
Finally, our data provide evidence for a lower serum 
calcium in the late~stage group. This phenomenon has 
to be studied in more detail, especially with regard to 
parathyroid function. 
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CHAPTER9 
BONE LOSS IN PATIENTS WITH LOW MAINTENANCE GLUCOCORTICOID 
TREATMENT FOR CHRONIC OBSTRUCTIVE LUNG DISEASE. IS TREATMENT WITH 
la-HYDROXYVITAMIN D3 1NDICATED? 
Part of this chapter has been published in Osteoporosis 1897, Christiansen C, Johansen JS, Riis BJ 
(eels.) Osteopress 1987, Kobenhaven, pp 1033-1036. 
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9.1 Introduction 
Chronic administration of glucocorticoids may induce bone loss and ultimately 
osteoporosis1. Despite the extensive use of glucocorticoids and occurrence of glucocorticoid-induced 
osteoporosis, little is known about the possible means to prevent this syndrome. Histological studies 
show decreased bone formation and increased bone resorption. This latter condition is probably due 
to an elevated parathyroid hormone (PTH) secretion2 •3 •4 or activity5• The first may be secondary to 
a low calcium absorption6 and increased renal loss of calcium7 • The negative effect of 
glucocorticoids on intestinal calcium absorption can be counteracted to some extend by activated 
vitamin D8 •9 •10• It is, therefore, of clinical interest whether active vitamin D derivatives can 
decrease glucocorticoid induced bone loss. In a previous study we showed a positive effect of six 
months treatment with 2 ug la-hydroxyvitamin D3 per day (la-(OH)D3) on the calcium absorption 
and on trabecular bone volume in bone biopsies taken from patients treated with glucocorticoids10• 
In the present study the long-term effect of a lower dose la:-(OH)D3 (1 ugjday) on the mineral 
bone mass was evaluated by photon absorptiometry of the lumbar spine and radius. 
9.2 Patients and methods 
After informed consent was obtained 30 asthmatic patients (26 males and 4 premenopausal 
females), who had received for more than 6 months and still received at least 7.5 mg prednisone per 
day entered the study and were followed during 2 years. The patients were matched according to 
age, sex, dose and duration of prednisone treatment. After matching, the patients were randomly 
divided and received either a placebo or a daily dose of 1 ug la:-
(OH)D3 (double blind). Before treatment the average peripheral and axial bone mineral mass proved 
to be the same in both groups. Patients characteristics are given in Table I. 
During the study period the prednisone dose was reduced in most patients, largely due to 
the increasing use of inhalation corticosteroids. This reduction resulted in a mean daily prednisone 
dose of 8.7 mg per day (range 5-15 mg per day). 
Peripheral bone measurements were performed by single photon absorptiometry (SPA) at 
the right forearm using a Norland-Cameron bone density scanner. The radius at one third of the 
length from the distal end was transversely scanned. The results are expressed as Bone Mineral 
Content (BMC in U/cm)11. Axial bone mass was assessed by dual photon absorptiometry (Novo 
BMC-lab 22a) at the lumbar spine (DPAspine) with L2-Lto as the region of interest12. The results are 
expressed in g Ha per region of interest. In our laboratory the coefficients of variation of SPA and 
DPA are 1 and 2.3%, respectively (the latter in osteoporotic patients). 
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Table I 
Pre-treatment patient characteristics and prednisone dose during 
treatment. 
Placebo 
================================================================== 
Age (years) 40±2.4 40±2.3 
Height (em) 175±1.7 173±2.5 
weight (kg) 78±2.7 76±3.6 
cumulative dose before 
study in g prednisone 10.5±2-0 9.5±1-6 
Mean daily dose mg 8.7±2.8 8.7±2.3 
Range in mg 5-15 5-12.5 
BMC,.~d.iUs (U/cm) 786±18 772±21 
BMCspine ( gHa/L,-L,) 34-64±2.1 33.39±2.3 
The data are expressed as means ± SO. There were no significant 
differences between the two groups. Mean daily dose and range 
expressed in mg prednisone per day during the study period. 
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Table II 
Results of bone mineral mass assessments and the maen daily dose 
of prednisone of both groups after treatment period. 
Placebo la(OH)Dl p 
================================================================== 
BMC~""iua (Ujcm) 783±21 775±23 NS 
(-0.004%) (+0.004%) 
BMCspins (gHa/L,-L.) 33.68±2.4 32.49±2.4 NS 
(-2.6%) (-2.7%) 
Mean values ± SD. Between paracenteses the percentile differences 
with the pretreatment values. None of the parameters showed a 
significant difference between the two groups. 
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Every three months serum calcium, creatinine, phosphate, albumin, alkaline phosphatase 
and 24 h urinary calcium and creatinine were determined. 24 H-urinary hydroxyproline was 
measured according to Goverde et alP 
Statistical analysis was done using the Wilcoxon matched-pairs signed-rank test, P< 0.05 
being regarded as significant. 
Results of the bone measurements were analyzed by linear regression. For each pair the 
difference of the slopes was tested by the Wilcoxon matched-pairs signed-rank test. 
9.3 Results 
The results of the biochemical determinants are calculateci as the means for both groups 
and the results of the serum calcium and creatinine measurements are depicted in the figures 1-2. 
At zero time the pre-treatment results are given, while the last measurements were performed after 
the treatment was stopped for three months (indicated by an arrow). The other serum assessments 
showed no differences between the groups before, during or after treatment (data not shown). The 
24-h urinary excretion of calcium and creatinine are presented as the ratio calcium/creatinine in 
figure 3. 
Because the subjects were paired (placebo versus active treatment) the results of the bone 
mineral assessments are expressed as the difference between the regression coefficients of the pairs 
of patients (figures 4-5). The results of the axial measurements showed for 7 pairs a higher loss of 
bone mineral in the 1a-(OH)D3 treated patients, while in the other 7 pairs the la-(OH)D3 treated 
patients had lower bone loss or more bone gain than the placebo treated patients. These results 
differ not significantly. For the peripheral measurements the results were slightly better for the la-
(OH)D3 treated patients. 4 Pairs showed more loss or less gain in bone mineral in the la-(OH)D3 
treated patients. The other 10 pairs showed less bone loss or more bone gain for the la-(OH)D3 
treated patients. Also these differences were not statistically different. 
Table II gives the overall results of the mean bone mineral assessments for both groups 
after treatment. There was only a very moderate bone loss of 1.3-1.4% per year for the axial 
measurements in both groups, while the peripheral measurements showed no bone loss or bone gain 
during the study period. 
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9.4 Discussion 
The results presented in this paper do not show a beneficial effect of treatment with 1 p,g 
1o:-(OH)D3 daily on both peripheral and axial bone mass in patients on maintenance therapy with 
glucocorticoids. However. it is important to emphasize that the bone loss was moderate. In the 
lumbar spine, only bone mass measurements showed a loss of 1,3-1.4% per year, while no loss was 
found in the appendicular skeleton. In other words it seems reasonable to suggest that a treatment a 
maintenance dose of prednisone of approximately 8.5 mg daily as used in our patients, do not 
induce an important loss of bone mass in the axial and appendicular skeleton. Recently we observed 
a similar phenomenon in patients with primary biliary cirrhosis kept on a low maintenance dose of 
prednisone14• Sambrook et al15 also reported that low dose glucocorticoids do not significantly 
diminish bone mineral content in patients with rheumatoid arthritis, while in a longitudinal study 
Ruegsegger et al16 only observed appendicular bone loss with the use of an average daily dose of 15 
mg prednisone and over. In retrospect, taking these considerations into account, it is questionable 
whether one could expect a beneficial effect of treatment with lo:-(OH)D3 in the patients included 
in this study. Of course this does not imply there is no favourable effect of active vitamin D in 
patients on higher maintenance doses of glucocorticoids. The results of the study of Braun et a110 
point in this direction. 
During the 2 years follow up there were no periods of hypercalcemia nor indications for 
the induction of a decrease of renal function. Therefore, a daily dose of 1 microgram lo:-(OH)D3 
given for 2 years in these glucocorticoid treated patients seems to be save with regard to the 
occurrence of hypercalcemia and with regard to the renal function. As could be expected the 
average 24 hours urinary calcium/creatinine ratio in the lo:-(OH)D3 treated patients exceeded the 
values in the placebo treated group, indicating the compliance of the patients. Only at three months 
the difference was significant. An interesting phenomenon is the gradual decline in the 24 hours 
urinary calcium/creatinine ratio, which might suggests that during treatment with lo:-(OH)D3 some 
kind of adaptation of calcium homeostasis may occur. One may even speculate if adaptation of the 
dosage of lo:-(OH)D3 during this study was warranted. Another explanation for the decline in 
calcium/creatinine ratio, might be a lower calcium intake by the patients on active treatment during 
the study period. In other longitudinal studies with vitamin D derivatives no such decline has been 
observed or reportedl7 18• 
We conclude that this dose of lo:-(OH)D3 used appears not to have a prominent role in the 
prevention of glucocorticoid-induced mineral bone loss, when the daily maintenance dose of 
prednisone does not exceed 7.5 mg per day. This does not imply that a higher dose of la:-(OH)D3 
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(e.g. 2 ugjday) is not beneficial in patients using higher doses of prednisone10• However, these last 
results were obtained during a shorter period of treatment. It is important that maintenance 
treatment with prednisone in an average daily dose of between 7.5 and 10 mg may be of only 
limited harm to the bone (mineral) mass. 
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CHAPTER 10 
PREDICTION OF FUTURE FRACTURES AND SCREENING FOR OSTEOPOROSIS 
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10.1 Introduction 
The increasing availability of effective preventive strategies for osteoporosis have raised 
the issue whether women should routinely have some kind of assessment in order to identify those 
at risk for osteoporotic fractures. There exists a reluctance on the part of physicians and the general 
public to implement a prophylactic program (e.g. calcium supplements, estrogen replacement 
therapy) on a widespread basis without making some attempt to identify those subjects who are at 
greatest risk for osteoporotic fractures and thereby will benefit most from treatment. There are 
several methods to assess putative risk factors, but the most appropriate experimental design is a 
prospective study in which the risk factors are identified and subsequently related to the occurrence 
of osteoporotic fractures. Or better: the end-point should include some kind of estimation of quality 
of life (as related to the incidence of fractures). One of the models to assess risk factors is the 
logistic regression analysis. With this procedure it is possible to investigate independently the 
influence of various variables like life-style, dietary factors, biochemical parameters and bone 
mineral mass assessments. Adjustments for potential confounders can be made (e.g. age). By 
comparing cases to controls one can calculate the fracture risk for each variable measured. This is 
mostly done by the method of the odds ratio (OR). which represents the odds (probability) of a 
fracture at one level of exposure (e.g. one SD below the mean) divided by the odds at another 
exposure level (e.g. one SD above the mean). This implies that an OR of 1.0 indicates that there is 
no correlation of a variable with the outcome (i.e. the occurrence of fractures). while an OR of 5.0 
for a difference in BMC of 2 SD indicates that there is a fivefold increase in risk for fractures. 
The first studies dealing with fracture risks were cross-sectional. case-controlled and/or of 
a too limited size to investigate risk factors independently. During the last five years however, 
several prospective studies have been published. In this chapter a survey is made of the usefulness 
of markers or determinants with regard to the prediction of osteoporotic fractures in the individual. 
Furthermore, several aspects of screening for osteoporosis will be discussed and recommendations 
will be put forward with regard to possible future screening programs. 
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10.2 Prediction of osteoporotic fractures. 
Factors influencing and determining bone mineral mass and bone strength are discussed in 
section 3.7. Naturally, these variables are taken into account in putative risk profiles. We can divide 
those variables into 5 groups: 
1) Clinical history. 
2) Anthropometric measurements. 
3) Biochemical measurements. 
4) Bone mineral mineral mass or density assessments. 
5) Prevalence of osteoporotic fractures. 
These five groups are discussed in further detail in the next paragraphs. Because clinical history and 
anthropometric data are mostly studied in combination they will not be discussed separately. 
10.2.1 Clinical history and anthropometric data 
A screening test should be simple, reasonably inexpensive, safe and acceptable to the 
general public. This is all true for the clinical history and the measurements of height and weight. 
But most important, a test for screening must have adequate predictive value, in other words predict 
future fractures. This has been investigated for the clinical history by several authors. Kleerekoper 
et al showed, in a retrospective study of 663 postmenopausal women, that in comparison with 
women without fractures, osteoporotic women reported a higher prevalence of a positive family 
history of osteoporosis and- had fewer children, but no differences were observed with regard to 
cigarette smoking, alcohol consumption, exercise habits, menstrual or menopausal history, dietary 
intake of milk or calcium1. They concluded that an assessment of the risk of osteoporosis cannot be 
based with sufficient sensitivity on the risk factors studied. This was confirmed by van Hemert et 
al2 in a prospective study of 742 women with one follow-up assessment after 9-years. They studied 
12 historical. anthropometric and radiological risk factors and none were found to be strong 
indicators of future fractures. Even for the upper risk score quintile (the risk score being composed 
of up to 5 selected variables) turned out to have a low sensitivity (0.48) and specificity (0.84) as to 
the prediction of osteoporotic fractures. 
In the studies mentioned above, the possible risk factors studied are related to the 
prevalence or incidence of fractures. An other approach to investigate risk profiles is based on the 
association of various putative risk factors (independent or combined) with bone mineral mass, 
under the assumption that bone mineral mass is strongly negatively correlated with the development 
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of osteoporotic fractures. In a group of 286 normal perimenopausal women it has cross-sectionally 
been investigated whether clinically available data (body mass index, reproductive history, 
menopausal status, calcium intake, physical activity and smoking) could provide an adequate risk 
profile for low bone mineral mass3 • No reliable predictions for spinal bone mass could be made. 
Additional information of the same type has been obtained by others" 5 • 
The value of anthropometries (weight, height, skinfold, calfcircumference and biacromal 
width) as determinants of bone mass has also been studied6• The results suggest that frame size, 
muscularity and adiposity have independent positive effeCts on bone mineral mass, but the 
associations were too weak to predict bone mass for individuals. Several investigators have addressed 
smoking as a risk factor for low bone mineral mass: some found no correlations7 8, others reported a 
negative effect of smoking on bone mineral mass in elderly men and women9, or a negative effect 
on endogenous estrogen levels and thereby on bone mass10 • Physical exercise as a determinant of 
bone mass has been studied extensively11 12 13 1" 15. Although bone mineral mass is undoubtly 
correlated to physical exercise, future fractures cannot be predicted by (the lack of) physical 
exercise. 
Unfortunally, one has to conclude that on the basis of clinical history and anthropometric 
data no sufficiently sensitive and specific risk factor status to select women for fracture prevention 
programs can be determined. 
10.2.2 Biochemical measurements 
There are several biochemical markers of bone turnover. Both osteoblasts and osteoclasts 
produce bone specific proteins which can be measured in the blood. These cells are also responsible 
for neosynthesized constituents or fragments of bone matrix which escape into the circulation. 
These substances can be measured in blood or urine. Markers of bone formation or osteoblastic 
activity are: alkaline phosphatase, serum osteocalcin (also called bone gla-protein) and the serum 
level of type I collagen propeptides. Markers of bone resorption include urinary hydroxyproline, 
plasma tartrate-resistant acid phosphatase, serum free gamma carboxyglutamic acid and urinary 
desoxypyridinoline. These biochemical markers are used in studies of metabolic bone diseases and 
proved to be useful in the follow-up of patients and in monitoring the effect of treatment. It has 
been suggested by the group of Christiansen that postmenopausal osteoporosis is correlated to 
several of these biochemical markers16• 
It is possible that the rate of bone loss in women with a low peak bone mineral mass is 
much lower than that in women with a high peak bone (mineral) mass. In this connection, it is of 
importance to quantify the rate of bone loss by multiple bone mineral measurements over a certain 
period of time. Based on densitometric results obtained at the forearm "slow and fast-losers" have 
been discerned by Christiansen et al17. They found that with the results of biochemical 
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measurements "slow and fast-losers" could be identified in approximately 80% of the cases. In 
another study the same group presented data about prediction of postmenopausal bone loss by 
measurements of four parameters: serum alkaline phosphatase, osteocalcin, fasting urinary calcium 
and hydroxyproline18• At present these findings are not confirmed by others5• Moreover, the rate of 
bone loss differs between the peripheral and axial measurements sites19 20 :ll. Therefore, it is 
possible that a subject can be a "fast loser" at one skeletal site, while being a "slow loser" at another. 
Furthermore, Hui et al. demonstrated that, because of biological variability in long-term rates of 
bone loss, it was difficult or even impossible to identify long-term "fast losersn22. 
At present, no reliable distinction between individuals with high or low bone (mineral) 
mass can be made by measuring biochemical markers of bone turnover. 
10.2.3 Bone mineral mass or density measurements 
Because there exists a strong positive correlation between BMD and bone strength23 24 , one 
would expect that the results of bone mineral mass or density measurements strongly predict bone 
fractures. In this paragraph an overview will be given how the relationship between bone mass data 
and future fractures have been explored. 
As is described in paragraph 3.6 it appeared to be impossible, in the individual, to predict 
BMD of the lumbar vertebrae or the hip from information obtained at other skeletal sites. 
Consequently, the next step was to study whether one could predict (already existing) osteoporosis 
(fractures) on the basis of densitometric measurements at the various fracture regions25 26 27 (see 
also Chapter 6). Cross-sectional studies have reported a positive correlation between low BMC and 
osteoporotic fractures28 29• Although the differences were small, vertebral BMD was more reduced 
than forearm BMD in the case of vertebral fractures and forearm BMD was more reduced than 
spinal BMD in peripheral fracture cases30• On a group basis the results were encouraging, but for 
the individual the results of these investigations were disappointing: no reliable information was 
obtained by peripheral and/or axial measurements on the degree of spinal osteopenia or the 
presence of fractures. However, the usefulness of a risk factor (in this case bone mineral mass or 
density) is not so much determined by how well it can diagnose existing disease (fractures), but 
rather how well it can predict future fractures. This cannot be demonstrated with a cross-sectional 
study design and several longitudinal studies addressing this issues have been published and will be 
discussed later on. 
It seems reasonable to assume that a middle-aged woman or man with a low bone mineral 
mass~ will bear a greater risk of sustaining osteoporotic fractures than a woman or man of the same 
age with a high-normal bone mineral mass. The best way to test this assumption is to monitor 
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(without selection) a cohort of women (or men) for a reasonably long period of time, perform at the 
outset of the study non-invasive measurements of bone mass at peripheral and/or axial sites in the 
skeleton and subsequently diagnose and quantify all fracture events. Using the distal and proximal 
forearm site for bone mineral density measurements it was found that in subjects aged 50-69 years 
the risk of a fracture (spinal or other) was over 10-16 years 3 to 6 times higher in the lowest BMC 
decile than in the highest decile31• 
In another prospective study it was shown that even a measurement site in the skeleton 
which is not prone to osteoporotic fractures (the calcaneus) can predict osteoporotic fractures 
elsewhere in the skeleton32• In this latter study a sevenfold greater probability of spinal fracture was 
observed in women at or below -1 SD from the mean at that age for calcaneus BMC than in women 
at or above +1 SD. Another prospective study using forearm densitometry demonstrated an increase 
of the fracture risk ratio of nonspinal fractures of 2.2 for each SD below the mean33• 
An interesting review has been published by Ross et al34• They analyzed 27 cross-sectional 
and 7 longitudinal studies on bone mass and fracture risk. The data were, if possible, recalculated to 
evaluate the relationship between bone mass and fractures by a logistic regression procedure. 
Finally, the authors selected 4 prospective studies in which valid data have been provided to 
calculate the risk of fractures expressed as the odds ratio. The odds ratio (OR) for a 2 SD difference 
in BMC (for I decade) appeared to be 2-4 for nonspinal fractures, and 4-8 for spinal fractures, 
varying somewhat as to the site of measurement. Most of these longitudinal studies lasted for an 
average of up to 10 years and the measurement devices have been highly improved during that 
period, e.g. it became possible to measure selectively cortical or cancellous bone and at sites prone 
to fractures. It may be expected that by using these newer techniques and methods a better fracture 
prediction may be possible. 
Based on these data, it seems reasonable to advise that if there is already a low bone mine-
ral mass (e.g. I SD below normal) and a suspicion of a high rate of bone loss (e.g. because of 
immobilization. the use of glucocorticoids etc.) prophylactic (therapeutic) measures should be star-
ted. 
10.2.4 Prevalence of osteoporotic fractures. 
Non-traumatic wrist, hip and vertebral fractures are called osteoporotic and having such a 
fracture will label a subject (by definition) as osteoporotic (specific processes like tumour metastasis 
being excluded). Hence. it is not surprising that such an individual is prone to future fractures. In 
one study it was shown that the prevalence of one of these osteoporotic fractures was a strong 
predictor of future osteoporotic fractures35• This observation, of course. can not be used for 
screening purposes but it underlines the necessity of therapy aimed at improvement of bone mass 
and quality in order to prevent future fractures. 
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10.2.5 Conclusion 
Current evidence suggests that bone mineral mass measurement is the most reliable method 
to predict future fractures, while several studies have shown that no item from an individual 
subject's history, physical examination or biochemical assessment is sensitive enough to predict 
fractures. 
10.3. Screening for osteoporosis. 
10.3.1 Introduction 
The purpose of screening is to select individuals with low bone mass and, subsequently, to 
treat them in order to prevent future osteoporotic fractures. This chain of events raises the 
following questions: Which bone mineral mass or density measurements is suitable for screening the 
general population? Is treatment effective, and acceptable to most individuals? Is screening and the 
subsequent treatment cost-effective? 
10.3.2 Which bone mass measurement device is suitable for screening? 
Photon absorptiometry and (conditionally) DEXA have a good accuracy and precision and 
thus are adequate to select women with a low bone mineral mass (see Table 1., chapter 2). Single 
energy QCT has a lower accuracy than absorptiometry and because of the higher radiation exposure 
and the higher costs, QCT appears not to be suitable for general screening purposes. Photon 
absorptiometry and DEXA- are relatively easy to perform, have low costs and a low radiation 
exposure. One single measurement at a peripheral or axial skeletal site (for instance performed 
perimenopausally) can predict future fractures at other sites. Especially with axial measurements 
(for example DEXA as a successor to DPA) better results as to predictability of osteoporotic 
fractures may be expected. Although different OR's are reported for the various measurement sites 
and osteoporotic fractures, at present no single measurement site appeared to be significantly better 
than the others in predicting future fractures36• SPA and (probably) DEXA are the methods of 
choice for screening. Based on present data no definitive choice can be made between SPA and 
DEXA, although it might be expected that. because of its better precision and lower radiation dose 
(as compared to DPA) DEXA will be the best candidate for screening the general population. 
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10.3.3 Treatment and the fracture risk 
Many case control studies have indicated the protective role of the postmenopausal use of 
estrogen37 38 39 40• Controlled prospective studies. that have shown the same, have mainly been 
carried out in normal postmenopausal women 41 " 2 " 3• In a cohort study a distinct reduction of the 
incidence of vertebral fractures in postmenopausal osteoporosis have been observed"". However, no 
long-term large scale prospective controlled studies have been published in which peri-or 
postmenopausal women with low bone mass (selected by screening from the general population) or 
with postmenopausal osteoporosis are treated with hormonal replacement therapy (HRT) and 
monitored for side effects and fracture incidence. It seems quite logical to start HRT directly after 
the menses cease. because most of the total bone loss occurs in the early postmenopausal years45• No 
data exist about the optimal duration of this therapy. Even in elderly postmenopausal women (up to 
the age of 74 years) estrogens may be protective"0• When estrogens were stopped after the age of 65 
years bone was (at the forearm) lost more rapidly than women of similar age who had never taken 
estrogens"3 • In other words the early postmenopausal bone loss appeared to have been postponed. 
Based on the prevention of bone loss one can recommend a life long duration for estrogen or 
hormonal replacement therapy. started as soon as possible after menopause. However, the optimal 
duration of HRT is not determined by its effects on bone alone. The long-term use of estrogen must 
also be considered in the light of a possible reduction of the risk of atherosclerotic cardiovascular 
disease"6 and the possible increased risk of breast cancer47 48• The combined use of estrogen and 
progestagen in women with an uterus will not lead to an increased risk of endometrial cancer"9• It is 
more likely that other aspects (side effects and the outcome of cost-benefit analyses) will be of 
importance in determining the optimal duration of this kind of therapy. Until these data become 
available, it seems to be reasonable to use this preventive treatment at least for 10 years50• 
In established osteoporosis several other therapeutics have been investigated and have been 
shown to reduce fracture incidence (bisphosphonates51 52 and vitamin D derivatives53). Although 
(long-term) fluoride therapy in the usual therapeutic doses will increase axial bone mineral mass5" 
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, the effect on fracture incidence is disappointing55• It has been demonstrated that intranasal 
calcitonin can counteract early postmenopausal bone loss56, but there is no information on the 
prevention of fractures by calcitonin. The effectiveness and safety of these therapeutics are not as 
well documented as the effectiveness of estrogens. Therefore, these therapies cannot as yet be 
recommended for preventive treatment in normal women who are selected by screening as to low 
bone mass. 
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10.3.4 Is therapy safe and will women accept preventive treatment? 
This is a difficult issue. Estrogen therapy has beneficial effects on bone mass and (if not 
combined with a progestagen) also on atherosclerotic cardiovascular disease" 6 57• To protect the 
endometrium against the induction of hyperplasia and carcinoma HRT has to consist of a 
combination of (continuous) estrogen and cyclical progestagen. When the uterus is still present HRT 
will inevitably result in vaginal bleeding. This is a major drawback of this kind of hormonal 
treatment and will result a high percentage of subjects ceasing to take it. There exists controversy 
about the increased risk of breast cancer from HRT. The answer to the question whether estrogens 
or HRT increase the risk of breast cancer has been difficult to obtain. Large epidemiological studies 
suggest that estrogens enhance the risk for breast cancer58• In a recent study, already after six years 
of follow-up an increased risk of breast cancer with the postmenopausal use of oestradiol was 
demonstrated59• In contrast, from other studies a reduction of the risk of breast cancer by HRT60 61 
has been reported. Recently, it has been shown by combining the results from multiple studies that 
menopausal therapy consisting of 0.625 mg/d or less of conjugated estrogens does not increase 
breast cancer risk62• 
Although the relation between HR T and the increased risk of breast cancer is delicate, there is no 
conclusive evidence that the relative risk of breast cancer outweighs the benefits of HRT in 
postmenopausal women. 
Acceptance of a preventive treatment with regard to osteoporosis might be better if a 
woman is well informed on the fracture risk she bears. This might be achieved by a bone mass 
measurement. The knowledge of a low bone mass and consequently a higher fracture risk for an 
individual may outweigh the negative aspects of HRT. 
10.3.5 Screening, treatment and cost-effectiveness 
This is of interest only if the answers to the other questions are favourable. Indeed, 
screening is possible and at least one effective preventive treatment (estrogens) is available for 
women with low bone mass. However, it is not known how well this therapy will be accepted in the 
general population. 
Ross et al. calculated a reduction of osteoporotic fractures by 33% if the women with the lowest 
47% of bone mass were selectively treated with an agent that is assumed to slow the rate of loss of 
bone by 50%63• In an early study (without bone mass measurements) it was concluded that the cost 
for each quality-adjusted year of life gained was comparable to the benefits of treating 
hypertension 6". Tosteson and colleagues55, have calculated that performing a single measurement of 
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bone density of the hip in perimenopausal women who did not have a hysterectomy. and prescribing 
a combination of estrogen and progestagen to those whose bone density is low, would -depending 
on BMD cut-off points at 0.9 or 1.0 gjcm2- cost $12000 to $22000 per quality adjusted year of life 
saved by prevention of deaths from hip fracture. 
All these estimates are aimed at estrogen use and osteoporosis, but in postmenopausal 
women there are also beneficial effects of estrogen if not combined with progestagen on 
atherosclerotic cardiovascular disease. These positive effects are much more important with respect 
to years of life gained and may outweigh the possible negative aspects of this preventive strategy. 
For these reasons it is mandatory to evaluate all the positive and negative effects of estrogens in the 
chain of screening and subsequent treatment in the case of low bone mass. The overall financial 
impact of starting HRT based on perimenopausal bone mineral mass measurements remains an issue 
not yet settled. 
10.4 Final conclusions 
The various determinants of bone mineral mass and putative risk factors for osteoporotic 
fractures are of no predictive value. Only the results of bone mass measurement can predict future 
fractures to some extent, and of the various measurements available only SPA and DEXA are 
suitable for screening the general population. Generally, early postmenopausal women (for screening 
purposes simplified to: women at the age of 50) will start to lose bone at a considerably higher rate 
than premenopausal women do. These women will therefore benefit most of bone sparing 
preventive interventions. For this reason screening would probably be best performed around this 
age. However, no consensus has yet been reached on specific screening programs in the general 
population66. Only a well designed screening program and treatment protocol will give information 
about the effectiveness of fracture prevention and improvement of the quality of life. 
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Summary 
It has now became possible to measure the bone mineral content in the axial as well as the 
peripheral skeleton. Moreover, with the use of computed tomography a selective assessment can be 
made of cancellous (trabecular) versus cortical bone mineral density. These technical achievements 
have led to a better understanding of the pathophysiology of osteoporosis and provided information 
on the effects of therapeutic interventions. Despite these sophisticated methods for bone mineral 
assessment the diagnosis of osteoporosis remains based on the occurrence of non-traumatic fractures 
and for that purpose an ordinary X-ray will be sufficient. 
For investigational use several non-invasive methods for measuring bone mineral mass have 
been developed, although only photonabsorptiometry (Single and Dual energy: SPA and DPA. 
respectively) and Quantitative Computed Tomography (QCT) are operational in large scale clinical 
practice. The advantages of photonabsorptiometry and the more recently developed Dual Energy X-
ray Absorptiometry (DEXA) over QCT are the lower radiation exposure, lower costs, better 
accuracy and precision and easier operation. The great advantage of QCT is the unique possibility to 
measure cancellous and cortical bone separately. 
With these non-invasive methods of bone mineral assessment is has been shown that 
women will lose during their lifes about 35 percent of their cortical and about 50 percent of their 
cancellous bone. We studied this pattern of age-related bone loss cross-sectionally in 171 healthy 
Dutch women and observed an accelerated bone loss around the menopause at all measurement sites 
(see Chapter 5). Further analyses showed that the onset of cortical bone loss as measured by SPA 
occurs on the average at least a decade later than the onset of cancellous bone loss which already 
manifests itself before the menopause. This pattern of cancellous and cortical bone loss during aging 
shows a parrallelism with the observed patterns of incidence of age-related fractures. The incidence 
of Colles fractures in women rises soon after the menopause and a plateau is reached around the age 
of 65. This type of fracture (distal forearm) occurs at a site containing a relatively high proportion 
of cancellous bone. On the other hand, the incidence of hip fractures increases slowly with age, 
which rise accelerates late in life in both men and women. This type of fracture characteristically is 
one of cortical bone. Somewhere between these two types of fractures the vertebral compression 
fractures take position. They occur soon after the menopause and the incidence apppears to rise 
over the two decades after menopause. The vertebral body contains about equal amounts of cancel-
lous and cortical bone. 
An important issue about the relationship between bone mineral mass and fractures is the 
"quality versus quantity" concept. The importance of this concept is already demonstrated by the 
fact that individuals with a bone mineral mass or density within the normal range may have typical 
osteoporotic fractures, while on the contrary individuals with a low bone mineral mass may sustain 
no fracture at all. These observations (among other evidence) have led to the hypothesis of a three-
dimensional fracture space with bone mineral mass. loss of bone connectivity and fatigue damage as 
important determinants of fracture (Chapter 3). 
The treatment (or secundary prevention) of osteoporosis is reviewed in Chapter 4. 
Treatment is based on modulation of one of two aspects of bone remodelling: increasing bone 
formation and decreasing bone resorption. In practice there are at the moment only two therapeutics 
available which may increase bone formation: fluoride and possibly anabolic steroids. 
The role of calcitonin and bisphosphonates as inhibitors of bone resorption in the treatment 
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of osteoporosis has to be investigated further, but these agents appear to be useful tools in future 
treatment regimes. 
For both normal or osteoporotic postmenopausal women oestrogens are beneficial in 
maintaining bone mass and in reducing fracture rate. Besides positive effects on bone, the long-
term use of oestrogen must also be considered in the light of a possible reduction in the risk of 
cardiovascular disease and with regard to a possible increased risk of breast cancer. For women with 
a uterus, the combined use of oestrogen and progestagen will not lead to an increassed risk for 
endometrial cancer. 
In Chapter 7, we report on the hormonal determinants of bone mineral density in elderly 
postmenopausal women. A positive correlation between (endogenous) serum estrone and bone 
mineral mass was observed. We found a significant negative correlation (by linear trend) between 
the level of Sex Hormone Binding Globulin (SHBG) in the serum and bone mineral density. 
However, correction for the difference in body mass index (BMI) led to the loss of differences in 
BMD between all groups. It was concluded that in elderly postmenopausal women BMJ is a main 
determinant of bone mass. 
Because of its complexity the pathophysiology of glucocorticosteroid induced bone loss is 
not well understood, although it is assumed that stimulation of bone resorption has a prominant role 
in the process. In Chapter 9. we report a longitudinal double-blind placebo controlled trial of the 
effect of la:-(OH) vitamin 0 3 over two years on bone los in glucocorticoid treated patients with 
chronic obstructive lung disease. No beneficial effect could be observed, but it was concluded that 
in the placebo-treated patients the average axial (lumbar vertebral) bone loss during treatment with 
an average daily dose of 8.7 mg prednisone was only about 1.3% yearly, while in the same group 
over two years no loss of bone mineral was found at the forearm. In a cross-sectional study in 
patients with Primary Biliary Cirrhosis (PBC) (Chapter 8) we found only a moderate and not sig-
nificant decrease in axial and peripheral bone mass in the patients who had used or were still using 
glucocorticoids as compared to those who never had been treated with glucocorticoids. These data 
are comparable with the results obtained in our asthmatic patients and support the view that 
relatively low doses of glucocorticoids (7.5-10 mg prednisone daily) on the long run have at most 
only a moderately negative influence on bone mineral mass. 
Another observation made in the patients with PBC is the negative influence of the 
histological stage of the liver disease on bone mineral mass. Furthermore the patients with the more 
severe histological grades of PBC and the lowest bone mineral mass had also a significantly lower 
serum calcium level. The lower serum calcium was not accompanied by a higher serum 
immunoreactive parathyroid hormone (iPTH), which suggests an impairment in the PTH production 
or secretion in these patients. 
One of the most interesting questions in the management of osteoporosis is: will it be 
possible to predict future fractures? This issue is discussed in detail in Chapter 10. We could not 
discriminate between a group of patients with postmenopausal osteoporosis and a group of healthy 
postmenopausal women of the same calender and postmenopausal age with various types of perip-
heral and axial measurement of bone mineral mass or density (Chapter 6). These results appeared to 
lead to the conclusion that it would be impossible to predict future fractures by bone mineral mass 
or density measurements. From 1986 onwards, however. several prospective studies have been 
published which showed a relationship between a low initial bone mineral density at a certain 
skeletal site measured by photon absorptiometry and a high relative risk of osteoporotic fractures. 
This relationship between low bone mineral mass and a subsequent high fracture incidence appears 
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to be strong enough for screening purposes in the general population. Therefore, despite the low 
correlation coefficients between the results obtained at the various measurement sites and despite 
the considerable overlap between the results of measurements in normals and osteoporotics there is 
evidence that the result of one single bone mineral mass measurement (preferably with SPA or 
DEXA) may indeed predict to some extent future fracture risk. 
It is concluded that non-invasive bone mineral measurements have been most helpful in 
elucidating the course of the natural occurring bone (mineral) loss during life. In controlled 
investigations these measurement techniques made it possible to study bone mineral loss and gain 
under various pathologic conditions and during therapeutic interventions. 
161 
Samenvating 
De laatste 20 jaar is het mogeiijk om de minerale botmassa zowel in het perifere skelet ais 
in het axiale skelet op niet-invasieve wijze te meten. Met de kom.st van de "computed tomography" 
is nu ook zeer selectief het trabeculaire en het corticate bot te meten. Deze nieuwe technieken 
hebben geleid tot een gedetailleerd inzicht in de pathofysiologie van osteoporose en in de resultaten 
van diverse therapieen voor osteoporose. Echter, de diagnose osteoporose wordt nog steeds gesteld 
door het aantonen van fracturen door middel van een gewone rOntgenfoto. 
Voor wetenschappelijk onderzoek zijn verscheidene niet-invasieve methoden om de 
minerale botmassa te meten ontwikkeld, alleen fotonabsorptiometrie (Single en Dual energy: SPA en 
DPA) en Quantitative Computed Tomography (QCT) worden gebruikt voor de dagelijkse 
patientenzorg. Het voordeel van fotonabsorptiometrie (en de recent ontwikkelde methode ROntgen 
absorptiometrie DEXA) boven QCT zijn de lagere radiatie dosis, de geringere kosten, de betere 
n::tuwkeurigheid (accuracy) en reproduceerbaarheid (precision). Voorts is de meetmethode van QCT 
ingewikkelder. Het grote voordeel van QCT is daarentegen, dat aileen deze techniek zowel 
trabeculair als corticaal bot onafhankelijk van elkaar kan kwantificeren! 
Met bovenstaande technieken is vee! onderzoek gedaan naar het normale (fysiologische) 
botverlies bij vrouwen. Zo is aangetoond dat vrouwen gedurende hun leven gemiddeld 35% corticaal 
en 50% trabeculair bot verliezen. Wij bestudeerden in een transversaal onderzoek bij 17 I gezonde 
vrouwen het verlies van bot op diverse plaatsen in het skelet (zie hoofdstuk 5), en vonden een 
versneld botverlies rond de menopauze terwijl het verlies van corticaal bot een decade later optrad 
dan het trabeculaire. Het trabeculaire botverlies lijkt reeds voor de menopauze te beginnen. Dit 
patroon van botverlies vertoond interessante overeenkom.sten met de incidentie van de verschillende 
osteoporotische fractureD. De incidentie van Colles-fracturen bij vrouwen stijgt direct na de 
menopauze totdat een plateau rond het 65ste jaar wordt bereikt. Deze fracturen van de onderarm 
ontstaan op een plaats die relatief vee! trabeculair bot bevat. Dit is in tegenstelling met de incidentie 
van heupfracturen die geleidelijk aan toeneemt met het ouder worden en vooral sterk toeneemt na 
het 70ste jaar. Dit type fractuur is typisch voor corticaal botverlies. Tussen deze twee typen 
fracturen in bevinden zich de wervelfracturen (infracties of compressie-fracturen). Osteoporotische 
wervelfracturen treden op vrij kort na de menopauze en blijven toenemen tot ongeveer 20 jaar na 
de menopauze. Ook qua botsamenste!ling nemen de wervellichamen een tussen-positie in: gelijke 
delen corticaal en trabeculair bot. 
De relatie tussen de minerale botmassa en het optreden van fracturen wordt zowel door de 
kwaliteit als kwantiteit van die minerale botmassa bepaald. Dit zogenaamde "quality versus quantity" 
concept wordt gelllustreerd met de observatie dat patienten met een normale minerale botmassa 
typische osteoporotische fracturen kunnen hebben, terwijl mensen met een !age minerale botmassa 
in het geheel geen fracturen vertonen. Deze bevindingen en andere gegevens hebben geleid tot de 
hypothese van de drie-dimensionale "fracture space". De drie assen de her fractuur risico bepalen 
zijn minerale botmassa, de onderlinge verbinding van de botbalkjes en -plaatjes ( "bone 
connectivity") en materiaal moeheid ("fatigue damage"). In hoofdstuk 3 wordt deze hypothese 
besproken. 
De behandeling (of secundaire preventie) van osteoporose is gebaseerd op het beinvloeden 
van twee aspecten van de botombouw: het verhogen van de botaanmaak en verminderen van de 
botafbraak. De diverse therapieen worden besproken in hoofdstuk 4. Alleen van fluoride (en 
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mogelijk ook van anabolica) is het bekend dat de botaanmaak gestimuleerd kan worden. Remmers 
van de botresorptie zijn calcitonine en de bisfosfonaten, de rol van deze middelen in de behandel.ing 
van osteoporose wordt momenteel uitvoerig onderzocht, de eerste resultaten zijn hoopvol. 
Oestrogenen zijn zowel voor normale als osteoporotische postmenopauzale vrouwen zinvol 
om botverlies tegen te gaan; tevens is overtuigend aangetoond dat zij het fractuurrisisco verlagen. 
Het langdurig gebruik van oestrogenen kent naast positieve effecten op de botmassa ook andere 
werkingen: er zijn aanwijzingen dat het cardiovasculaire risico gunstig wordt beinvloed, daarentegen 
wordt mogelijk een Iicht verhoogde incidentie van borstkanker waargenomen. Indien de oestrogeen-
therapie wordt gecombineerd met een progestativum is bet risico op baarmoederkanker niet 
verboogd. 
De relatie tussen de bormonale status en de minerale botmassa in oudere postmenopauzale 
vrouwen werd door ons onderzocbt in een transversaal uitgevoerd onderzoek (zie boofdstuk 7). Een 
positieve correlatie tussen endogeen oestron en botmassa werd aangetoond, terwijl bet "Sex Hormone 
Binding Globuline" (SHBG) een significante negatieve relatie vertoonde met de minerale botmassa. 
Ecbter, wanneer er werd gecorrigeerd voor bet lichaamsgewicht (in ons geval "body mass index", 
BMI) verdween bet verscbil in botmassa tussen de groepen. De conclusie was dan ook dat de BMI 
voor oudere postmenopauzale vrouwen een belangrijke determinant is van de minera!e botmassa. 
De patbofysiologie van glucocorticoid geinduceerde osteoporose is ingewikkeld en 
onvoldoende begrepen. Algemeen wordt aangenomen dat een gestimuleerde botafbraak een 
belangrijke rol speelt bij bet ontstaan van deze vorm van osteoporose. In hoofdstuk 9 maken wij 
melding van een longitudinale studie, dubbel blind en placebo-gecontroleerd, naar bet effect van 
la:-(OH) vitamine 0 3 (gegeven in een periode van twee jaar) op de botmassa van met 
glucocorticoiden behandelde astmapatienten. Een positief effect kon niet worden vastgesteld. Dit 
kan deels worden verklaard door het feit dat de gemiddelde prednison-dosis laag was (8.7 mg per 
dag) en met een relatief gering gemiddelde botverlies (1.3% per jaar in bet axiale skelet en 
nauwelijks botverlies in de onderarm). In een andere studie-opzet werd bet effect van 
glucocorticoiden bestudeerd in patienten met primaire biliaire cirrhose (PBC) (boofdstuk 8). In deze 
groep patienten vonden wij slechts een matige en niet significante daling van de minerale botmassa 
ter plaatse van de lumbale wervelkolom en de onderarm in PBC patienten. die glucocorticolden 
gebruikten of hadden gebruikt, vergeleken met PBC patienten, die nooit glucocorticoicien hadden 
gebruikt. Deze resultaten steunen de de conclusie verkregen uit bet onderzoek verricht bij onze 
astma-patienten dat relatief Iage doses glucocorticoiden (7,5-10 mg prednison per dag) gedurende 
langere tijd op zijn hoogst slechts een matig negatief effect bebben op de minerale botmassa. 
Een andere observatie uit het PBC onderzoek betreft de negatieve relatie tussen het 
histologische stadium van de lever ziekte en de minerale botmassa. Tevens bleek dat patienten met 
de histologisch meer ernstige stadia van PBC en met een lagere minerale botmassa ook een 
significant lager calciumgehalte van het serum hadden. Het verlaagde serum calcium ging ecbter 
niet gepaard met een boger gehaite immuno-reactief paratbyroied bormoon (iPTH), betgeen wijst 
op een onvoldoende produktie of secretie van PTH bij deze patienten. 
De vraag of bet mogelijk is om toekomstige fracturen te voorspellen heeft tot veel 
onderzoek geleid. In boofdstuk 10 wordt op de verschil.lende aspecten hiervan dieper ingegaan. Wij 
onderzochten met de meest gangbare niet-invasieve meettechnieken twee groepen vrouwen: een 
groep postmenopauzale vrouwen met osteoporotische wervelinfracties en een groep gezonde 
vrouwen vergelijkbaar wat betreft kalender- en postmenopauzale leeftijd. Het bleek, op basis van 
botmassametingen, onmogelijk aile vrouwen in een van beide groepen te classificeren (hoofdstuk 6). 
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Deze resultaten en de matige correlaties tussen de resultaten van de perifere en axiale metingen 
hebben aanvankelijk tot de veronderstelling geleid dat bet onmogelijk zou zijn met behulp van 
botmassametingen toekomstige fracturen te voorspellen. Echter, vanaf 1986 tot heden zijn diverse 
prospectieve onderzoekingen gerapporteerd waarin een lage initiele botmassameting gecorreleerd 
bleek te zijn met een hogere incidentie van osteoporotische fractuur. Deze relatie blijkt zelfs sterk 
genoeg te zijn om eventuele screening van de vrouwelijke bevolking serieus te overwegen. 
De niet-invasieve botmassametingen zijn van grote waarde gebleken voor bet onderzoek 
naar en in kaart brengen van bet natuurlijk verlopend botverlies gedurende bet leven. Tevens is het 
mogelijk met deze meettechnieken bet verlies of de toename van bot(mineraal) nauwkeurig te 
bestuderen tijdens ziekte of behandeling. 
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APPENDIX 
A COMPARISON OF TWO METHODS 
FOR CACULATING LUMBUR BONE MINERAL CONTENT 
P.P.M. Kooij~ F.N.R. van Berkum~ T. Stijnen 
E.P. Krenning, J.C. Birkenhl:i.ger. 
submitted for publication 
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Abstract 
Dual photon absorptiometry of the lumbar spine is widely used to determine bone mineral 
content. A modified software program for calculating the bone mineral mass of the lumbar spine is 
reported here. Comparing this program with the original one it appeared that the program gives a 
two-fold reduction of the time needed for the analysis of the patient data. The program has a 
similar interobserver variability with regard to the total bone mineral content, while the interobser-
ver variability of the bone mineral density is significantly improved. Furthermore, with the 
modified program the repositioning of the baseline and side cursors in follow-up studies is easier 
because of the reduced number of variables. 
Introduction 
Measurement of the lumbar spine by dual photon absorptiometry is used as a tool in the 
detection and monitoring of patients with osteopenia or osteoporosis1 . Nowadays, several dual 
photon scanners are commercially available. Most scanners use a Gadolinium (Gd-153) source, but 
they differ considerably in their algorithms for calculating bone mineral mass2• There exist 
diversities in the edge-detection routines, the baseline calculation and positioning, calibration 
procedures and in precision and accuracy. A disadvantage of our DPA system is the complex and 
time-consuming calculation procedure, which may take up to 15 minutes. The costs of the measure-
ment of one patient consist mainly of personnel costs based on time needed for both measuring and 
calculation. A reduction of one of these periods would be most welcome. 
Tothill et. all introduced3 a method in which they use a summation technique to calculate bone 
mineral content for a low activity Gd-153 source. In this paper we describe for our scanner a 
modification of the original calculation routine in which we use a summation technique as well. The 
activity of the source we used was according to the specifications (37-8 GBq) indicated by the 
manufacturer of the scanner. The program results in a two-fold reduction of the time needed for 
the analysis of the patient data. Moreover, the interobserver variability with regard to bone mineral 
density is slightly improved. Image quality is improved by introducing the possiblity to subtract a 
background. Thus it is easier to delineate the top of L2 and the bottom of L4. 
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scanprofile. 
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Materials and methods 
Our DPA system (BMC-Lab 22A, Novo Diagnostic Systems) is equipped with a standard 
computer and floppy discdrive (HP-85A. Hewlett Packard Co.). The scanner device uses a 4x4 mm 
pixel size. Each scan profile has a width of 12.8 em. thus there are 32 pixels per scan profile. The 
numeric value measured in each pixel is plotted as a function of its position (Fig. 1). Over the 
region of interest (ROI) (L2-L4) there are generally 22-26 scan profiles. 
The original program (Fig. 5. left side) offers the possibility to position the side delimiters 
and delineate the baseline by the operator on each scan profile. The side delimiters are positioned 
on all scans in the ROI. This leads to an irregular ROI along the lumbar spine. The scans 
recommended to use to delineate a baseline are the scans containing the intervertebral discs. In Fig. I 
examples of such a scan profile are depicted. The original program includes an algorithm to 
calculate automatically the baselines. which have to be accorded or readjusted (and then accorded) 
by the observer. Not all scan profiles can be used to determine a baseline. Therefore, for the 
remaining scan profiles the baselines are automatically calculated using a linear 
regression analysis on the accorded baselines. The next step is the calculation of the area under the 
curve (AUC) for each scanline. Subsequently the observer determines the ROI (mostly L2 to L4). A 
summation of the results of the individual AUC's in the ROI is performed. Finally, after 
calibration, the results are expressed as bone mineral content (BMC) in grams hydroxyapatite (g 
HA) for the ROI. Dividing the BMC by the surface of the projected ROI results in bone mineral 
density (BMD) expressed in g Ha/cm2• As the average ROI contains about 24 scanlines the number 
of variables may be up to 74 with a minimum of 5 (one baseline, two side delimiters and two 
delimiters for the ROI). 
In the new program (Fig. 5, right side) the calculation is done as follows. First the ROI 
(L2-L4) is defined by the observer. The computer program then summates all pixels for each 
column in this ROI and plots the summated curve of all 32 columns (Fig. 2). In this curve the side 
delimiters have to be placed by the observer. The baseline is automatically calculated by the 
program using the same algorithm as in the original program, and may eventually be readjusted 
before accordation. With the accorded baseline and the adjusted side delimiters. which are thus all 
three the same for all scanprofiles. the bone mineral content is calculated for each scan profile. Like 
in the original program this profile is displayed on the screen as a histogram together with the total 
scan image (Fig. 3). It is possible to adjust the ROI at this stage. If the ROI is adjusted the program 
continues with the calculation of the summated curve for the new ROI. If the ROI is not adjusted 
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the program prints the final scan report. 
As a conseQuence of our program the total ROI is always rectangular (Fig. 3) and the number of 
variables always equals five. 
Another modification in the new program is the possibility to subtract a background as a 
percentage of the maximal pixel value in the scan, which improves the quality of the scan image 
and makes the localization of the ROI easier (Fig. 4). 
Figure 4. 
. -~ . 
Left : The original scan image. 
Right: The same image with a lower threshold of 20%. 
Note for example the improved image quality in L2. 
This vertebrae is, in contrast to the original image, 
clearly asymmetric on this image. 
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Results 
We measured the bone mineral mass of the lumbar spine per L2 to L4 in 49 women, 
randomly chosen from a larger group of normal women described elsewhere4• Individual data of 
these patients were analyzed by one observer using both calculation programs and expressed as bone 
mineral content (BMC) and as bone mineral density (BMD). The results of both programs show 
very high correlation coefficients (for BMC: r"'0.9966 ; for BMD: r=0.9957). The regression lines 
relating the results of the original and new program do not pass through zero. The BMC and BMD 
values obtained with the new program are somewhat higher. The conversion formulas from original 
to new program and vice versa are given in Table I. 
In order to compare the interobserver variability of the two calculation methods, the BMC 
and BMD of 20 patients, out of the group of 49, were calculated by 4 observers with both programs. 
As a measure for interobserver variability the standard deviation between the measurements of the 4 
observers was chosen. For each of the twenty patients two standard deviations were calculated, one 
based on the measurements of the 4 observers with the original program, and one based on the new 
calculation program. The means of these standard deviations over the twenty patients were for BMC 
0.66 (original program) and 0.51 (new program), and for BMD 0.010 (original) and 0.006 (new). The 
values of the standard deviations of the two calculation programs were compared by means of 
Wilcoxon's signed rank test. For BMC the result was not significant, while for BMD the 
interobserver variability for the new method appeared to be significantly lower (p<O.Ol) than for 
the original program. Looking at the coefficients of variation instead of the standard deviations give 
comparable results. 
Another advantage of the new program is the reduction of the time needed for the analysis and 
print-out of the scan results. Using the original software program this takes about 15 minutes per 
patient. In contrast the new program takes 8 minutes per patient. In the original and the new 
program the time needed for the computer to calculate, display the images and print the scan report 
amounts 6 and 5.5 minutes respectivily. The reduction in the time needed for the analysis is thus 
almost completely due to the reduced number of actions, that have to be done by the observer. 
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Table I. Conversion formulas for data obtained with the 
original and the new program. 
====================================================== 
BMC 
(g Ha/L2-L4) 
ori->new -1.79 + 1.02*new 
-0.02 + l.Ol*new 
new->ori 2.03 + 0.97*ori 0.03 + 0.98*ori 
======================================================= 
Figure 5. 
ori=original program new=new program 
~ Select scan profile I ,-----4 SelectROI 
I Mark side delimiters I I Summated curve is I and/or baseline displayed 
J 
I More profiles? I I Mark side delimiters I 
lves 
and baseHne 
No 
l Total scan image I I Total scan image I 
~ 
I SelectROI I I ChangeROI? I 
lves No 
I Scan report I I Scan report I 
Flowchart of the original (left) and the new program 
(right). 
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Discussion 
The accuracy and precision of lumbar spine scanning for 
measuring the bone mineral content by DPA depend on variations in the technical approach of the 
scanning procedure, and also on the computational routines. Problems arising by variations in the 
source strength and by soft tissue calcifications, osteoarthritic lesions and other interfering lesions 
are well known5 5 7 8 9• 
Only a few reports consider the problems of the analysis of the raw data. such as edge 
detection, baseline positioning and calculation time3 10 11• 
Another important issue is the inter- and intra-observer variation12• These variations are 
mainly due to the interpretation of the scanprofiles. In practice it appears that the automatic 
calculation of the baseline, especially in adipose patients with low bone mineral mass and in 
osteoporotics, often fails. In such cases the observer has to determine the baseline. This can 
introduce variations of the baseline of 5 to 20% and variations in the final results of I to 20% (data 
not shown). 
In order to reduce these variations we developed a calculation program based on an average 
baseline detection over the ROI (L2-L4). Our results show that an average baseline over the ROI is 
reproducible, even in the hands of several operators. The inter-observer variations were of the same 
order of magnitude as in the original software program (for BMC) or better (for BMD) in our group 
of normals. However. the most important advantages of the new program in comparison with the 
original program are the shorter time for the analysis of the scan results and the diminished 
observer actions. Because of these improvements it is possible to analyze two patients simultaneously 
using two computers. 
In follow-up studies the new software furthermore turned out to have the advantage that 
the curve obtained at a later stage shows impressive similarity with earlier curves of the individual 
studied. This enables the operator to obtain more precise positioning of baseline and side cursors, in 
comparison with the previous scans. This might greatly improve the long-term precision. In a 
longitudinal study the original and the new software program are compared in this respect. 
We realize that the computer equipment we used is not up to date with respect to the time 
needed for both the calculation and the displaying of the scan images. With more modem equipment 
these times will be markedly reduced. We think however that the method itself deserves 
consideration for more modern equipment as well. 
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NAWOORD 
Graag wil ik allen danken die door hun hulp en steun hebben bijgedragen tot bet tot stand 
komen van dit proefschrift. 
Allereerst mijn opleider en promotor prof. dr. J.C. Birkenhager. die mij enthousiast wist te 
maken voor het moeilijke gebied van bet patient-gebonden onderzoek. Zijn stimulerende en 
optimistische begeleiding, met name ook in het geval van teleurstellende resultaten, zijn essentieel 
geweest voor het afronden van dit proefschrift. 
Huib Pols heeft mij op plezierige wijze ingewijd in het zinvol en leerzaam bezoeken van 
congressen ("wie is wie in osteoporose-land"). Naast de vele discussies die wij samen voerden, heb ik 
van hem geleerd dat de "ivoren toren van de wetenschap" in tijden van universitaire bezuinigen 
aileen met goed management (en contacten buiten de eigen universitaire gemeenschap) kan worden 
behouden of uitgebouwd. 
De metingen van de minerale botmassa werden op voortreffelijke wijze verricht door de 
medewerkers van de afdeling nucleaire geneeskunde en de afdeling experimentele radiologie. Peter 
Kooij heeft met zijn "kritische" en mathematische aanpak de fotonabsorptiometrie begeleid, hetgeen 
resulteerde in een verbeterde rekenmethode. 
Zonder de medewerking van gezonde vrijwilligers en de vele patienten was dit promotie-
onderzoek niet mogelijk, hen ben ik veel dank verschuldigd. 
Mijn "maten" Herman Gertrouw en Cees Geers wil ik bedanken omdat zij altijd voor mij 
k1aar stonden om waar te nemen, wanneer ik ons ziekenhuis verliet om de universiteit te bezoeken. 
Aan Trees Steenhorst, onze secretaresse, beloof ik dat het vele kopieren nu echt voorbij is. 
Hoe belangrijk ook, dit proefschrift is slechts een stap in de opleiding tot volwaardig mens. 
De eerste stappen werden gemaakt onder leiding van mijn ouders, zij hebben het klimaat gecreeerd 
waarin bet plezierig en vanzelfsprekend was om hobbies te hebben. te sporten en te studeren. 
Tijdens het schrijven van het manuscript hebben zij mij gesteund met hun interesse en 
aanmoedigingen. Van praktisch nut bleek hun grote vriendenkring: vrijwel aile gezonde 
proefpersonen werden daaruit geacquireerd. 
Penny, liet mij werken, maar haalde mij op de juiste momenten achter bet beeldscherm 
vandaan, en wist daarmee duidelijk te maken dat ons gezinsleven nog vele malen boeiender is dan 
de wetenschap. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 3 december 1956 te Rotterdam. Na het 
behalen van bet Atheneum B diploma aan bet Sint Montfort college te Rotterdam werd in 1975 met 
de studie geneeskunde aangevangen aan de Erasmus Universiteit Rotterdam. Gedurende deze studie 
werd ervaring opgedaan in wetenschappelijk onderzoek op de afdeling chemische endocrinologie 
(hoofd prof. dr. H.J. van der Molen.) Tevens was hij student-lid van de Vaste Commissie 
Wetenschapsbeoefening. In januari 1981 werd het artsenexamen afgelegd (met lof). In afwachting 
van zijn opleiding tot internist werkte hij als arts-assistent op de afdeling Interne Geneeskunde in 
bet Bergweg Ziekenhuis (hoofd Dr. G.J.H. den Ottolander) en op de afdeling Cardiologie van bet 
Zuiderziekenhuis (opleider X.H. Krauss). Vanaf 1983 tot 1988 werd de opleiding tot internist 
gevolgd in de afdeling Inwendige Geneeskunde III van bet Academisch Ziekenhuis "Dijkzigt" te 
Rotterdam (hoofd prof. dr.J.C. Birkenh~ger). Het onderzoek beschreven in dit proefschrift werd op 
deze afdeling en de afdeling Nucleaire Geneeskunde verricht (in samenwerking met de afdelingen 
Radiodiagnostiek, Pathologic en Inwendige Geneeskunde II). Na zijn registratie als internist in 1988 
werkte hij in het van Dam-Bethesda ziekenhuis te Rotterdam. In juni 1990 volgde de overgang naar 
Spijkenisse, alwaar bet Ruwaard van Putten Ziekenhuis werd geopend. 
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